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Summary 
Telomeres are nucleoprotein structures that contain non-coding (TTAGGG) tandem repeats 
and associated telomere binding proteins at the end of chromosomes. As a consequence of 
end-replication losses, telomeres undergo gradual erosion with ongoing cell division. It is 
hypothesised that in addition to the end-replication problem, mutational mechanisms may 
contribute to telomere erosion by generating large-scale telomeric deletion events. As short 
dysfunctional telomeres are capable of fusion to other chromosome ends, large-scale 
telomeric deletions can lead to genomic instability which in turn may drive tumour 
progression. 
The primary aim of this thesis was to investigate putative mutational mechanisms that could 
lead to large-scale telomeric deletion. The role of oxidative stress and it potential 
contribution to telomere dynamics was assessed. The induction of fragility and replication 
inhibition at telomeres was also examined. Furthermore, the role that G-quadruplex 
structure within telomere repeat sequences and the possible induction of replication fork 
stalling and resolution as single or double stranded breaks was also considered as a 
mutational mechanism that could lead to telomere deletion. 
High-resolution analysis of telomere dynamics using Single Telomere Length Analysis 
(STELA), following the induction of oxidative stress in IMR90 fibroblasts, revealed that 
oxidative damage does not appear to affect the rate of telomere erosion, or the frequency 
of large-scale telomeric deletion. The data are more consistent with the view that 
premature senescence does not arise as a consequence of accelerated telomere erosion, 
but instead more likely results from stochastic DNA damage across the rest of the genome. 
The analysis of telomere dynamics following the induction of chromosome fragility, showed 
that telomere length in Seckel cell (SCK) fibroblasts were significantly different from those of 
untreated cells following treatments with aphidicolin with an increase in stochastic 
telomeric deletion. Whilst in MRC5 fibroblasts, the induction of the telomere fragility 
impacted on the upper to lower allele ratio, with a loss of the longer telomere length 
distributions.  
The stabilisation of G-quadruplex structures using the G-quadruplex ligand (RHPS4), 
together with ATRX knockdown, showed that an absence of ATRX sensitised cells to the 
ligand, but that the stabilisation of G-quadruplexes, did not significantly affect the telomere 
dynamics as determined using STELA. 
Taken together, the data presented in this thesis are not consistent with a role for oxidative 
stress, or the formation of G-quadruplex structures, in generating large-scale telomeric 
deletion; however telomeric mutational events may occur following the induction of 
chromosome fragile sites, specifically in the context of an ATR deficiency. 
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Chapter 1 
Introduction 
 
1.1 The History of Telomeres 
During the 1930s, Hermann Muller became the first researcher to notice that the ends of 
chromosomes had distinct features (Mueller, 1939). Based on their position on 
chromosomes, Muller named these ends TELOMERES (from Greek word telo, which means 
“end” and mere, which means “part”). Later, in his Drosophila mutagenesis experiments, he 
used X-rays to create different internal rearrangements such as deletions, inversions and 
translocations. Muller was surprised to note that the ends of the chromosomes were not 
being affected by the mutagenic X-rays. He concluded that the genes at these terminal ends 
could be having a special function, which prevented chromosomal alterations and helped 
maintain the integrity of the chromosome. 
In 1939, two years after Muller’s discovery, Barbara McClintock’s observed that in maize 
(Zea Mays), the loss of these end structures after an X-irradiation stimulated sister 
chromatid fusion events. These fusion events by sister chromatids resulted in dicentric 
chromosomes that formed a “bridge” between the two daughter cells in the meiotic 
anaphase of cell division. At the end of anaphase, dicentric chromosomes break inducing an 
unequal break site in the two daughter chromosomes. Mitosis of the daughter cells can 
induce continuous cycles of replication, sister chromatid fusion and unequal breakage 
events (Breakage-Fusions-Bridge (BFB)). Consequently, several BFB cycles can lead to 
unequal exchange of genetic information causing gene duplications and deletions. 
McClintock noticed that BFB cycles were only maintained in somatic cells, whereas in 
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embryonic cells the BFB cycles were interrupted and chromosomal breakage were 
permanently healed (McClintock,1941).  
1.2 The Structure of the Telomere 
Telomeres are specialised DNA structures which are located at the chromosomes terminus 
(Blackburn, 2000). Since the work by Muller (Muller, 1939) and McClintock work 
(McClintock, 1941), telomeres have been shown to offer protection to chromosome ends 
against end-to-end fusion and degradation. They are made of repetitive G-rich DNA 
sequences and associated proteins, which distinguish natural chromosome ends from 
damage caused by DNA breaks. 
 T-Loop Structure 
Telomeric repeats and associated proteins form the Telomere Loop (T-loop) structure, in 
which the extended 3’end single-stranded overhang invades the DNA double strand to 
protect the chromosomal ends and to become effectively hidden from being considered as 
DNA damaged (Figure1). T-loop has been observed in protozoa, plants, yeast and human 
(Griffith et al., 1999). 
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Figure 1: T-Loop structure. Chromosome ends are capped and protected by telomeres and 
associated proteins which consists of (TRF1, TRF2, TIN2, POT1, TPP1 and RAP1). The leading 
strand (TTAGGG) overhang invades the double-stranded helix, forming T loop. (Diagram is 
reproduced from Calado and Young, 2009).       
1.2.1 Diptera 
Drosophila melanogaster telomeres have a unique telomere structure compared to the 
conserved G-rich structure of eukaryotic telomeres. The chromosome ends of Drosophila 
are formed in arrays of telomere-specific non-Long Terminal Repeat (LTR) 
reterotransposons (Pardue and DeBaryshe, 2003). Drosophila melanogaster telomeres are 
maintained by non-LTR reterotransposons; HeT-A and TART. HeT-A and TART 
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reterotransposons elements transpose to chromosome ends where they arranged head to 
tail.    
1.2.2 Protozoa 
In 1978, Blackburn and Gall carried out a study in which they sequenced the termini of 
Tetrahymena thermophilia which showed between 20 and 70 repetitive sequences TTGGGG 
(Blackburn and Gall, 1978). In ciliates such as Oxytricha fallax and Stylanychia pustulata, the 
macronuclear DNA is capped by 20 bp of TTTTGGGG telomeric repeats sequence that end in 
an extra 16 bp 3′-overhang (Chiurillo et al., 1999). T-loop structure has been found in 
ciliates. Telomeres of Trypanosome have TTAGGG repeats similar to those that occur in 
eukaryotes. Chromosomes from Trypanosome brucei terminate in telomeric repeats of 10-
20 kb and display a 3′-overhang of 21-250 nucleotides of TTAGGG repeats. The end of T. 
brucei DNA also has a T-loop formation (Munoz-Jordan et al., 2001). In addition to having a 
comparable structure to T. brucei, T. cruzi has a G-rich overhang with 9-50 nucleotides 
(Chiurillo et al., 1999). 
1.2.3 Fungi  
Telomere sequences of budding yeast Saccharomyces cerevisiae found to have a proximal 
domain containing 120 to a 150 bp of G₂₋₃ (TG) ₁₋₆ repeats and a distal domain containing 
TG₁₋₇ repeats. (Shampay et al., 1984, Wang and Zakian, 1990). On the other hand the 
telomeres of fission yeast Schizosaccharomyces pombe are composed of 300 bp of the 
degenerated telomeric repeat sequence, TTAC(A)(C)G₂₋₈ repeat (Hiraoka et al., 1998). Both 
budding and fission yeast S. pombe and S.cerevisiae have a G-rich single stranded overhang 
at their chromosome termini (Gravel et al., 1998, Tomita et al., 2003).  
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1.2.4 Plants 
In majority of the plants, the telomeres are composed of recognized TTTAGGG repeats (Riha 
and Shippen, 2003). But the telomeres are of different lengths in different plant species. For 
example in Arabidopsis, the length of the telomere measures between 2 and 5 kb, whereas 
in tobacco, telomere repeats exceed 150 kb (Fajkus et al., 2005). However, the normal 
TTTAGGG repeat seen in other plants is absent in algae such as Chlamydomonas and related 
species. These members of the Asparagales have the six base human-type telomere repeats 
TTAGGG (Bowers, Chapman, Rong & Paterson, 2003). The Alliaceae family (onions) does not 
have any kind of G-rich telomere repeats and demonstrates an unknown telomere structure 
(Pich et al., 1996). Similar to telomere length, the G-rich 3′-overhang also possesses variable 
lengths in plants, which range from 20 to 30 nucleotides in Arabidopsis to about 75 kb in 
Pisum sativum (Cesare et al., 2003). The G-rich 3′-overhang does not occur in all plants 
chromosomal termini, which signifies the presence of unknown telomeric structures in 
plants (Watson and Riha, 2010).  
1.2.5 Mammals 
The chromosomal ends in mammels are capped by the same telomere repeat sequence 
which consist of TTAGGG (Meyne et al., 1989) and telomere length varies in different 
species and sub-species. The wild Mus. musculus and Mus. spretus display telomere length 
vary from 5-20 kb, whereas inbred strains have much longer telomere length ~150Kb. The 
variation in telomere length has been also observed in mouse strains. For instance, DBA/2 
mouse strain has telomere length ranging from 20-150Kb, whereas C57BL/6 strain displays a 
telomere length of 20-65 kb (Kipling and Cooke, 1990).  
Human telomeres consist of TTAGGG repeat arrays, with length varying from 5-20Kb. In 
addition to TTAGGG repeats, human telomeres contain Telomere Variant Repeats (TVR) 
6 
 
such as TTGGGG, TGAGGG and TCAGGG. TVRs are contained within the proximal 1-2Kb of 
telomere repeat arrays (Baird et al., 1995, Brown et al., 1990 and de Lange et al., 1990). 
1.3 Telomere-associated proteins 
1.3.1 Shelterin 
 Human telomere repeats interact with the six protein complex known as SHELTERIN 
COMPLEX. The shelterin complex presents only and abundantly at the chromosomal ends. 
Telomere and shelterin proteins protect chromosomal ends from being recognised as DNA 
damage, prevent inappropriate end-to-end fusion and chromosomal abnormalities and 
maintain telomere length. Shelterin is made up of Telomeric Repeat Binding protein Factors 
1 and 2 (TRF1 and TRF2), TRF1-Interacting Nuclear factor 2 (TIN2), Protection Of Telomeres 
1 (POT1), Repressor/Activator Protein 1 (RAP1) and (TPP1) (Diehl et al., 2009) (Figure2). 
 
 
 
 
 
 
 
 
 
Figure 2: Shelterin complex. TRF1 & TRF2 bind to double-stranded and POT1 binds to 3’end single-
stranded and these three proteins are held together by TIN2 & TPP1. (Original diagram using 
information from Diehl et al., 2009).   
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1.3.1.1 TRF1 and TRF2 
TRF1 was the first binding protein of shelterin complex to be identified (Zhong et al., 1992). 
TRF2 was identified afterwards as a distant homologue of TRF1 (Broccoli et al., 1997). TRF1 
and TRF2 are similar in their structures; both are operate as homo-dimers that bind to 
double stranded TTAGGG repeats via C-terminal helix-turn-helix SANT/Myb DNA-binding 
motif (Bianchi et al., 1999, Broccoli et al., 1997). Both TRF1 and TRF2 have identical 
biochemical features, however, their roles in the functioning of the telomere are very 
different.  In vivo and in vitro studies show that TRF2 facilitates the formation T-loop where 
the 3′ telomeric overhang is occupied into the previous array of duplex telomeric repeat. 
The overexpression of the dominant-negative TRF2 triggers the ATM/p53 and/or p16/RB 
pathways. In addition, it prompts cellular apoptosis. Besides, the inhibition of TRF2 triggers 
end-to-end fusion and chromosomal abnormalities. This is an indication of the critical role 
played by TRF2 in the “functional telomere structure” and also protects ends of the 
chromosome.  
The role of TRF1 is to negatively regulate the length of the telomere (Steensel & de Langue, 
1997). An overproduction of dominant-negative TRF1 triggers advanced elongation of the 
telomere. However, overproduction of the wild-type TRF1 triggers shortening of the 
telomere. TRF1 protein appears to be associated with TANKYRASE 1& 2 that regulate the 
length of the telomere. Both tankyrase 1 and 2 are polymerases (poly-ADP-ribose), which 
targets TRF1 and triggers gradual lengthening of the telomere by dissociating TRF1 from the 
telomeric structures (Smith & de Langue, 2000). On the other hand, TIN2 mimics TRF1 
function to negatively regulate telomere length (Kim, Kaminker, & Campisi, 1999). Studies 
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have suggested that the main function of TRF1 is control telomere length (Steensel & de 
Langue, 1997).  
1.3.1.2 TIN2 
TIN2 (TRF1- and TRF2-interacting nuclear factor 2) is a novel protein that binds TRF1 and 
seems to regulate telomere length. It does this by providing a steadying scaffold for the 
shelterin complex during its interaction with TRF1, TRF2 and TPP1 (Kim et al., 2004). It binds 
ssDNA-binding protein TPP1/POT1 to dsDNA-binding protein TRF1 and TRF2 (de Lange, 
2005). TIN2 protein has 3 different binding sites for every binding partner (Ye al., 2004a). 
For instance, the TRF1 binding site occurs on the C-terminus of TIN2, on the other hand, the 
N-terminus is related to TRF2 binding. Another role of TIN2 is to recruit TPP1-POT to 
telomeres through the use of a third binding site, which is found within the N-terminus, by 
doing so, TIN2 helps link double stranded and single stranded telomere repeats 
(Houghtaling et al., 2004). In addition, TIN2 prevents the release of TRF1 from the telomere 
by inhibiting TRF1 poly (ADP-ribosylation using tankyrase1 (Ye et al., 2004b). Moreover, 
TIN2 forms a bridge between TRF1 and TRF2 to stabilise TRF2 binding to telomere (Kim et 
al., 2004, Ye et al., 2004a). In human cells, the over-expression of TIN2 inhibits telomere 
elongation by limiting telomerase access. Based on that, TIN2 is considered as a negative 
telomere length regulator (Kim et al., 1999).  
1.3.1.3 TPP1 
TPP1 is also known as TINT1, PTOP or PIP1. TPP1 was first identified through two hybrid 
screens using TIN2. TPP1 protein is critical in binding between TIN2 and POT1 (Liu et al., 
2004b). The TPP1 binds to carboxyl terminus of POT1 in order to recruit it to the telomere 
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whereas, the carboxyl terminus of TTP1 binds to TIN2 (Ye et al., 2004b). Serine rich region 
been found between two protein binding domains, thus have multiple potential 
phosphorylation sites (Palm, de Lange 2008), furthermore, the telomerase-interacting 
domain found in the N-terminus of TPP1, which indicates that TPP1 plays a role in the 
recruitment and regulation of telomerase activity at the terminus (Xin et al., 2007, Ye et al., 
2004a).  The absent of TPP1 leads to the loss of POT1 from the telomere and resulting in 
telomere de-protection and telomere length alterations, a similar phenotype to the one 
observed after POT1 loss (Xin et al., 2007). 
1.3.1.4 POT1 
POT1 (Protection of Telomeres 1) binds specifically to repeats of single-stranded TTAGGG 
and guards the telomere against rapid degradation (Baumann & Cech, 2001). The HPOT1 
has two oligosaccharide/oligonucleotide-binding (OB) folds, which are specific for 
5’TTAGGG-3′ sequence. One study has indicated that  POT1 cannot bind to telomeric DNA 
when TPP1 is absent (Loayza et al., 2004). However, evidence from a number of other 
studies showed that POT1 can be localised to the telomere when functional TPP1 is absent 
(Colgin et al., 2003, He et al., 2006).  In a study by Chen et al., (2007), they reported that 
POT1 needs the presence of TPP1 for its nuclear localisation (Chen et al., 2007). The removal 
HPOT1 led to the elongation of the telomere and several telomeres fused (Chen et al., 
2007).  Arabidopsis thaliana contains two distinct POT1 paralogs, which do not show 
telomeric DNA binding and which appear to regulate telomerase rather than be involved in 
protection of chromosome end (O'Malley, Ecker, 2010). The role of POT1 on telomerase 
activity at the molecular level remains unknown. However, POT1 appears to play a role in 
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the stabilization of t-loop formation when it binds to displacement G-strand within the D-
loop (Loayza et al., 2004). 
1.3.1.5 Rap1 
Human Rap1 (Repressor/Activator Protein 1) is recruited by and depends on TRF2 in order 
to remain stable (Celli and de Lange, 2005). RAP1 is a characteristic sequence-specific DNA-
binding protein. Rap1 has different domains; C-terminal domain to interact with TRF2 and 
Myb domain which enables the binding unknown protein partner (Palm and de Lange, 2008 
& Hanaoka et al., 2001). Unlike in yeast, human Rap1 does not bind directly to telomeric 
DNA (Li and de Lange, 2003).  Although the precise function played by hRap1 is not yet 
understood, its structure suggests that it could be involved in protein-protein interactions 
(Denchi, 2009). In addition, recent evidence supposes that RAP1 functions in NHEJ inhibition 
(Sarthy et al., 2009). 
1.3.2 Transient associated telomeres proteins 
In addition to the shelterin complex, there are a number of additional proteins that have 
been found in telomeres. Majority of these proteins are involved in DNA signalling and DNA 
damage repair. They are transiently associated with the telomere during specific phases of 
the cell cycle. The primary role of every transient associated telomere protein is 
independent of telomere biology. Examples of these proteins are WRN RecQ helicase 
(Crabbe et al., 2004, Opresko et al., 2002), bloom syndrome helicase (BLM), Tankyrase1 and 
Tankyrase2, ATM, and PinX1.  
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1.3.2.1 PinX1 
PinX1 is a novel TRF-binding protein which has a direct inhibition function on telomerase 
activity. PinX1, together with MCRS2 (cell cycle dependant protein that accumulates in S-
phase) are involved in the regulation of telomeric length, and binds directly to TRF1 and 
TERT (Zhou and Lu, 2001). Human PinX1 contains an N-terminal G-patch domain, which is 
common among all RNA binding protein (C-terminal TRF1-binding domain) (Chen et al., 
2008; Zeng et al., 2010). Ectopic pinX1 has been shown to co localize with ectopic TRF1 
leading to the increase of the quantity of TRF1 on the telomeres (Yoo, Oh & Park, 2009). 
PinX1 is also shown to interact with telomerase RNA and protein subunits, where PinX1 
becomes bound to the TERT region that interacts with TERC RNA subunit (Banik and 
Counter, 2004). Ectopic PinX1 impedes the activity of telomerase (Zhou et al., 2011), while 
PinX1+/− displays higher telomerase activity.  These data are consistent with a role for PinX1 
in telomerase regulation (Zhou et al., 2011).   
1.3.2.2 Tankyrase1 and Tankyrase2 
Tankyrases are proteins containing poly (ADP-ribose) polymerase (Cook et al., 2002). 
Tankyrase1 is a 140 kD protein that was first discovered in two hybrid screen of yeast (Smith 
et al., 1998). Tankyrases in human cells post-translationally alter several proteins that are 
involved in telomere length maintenance and bridging sister telomeres. Both Tankyrase1 
and Tankyrase2 bind to poly(ADP-ribosyl)ated TRF1. A poly(ADP-ribosyl)ated TRF1 is 
inhibited from binding to telomeres, which frees the chromosome termini for telomerase 
activity (Cook et al., 2002). In addition tankyrase1 associated with NuMA (mitotic apparatus 
protein) that regulates the function of the mitotic spindle (Chang et al., 2005). Tankyrase1 
overexpression within the nucleus facilitates the elongation; this suggests that tankyrase1 
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could be regulating the contact between telomerase and the telomeric complex. Hsiao and 
Smith (2008) showed that the inactivation of tankyrase1 from a cell makes it unable to 
assemble bipolar spindles (Hsiao and Smith, 2008). Moreover, tankyrase1 is critical for the 
resolution of sister telomeres during the process of mitosis. Deficiency of tankyrase1 causes 
fusion of the two unprotected sister chromatids. The roles of tankyrase2 within the cell are 
not very clear; however, it looks like it shares similar roles with tankyrase1 (Cook et al., 
2002).  
1.3.2.3 Ataxia Telangiectasia Mutated (ATM) 
 ATM is a gene that encodes a PI3/PI4-kinase family protein. The protein is crucial in cell 
cycle as it is involved in phosphorylation. Therefore, it works as a regulator of various 
downstream proteins such as p53, BRCA1, RAD17, RAD9, CHK2, and NBS1 (Meyn, 1999). 
1.3.2.4 BLM 
BLM is a RecQ helicase (Ellis, Groden, Ye, et al., 1995) involved in homologous 
recombination (Johnson, Lombard, Neff, Et al., 2000). In addition, BLM can move through 
Holliday junctions (Walpita, Plug, Neff, German & Ashley, 1999) where it unwinds G4-DNA 
(Karow, Constantinou, Li, West, & Hickson, 2000), which is formed in vitro at G-rich 
sequences, for instance, telomeres. When mutations occur in BLM, they cause Bloom 
syndrome, which us a rare congenital disorder that’s characterized by slow growth, low 
immunity, chromosomal instability and cancer (German, 1993). In human cells, BLM binds to 
PML bodies (Zhong, Hu, Ye, Stan, Ellis & Pandolfi, 1999). Recent studies have shown that 
BLM also co-localize with telomeric foci within the ALT cell line (Yankiwski, Marciniak, 
Guarente & Neff, 2000). However, its role in telomere maintenance is unclear. 
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1.3.2.5 WRN 
WRN plays an essential role in genome stability particularly during DNA replication and in 
telomere metabolism. WRN encodes a protein that contains a 3’ to 5’ DNA helicase domain 
from the RecQ family (Martin and Oshima, 2000). RecQ helicase are involved in numerous 
biochemical processes such as DNA recombination. The protein also has several other 
conserved domains such as 3’ to 5’ exonuclease domain, which is a nuclear localization 
sequence, and DNA-protein binding domain (DPBD), which interacts with both proteins and 
DNA (Orren, 2006). WRN interacts with POT1, TRF1 and TRF2. It also interacts with Ku 70 
and Ku 80, a protein that’s involved in non-homologous-end-joining (NHEJ) that is involved 
in telomere length maintenance.  
According to Johnson et al., (2000), WRN interacts with TRF2 via the DPBD domain.  WRN 
localization to the telomeres seems to be specifically at the s phase of the replication cycle. 
By interacting with TRF2, WRN’s 3′-5′ exonuclease and weak 3′-5′ helicase activities become 
induced (Opresko et al., 2002), this activity can resolve telomeric D-loops. Thus, WRN is 
involved in normal telomere replication by resolving abnormal secondary telomeric 
structures during the progression of the replication fork. 
1.4 Telomere function  
1.4.1 Chromosome capping and DNA damage response 
Early studies on Drosophila melanogaster and Zea mays revealed that chromosomes 
disrupted through treatment with X-ray suffered different forms of chromosomal 
rearrangements (McClintock, 1939, Mueller, 1938). Muller and McClintock observed that 
during these alterations, the ends of the chromosomes were never affected. This is where 
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the idea of “capping” emerged which recognises the natural end of the chromosome from a 
DNA double strand break. When the chromosome ends were analysed using electron 
microscopy, it was realised that large duplex loops, the T-loop, were “caps” (Griffith et al., 
1999). The formation of this T-loop is dependent on TRF1 and TRF2 that have been 
suggested to remodel telomeric DNA into large loops (Griffith et al., 1999, Stansel et al., 
2001). 
The protection of chromosome termini from DNA damage repair and differentiating it from 
DNA double strand breaks is one of the main functions of the telomeres. TRF2 and POT1, 
two important members of the shelterin complex, play a critical role in the interaction 
between telomeres and the DDR. For instance TRF2 dominant negative mutant is expressed 
as a consequence of the recognition of telomeres as DNA double strand breaks that lead to 
the stimulation of the ATM/P53 damage response pathway (Karlseder et al., 1999). 
Furthermore, TRF2 is also assumed to be capable of inhibiting the autophosphorylation and 
activation of ATM thus abrogating the ATM signalling pathway (Bradshaw et al., 2005). Both 
POT1 and TRF2 are essential for repressing DNA damage signalling pathways. These two 
proteins act independent of each other. On one hand, TRF2 inhibits ATM kinase; while on 
the other hand, POT1 represses ATR (Denchi and de Lange, 2007). Conversely proteins that 
detect DNA damage, repair, and DDR signalling are also bound to functional telomeres. 
Evidence from recent studies shows that for telomere replication to occur, the telomeres 
should have DDR machinery (Verdun et al., 2005). 
1.4.2 Telomeres in mitosis and meiosis 
Meiosis and mitosis are cell division process common in majority of eukaryotes. Recent 
evidence points to the involvement of telomeres in homologue pairing during meiotic cell 
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division. For instance, during meiotic prophase, the ends of the chromosomes are clustered 
and become attached to the spindle polar body in a process which requires silent chromatin 
assembly that forms a bouquet-like configuration. This bouquet occurs in many eukaryotes 
and promotes meiotic paring and the ensuing homologous recombination through 
chromosomes alignment.  
However, the mechanism through which the “bouquet” is formed is absent in 
Caenorhabditis elegans and Drosophila (McKee, 2004, Scherthan, 2001). In addition, studies 
on maize, mice and human have showed that telomeres become attached to the Nuclear 
Envelop (NE) in a random manner during lepotene and that they continue to move around 
the nuclear envelop until they come into close contact (Bass et al., 1997). This process is 
very active and is tightly modulated and switched off during early pachytene. It is suggested 
that the formation of the bouquet increases the efficiency of meiotic prophase (Harper et 
al., 2004). In humans, two TRF2 proteins are involved in the tethering of the chromosomes 
ends to the nuclear envelop (Luderus et al., 1996). 
Meiosis occurs in several stages. During the first stage, lepotene, the unfolded bundles of 
chromatin are organized into long and slender fibres. Towards the end of lepotene and the 
start of zygotene stage, telomeres become bound to the nuclear envelope and gather 
together to form a bouquet. In zygotene stage, homologous chromosomes start to come 
together at the synapse following the installation of the synatonemal complex’s central 
element. The formation of the bouquet is spread throughout the whole zygotene stage and 
into the start of pachytene phase. Towards the middle of the pachytene phase, the 
formation of the synatonemal complex comes to an end and meiotic recombination among 
homologes is determined. At this point, the telomeres are no longer huddled together. 
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Following the dispersion of the bouquet, the cells proceed through diplotene when 
synatonemal complex dissociates and chiasmata, which holds the homologs together until 
anaphase 1, is easily visible.  During diakinesis, the chromosomes enter the final stage 
condensation and shortly after, nuclear envelope breaks down and metaphase starts 
(Harper et al., 2004). 
1.4.3 Senescence  
Leonard Hayflick and Paul Moorhead (1961) discovered that normal human fibroblasts 
possess a limited proliferative capacity, a phenomenon they called replicative senescence. 
They argued that this predetermined passive potential, later called “Hayflick limit” was 
caused by an asynchronous self-replicating mechanism, and that it forms the basis of the 
mechanism behind organismal aging. Consistent with this assumption, telomeres shorten as 
normal cells attain their passage potential, and act as mitotic clocks in modulating 
replicative senescence (Shay & Hayflick, 2000). Senescent cells are characterised by a 
perpetual cell-cycle arrest. However, unlike with replicative senescence, cells undergoing 
senescence do not require telomere deterioration; instead, they can be prompted by 
various stressors such as UV light, reactive oxygen species, excessive mitogenic signalling, 
chemotherapeutics, ionizing radiation, and distortion of chromatin structure. Through 
different signalling pathways, these inducements engage p53 or retinoblastoma protein 
(RB), or both, subject to the stressor and the level of the stress (Campisi & d’Adda di 
Fagagna, 2007). Senescent cells that have attained Hayflick limit are large and flat. 
Oftentimes, they are convoluted and multinucleated. In addition, they show a high 
frequency of nuclear abnormalities. Their telomeres have eroded lengths and display 
17 
 
characteristics dense foci of heterochromatin. When stained with acidic-galactosidase, they 
display increased acidic-galactosidase activity at a pH 6.0 and a blue precipitate. 
1.4.3.1 Senescence associated β –galactosidase activity 
Senescent cells increase with aging in different tissues and organs. This was first discovered 
in vivo by use of a pH-dependent β-galactosidase, now called Senescence-Associated-β-Gal 
(SAβ-Gal). This is enzyme activity that enables researchers to tell the difference between 
senescent cells from postmitotic and quiescent cells. The activity is detected at a pH 6.0 and 
is used in studies which evaluate the induction of senescence in cells and tissues (Itahana, 
Campisi, Dimri, 2007). Although the method is widely used, there exists conflicting data with 
regard to the status of SA-β-Gal as a senescence marker. For instance, confluent quiescent 
presenescent cells show in situ expressions of the SA-β-Gal activity. SA-β-Gal activity arises 
from increases in lysosomal mass during the aging process within cells. Fibroblasts obtained 
from patients with lysosomal disorder do not display SA-β-Gal activity. In addition, SA-β-Gal 
activity is observed in low pH in non-senescent cells that possess high lysosomal content, for 
instance in vascular smooth muscle and endothelial cells. Thus, it appears that SA-β-Gal 
activity is not a measure of senescence but a marker of lysosomal changes that occur as a 
result of senescence (Yang, 2005). 
1.4.3.2 The end replication problem 
The replication of DNA in a semi-conservative manner causes a distinct problem: the 
process only functions in a 5’ to 3’ direction, and DNA polymerase needs to bind to an RNA 
primer. Even before the discovery of the telomeres, both Olovnikov (1971) and Watson 
theorised that the consequence of this process and termed it as an end replication process. 
This occurs due to the expected loss of a small 5’ nucleotide segment during DNA synthesis, 
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followed by a replication-induced shortening of the telomeres (figure 3). While the leading 
strand is always replicated from a 5′  3′ direction following the firing of the replication 
origin, the late synthesis of the lagging strand occurs in the form of small defined Okazaki 
fragments that are 50-150 nucleotides long. DNA polymerase α/primase complex then 
synthesises a RNA-DNA primer that generates a free 3′-OH group that acts as a base for 5′ to 
3′ elongation by a DNA polymerase δ. 
The formation of a novel Okazaki fragment stops after pol δ complex touches the preceding 
Okazaki fragment. So as to yield an unbroken DNA strand, two enzymes, RNase HI and FEN1, 
eliminate the original RNA primer, fills the small gap falling between the two fragments, 
before the two matured Okazaki fragments are combined together by DNA ligase I (Waga 
and Stillman, 1998). But, at the chromosome end, the exclusion from the lagging strand of 
the RNA primer results in an unoccupied gap that ranges from a single RNA primer in size to 
a whole Okazaki fragment (10 - 150 nucleotides). As a consequence, the shortened lagging 
strand causes a steady shortening of the chromosome end during every successive 
replication cycle. 
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Figure 3: The end-replication problem. During replication process, RNA primer fragments are 
extended by DNA polymerase, (unidirectional 5’ to 3’), in order to synthesis the lagging strand, 
subsequently the RNA primer are degraded and all the gaps are ligated and filled in by DNA except 
the region at 5’end, which results in producing 3’end single-stranded overhang. (Diagram is redrawn 
from Blackburn et al., 2009). 
1.4.3.3 Telomere-dependent replicative senescence   
Various stimuli that cause DNA damage within cells can result in phenotypes that overlap 
with telomere-dependent replicative senescence. The end replication problem results in a 
gradual loss of the telomeric DNA following successive cell divisions, until very short, 
dysfunctional telomeres prompt a DNA damage response (DDR). The stimulated p53 and 
p16-pRB tumour suppressor pathways lead to a permanent growth arrest (Gire et al., 2004, 
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Takai et al., 2003). Analogous to DNA double strand breaks, there is a recruitment of DNA 
damage sensors, which includes mediator of DNA damage checkpoint 1 (MDC1), p53 
binding protein 1 (53BP1), Mre11/RAD50/NBS1 complex, and Rad17, to the chromosome 
end (d'Adda di Fagagna et al., 2003). In turn, the sensor proteins enlist Ataxia Telangiectasia 
Mutated (ATM), protein kinases and RAD3-related (ATR), to the end of the chromosome 
(Shiloh, 2006). 
In a characteristic positive feedback loop, ATR and ATM activate phosphorylation of 
heterochromatin H2AX (γH2AX) (Campisi and d'Adda di Fagagna, 2007). The 
phosphorylation of secondary kinase such as Chk1 and Chk2 causes the amplification of DNA 
damage signal (Jackson et al., 2002) that in response triggers cell division cycle 25 (CDC25) 
and p53 pathway. DNA damage response induces replicative senescence using the p53 
pathway. Nevertheless, conditional to type of the cell or species, DDR may also arrest cells 
permanently by utilizing the p16-pRB pathway (Campisi and d'Adda di Fagagna, 2007).  
1.4.3.4 Telomere-independent replicative senescence 
Replicative senescence is not just caused by telomere erosion alone, DNA damaging agents, 
oxidative stress and oncogene overexpression can trigger early replicative senescence and 
thus significantly restrict cell’s replicative lifespan (Dumont et al., 2000, Serrano et al., 
1997). Replicative senescence resulting from end replication problem can be avoided 
through ectopic expression of TERT, a catalytic protein constituent of human telomerase 
(Bodnar et al., 1998). But telomerase alone cannot stop replicative senescence resulting 
from other senescence triggers (Campisi and d'Adda di Fagagna, 2007). 
Many cell types experience senescence as a result of build-up of DNA damage (Di Leonardo 
et al., 1994, Parrinello et al., 2003). DNA damage triggered by senescence depends on p53 
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and is complemented by the manifestation of p21 (Di Leonardo et al., 1994, Herbig et al., 
2004). This forms the basis of the hypothesis that DNA damage prompting chemotherapy 
could result in senescence in tumour cells. But, tumour cells which possess functional p53 
pathways are expected to undergo senesce than those with mutated p53, particularly in 
cancer-prone mouse models (Roberson et al., 2005, Schmitt et al., 2002). 
Premature senescence is also caused by forced overexpression of active oncogenes within 
normal cells. The alteration of human cells with Ras, a transducer of mitogenic signals, leads 
to premature initiation of cellular senescence (Serrano et al., 1997). When other members 
of the Ras signalling pathway and nuclear proteins such as E2F-1 were used, comparable 
results were obtained (Zhu et al., 1998; Dimri et al., 2000). Because oncogenes such as 
member of the Ras signalling pathway induce cell growth and can motivate unmediated cell 
proliferation, then, oncogene prompted senescence could have risen as a tumour 
suppressor mechanism, in order to prevent tumourgenesis (Braig and Schmitt, 2006). 
Oncogene-induced senescence, like telomere-dependent senescence, provokes a DDR. But, 
the DDR is also active in initiation and maintenance of oncogene-induced senescence, 
because, when DDR are down regulated, cell proliferation and oncogenic transformation 
occur (Di Micco et al., 2006). 
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1.5 Telomere Maintenance Mechanisms (TMM)    
1.5.1 Telomerase 
1.5.1.1 Structure 
The initiation of telomere maintenance process is inexorable for the immortalization of 
cells.  Many cancerous cells preserve their telomeres through the activation of 
TELOMERASE, which is a ribonucleoproteic complex that adds telomeric repeats at the 
chromosome termini of cancer cells or germline cells. Telomerase was first discovered in 
Tetrahymena thermophilia (Greider and Blackburn, 1985). Over time, the activity of 
telomerase has been identified in protozoa (Zahler and Prescott, 1988), fungi (Lingner et al., 
1997) and in mammalian cells. 
Dynamic human telomerase is made up of 3 essential elements; telomerase RNA 
component (TERC), the TERC-binding protein dyskerin (DKC1) and reverse transcriptase 
telomerase (TERT). Furthermore, there are other elements, which are associated with the 
telomerase to form a holoenzyme. These are species-specific accessory proteins, which 
control biogenesis, telomerase function and cellular localization. In human cells, these 
proteins include NTPase proteins NHP2 and NOP10, ATPases potin and reptin and TCAB1 
(telomerase Cajal body protein 1) (Cohen et al., 2007). 
Dyskerin, a putative pseudouridine synthase, also distinguishes the H/ACA sequence motif. 
The motif can occur in TERC (Mitchell et al., 1999). The function of the dyskerin is to provide 
support to telomerase biogenesis and stability of the TERC (Mitchell et al., 1999). Evidence 
indicates that dyskerin, NOP10 and NHP2 are essential for the build-up and maintenance of 
TERC (Fu and Collins, 2007). In addition, Pontin binds directly with dyskerin and TERT. The 
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quantity of TERT interacting with reptin and pontin is optimum during the S phase of cell 
division, which provides proof of cell-cycle-dependent TERT regulation. Reduction of reptin 
and pontin is damages the build-up of TERT, which is an indication of the important role it 
plays in telomerase assembly (Figure4).  
               
 
 
 
 
 
 
 
          
      
                              
Figure 4: Telomerase structure. Telomerase consists of telomere reverse transcriptase (TERT), RNA 
template (TERC) and dyskerin with associated proteins (GAR, NHP2 and NOP10) (DKC1). (Figure is 
redrawn from Calado and Young, 2009). 
 
1.5.1.2 Function 
Telomerase is severely inhibited in most somatic cells apart from S-phase where it occurs in 
low activity level, and may take part in the upkeep of the telomeric overhang in typical 
human cells (Dionne and Wellinger, 1998). Unlike in normal human cells, almost all (90%) 
human cancer cells exhibit reactivation of telomerase (Broccoli et al., 1997). TERC is 
manifested in all tissues; whereas TERT expression is highly regulated (Masutomi and Hahn, 
2003). Nonetheless, telomere length and the extent of telomerase activity are not 
associated with the expression levels of either hTERT or hTERC (Swiggers et al., 2004).  
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Telomerase extends telomeres through catalysis of numerous copying rounds of its own 
RNA template. During the initial step, the RNA template of the telomere anneals to 3′ end of 
the DNA substrate. In the next phase, new nucleotides are synthesised onto the growing 
DNA substrate to the point where the template’s 5′ end is reached. In the final stage, 
telomerase moves and readjusts to the freshly produced 3′ end, and initiates another round 
of telomere synthesis (Greider and Blackburn, 1996) (Figure 5). 
 
              
 
 
Figure 5: Telomerase function. 1- (Telomerase-telomere association): the telomeric single strand 
recognised and hybridized to RNA template (hTR), subsequently 2- (Elongation step): where 
nucleotides are added by catalytic reverse transcriptase (hTERT) by copying its RNA sequences to 
extend the strand and 3- (Translocation step): where telomerase repositions then the 3’end of the 
strand are hybridised to (hTR) again and extend the strand. (Figure is reproduced from Olaussen et 
al., 2006).    
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1.5.1.3 Telomerase regulation 
Telomerase activity is highly regulated and its activity is limited to cells which extend 
proliferation potential such as the germ line cells, self-renewing stem cell, embryonic 
tissues, and skin.  In human cells, the activity of telomerase is stringently regulated during 
oncogenesis and development. TERT and the telomerase’s RNA subunit are implicated in the 
regulation of telomerase. The reduction of TCAB1 through RNA interference stops TERC 
from interacting with Cajal bodies, disturbs telomerase-telomere interaction, and repeals 
telomere production by telomerase. Therefore, TCAB1 regulates telomerase trafficking and 
is necessary for the synthesis of telomere cancerous human cells (Venteicher et al., 2009). 
1.5.2 Alternative Lengthening of Telomere (ALT) 
The Alternative Lengthening of Telomere (ALT) is a telomere length maintenance 
mechanism which does not rely on telomerase activity. The process occurs in 15% of all 
human cancers in which the activity of telomerase is not evident. In these cancers, the 
preservation of telomere length is achieved through homologous recombination and mis-
regulation of the usual telomere homeostasis (Bryan et al., 1997, Dunham et al., 2000). ALT 
cell lines and tumours are characterised by an abundance of extrachromosomal telomeric 
DNA that presents itself in the form of telomeric circles (t-circles) (Cesare and Griffith, 2004) 
(Figure 6). 
Telomeric DNA and related proteins occur in promyelocytic leukaemia nuclear bodies (PML 
nuclear bodies). PML bodies comprise of telomeric chromatin and usually occur in ALT cells, 
thus, they are sometimes called ALT-associated PML bodies (APBs) (Yeager et al., 1999). 
PML proteins are important in the accretion of p53 as a reaction to DNA damage. In 
addition, APBs encompass replicative factor A, RAD52, RAD51and the MRN complex, which 
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are all engaged in DNA recombination and synthesis (Wu et al., 2000). These APBs may 
stimulate the homologous recombination leading to ALT, even though a debate rages on the 
exact function of APBs.  
 
 
Figure 6: Recombinational Telomere Elongation (RTE) in ALT cells. A Shortened telomere invades 
another telomere and anneals with its complementary strand, that works as template and extend 
the shortened telomere, subsequently its lagging strand can be synthesis and filled in. B shortening 
telomere extends to subtelomeric repeats, that replaced by telomeric repeats (TTAGGG) by RTE 
process in ALT cells (Diagram is reproduced from Reddel, 2003).  
1.6 Telomeres and Disease 
1.6.1 Cancer  
Age is one of the greatest risk factors associated with the development of cancer, with the 
incidence rising steadily in midlife in both man and mice. A cancer cell is one that grows 
uncontrollably by disregarding signals to discontinue dividing and is incapable of recognising 
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its natural limits. The progression of cancer is said to be a somatic evolution, where certain 
mutagens lead to the production of a cell that possesses selective proliferative benefits 
(Cahill et al., 1999). It is argued that most cancers originate from stem cells which are 
capable of proliferating indefinitely.  
 The cells the facilitate carcinogenesis by homeostatic processes that manage tissue repair 
and cell self-renewal (Beachy et al., 2004, Reya et al., 2001). Telomerase negative cells have 
lost their telomeric function as a result of progressive erosion of their telomeres that arises 
in chromosomal fusion events and non-reciprocal translocations. Such cells avoid replicative 
senescence by sidestepping the pRB and p53 pathway checkpoints and thus causing the 
formation of cancer (Artandi and DePinho, 2000) (Figure7). 
The majority of cancerous cells preserve their telomeric length by the re-activation the 
telomerase enzyme or ALT pathway (Holt and Shay, 1999). The manifestation of both hTERC 
and hTERT subunits of telomerase is increased in nearly all human and mice malignant 
tumours. Thus, telomerase activity is an important pointer of consequence and 
development of cancer (Hiyama, 2002). As such, telomerase is a significant focus in the 
development of anti-cancer therapies (Keith et al., 2004).  
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Figure 7:  Telomere erosion.  A- Germ cells maintain their telomeres length over cell division by 
telomerase enzyme. B- Telomere length shortens in the somatic cells over cell division reaching to 
the critical length (Hayflick limit), when cells arrested by p53 (cellular senescence M1). If p53 
inactive, cells bypass the senescence to (crisis M2), cancer cells emerge from crisis and their 
telomere length replenished by telomerase or ALT. (Original figure using information from Diehl et 
al., 2009 and Reddel, 2003). 
1.6.2 Werner Syndrome  
Werner Syndrome (WS) also known as “adult progeria” is an erratic autosomal recessive 
syndrome that occurs as a result of mutations in the WRN gene. The disease is characterized 
by the appearance of premature aging, signified by cataracts, skin atrophy, type II diabetes, 
atherosclerosis, soft tissue calcifications and osteoporosis (Martin, 1982). Furthermore, the 
disease is linked to genomic instability and an early cancer onset (Davis and Kipling, 2009). 
In individuals with the disease, over 90% of all WS cells display premature senescence 
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(Tollefsbol and Cohen, 1984). WS cells have a tendency to developing chromosomal 
rearrangements such as inversions, translocations, and deletion (Salk, 1982). They also show 
a higher incidence of chromosomal deletions (Fukuchi et al., 1989).  
1.6.3 Bloom’s Syndrome 
Bloom’s syndrome (BS) is an inherited disorder and is characterized by short stature, sun 
sensitive telangiectasia skin, compromised immune response and a higher risk of developing 
cancer (Bloom, 1954). The disease is caused by mutations in the BLM gene which provides 
the instructions for synthesizing proteins called RecQ helicases. Helicases are enzymes 
which interact with DNA and help the DNA’s unwind the two spiral strands. This event is 
crucial in DNA replication, repair and cell division. BS patients have increased levels of Sister 
Chromatid Exchange (SCE) following treatment with DNA damaging agents (German et al., 
1977). At homologous sites, there are symmetrical quadriradials, which are chromosomal 
re-arrangements among homologous chromosomes (German et al., 1965). A RecQ ATP-
dependent DNA helicase is the affected protein in BS (Ellis et al., 1995). BLM helicase is 
essential in Holliday branch migration, homologous recombination and stability of the 
genome (Wu et al., 2001). POT1 induces both WRN and BLM to relax D-loop structures and 
long telomeric duplexes. 
1.6.4 Dyskeratosis Congenita 
Dyskeratosis Congenita (DC) is congenital disorder which affects many parts of the body. It is 
characterised by fingernails and toenails dystrophy, changes in skin pigmentation and bone 
marrow failure (Marrone and Mason, 2003). There are two different types of the disease; X-
linked recessive Dyskeratosis Congenita and autosomal dominant Dyskeratosis Congenita. 
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The X-linked DC is associated with mutations of the DKC1 gene at Xq28.  Dyskerin, the 
encoded protein, interacts with a sub group of small nucleolar RNAs and TERC (Mitchell et 
al., 1999). The autosomal dominant Dyskeratosis Congenita occurs as a result of mutations 
in TERC itself (Vulliamy et al., 2001). Both forms of dyskeratosis congenital are characterised 
by undersized dysfunctional telomeres. 
1.6.5 Ataxia Telangiectasia (AT) 
This is a rare inherited disease that affects the immune system, nervous system, and related 
body systems. The disorder is characterised by progressive challenges in controlling 
movements (ataxia) and starts as early as 5 years of age. Ataxia Telangiectasia occurs as 
consequence of mutations in the ataxia telangiectasia mutated ATM gene found on 
chromosome 11q22 (Savitsky et al., 1995). The ATM kinase plays an important role in DNA 
damage response, mitogenic signal transduction and cell cycle control (Hoekstra, 1997).  
Patients of AT seems to have augmented telomere erosion and an increased number of 
chromosomal fusions (Metcalfe et al., 1996). 
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1.7 DNA repair mechanisms 
DNA double strand breaks (DBSs) and single-strand breaks (SSBs) occur continuously in cells 
and are primarily caused by ionizing radiation, ultraviolet light, reactive oxygen species ROS, 
errors during DNA replication, and enzymes during meiosis. The repair of these DSBs and 
SSBs is essential to maintain genomic fidelity and stability. In order to combat DBSs and 
SSBs, cells have developed multiple distinct DNA repair mechanisms which detect damaged 
DNA, signal its presence and promote the repair of the damage (Jackson and Bartek, 2009). 
One of these mechanisms is base excision repair (BER). BER is a multi-step process that 
corrects non-bulky damage to bases resulting from oxidation, methylation, deamination, or 
spontaneous loss of the DNA base itself. In BER, DNA glycosylase recognises the damaged 
base and mediates base removal before proliferating cell nuclear antigen (PCNA), 
polymerase β and DNA ligase I or DNA Ligase III complete the repair process (Jackson and 
Bartek, 2009, David et al., 2007). Nucleotide excision repair (NER) is perhaps the most 
flexible of the DNA repair pathways. NER recognizes and repairs lesions which are caused by 
helical distortion of the DNA duplex and pyrimidine dimers (cyclobutane pyrimidine dimers 
and 6-4 photoproducts) which are caused by the UV component of sunlight. Other NER 
substrates include bulky chemical adducts, DNA intrastrand crosslinks, and some forms of 
oxidative damage. Two distinct NER pathways exist: transcription-coupled NER which 
focuses on lesion blocking transcriptions and global genome NER which surveys the entire 
genome for distorting damage (Jackson and Bartek, 2009, David et al., 2007). DNA mismatch 
repair (MMR) pathway plays an essential role in the correction of replication mistakes such 
as base-base mismatches resulting from errors of DNA polymerases which escaped the 
proof reading function and insertion/deletion loops caused by template slippage. In 
eukaryotes, DSBs are repaired by either homologous recombination (HR) or non-
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homologous end joining (NHEJ). Both pathways require the MRN complex to bind to 
unprocessed DNA breaks, tethering the ends and aligning them for DSB repair (Williams et 
al., 2008). The error-free HR is limited to late S and G2 phase and utilises homologous 
repeat sequences like the sister chromatids to repair DNA damage. NHEJ-mediated DNA 
repair is relatively error-prone and is composed of two distinct pathways termed classic 
NHEJ (C-NHEJ) and alternative NHEJ (A-NHEJ). C-NHEJ can be observed throughout the cell 
cycle and is dependent on Ku70/80 and DNA Ligase IV/XRCC4. In contrast, A-NHEJ is 
associated with G2 phase and requires PARP1 and DNA ligase III/XRCC1 or DNA ligase I 
(Weterings and Chen, 2008).  
1.7.1 Homologous Recombination (HR)  
DNA repair by Homologous recombination (HR) occurs in all life forms and is important in 
the repair of damaged chromosomes which avoids termination of broken replication forks, 
and for several other aspects of chromosome maintenance.  HR is responsible for genome 
integrity, but ought to be regulated to prevent deleterious events in DNA which may lead to 
diseases like breast and ovarian cancer, Bloom’s syndrome and Fanconi anaemia (Hunters, 
2007). In addition HR plays a prominent role in faithfully duplicating the genome by 
providing critical support for DNA replication and telomere maintenance (Li and Heyer, 
2008). DNA replication involves the separation of homologous chromosomes in meiosis.  
Programmed DNA double-strand breaks (DSBs) that occur in meiosis are thought to 
stimulate HR. Recombination also occurs in response to unscheduled DSBs and other DNA 
lesions and is restricted to the S and G2 phase of the cell cycle (Hartlerode and Scully, 2009). 
Certain types of DNA damage pose a strong impediment to the DNA-replication machinery, 
33 
 
and recombination of a damaged DNA with its sister chromatid re-establishes the DNA 
replication fork (Li and Heyer, 2008). 
After the DSB formation, the DNA ends are processed by nucleolytic resection to give single-
strand tails with free 3′-OH ends. These ends become the substrate for the HR protein 
machinery in order to form the recombinase filament on the single stranded DNA end. After 
a successful homology search, strand invasion occurs to form a nascent D-loop 
intermediate. DNA polymerase synthesizes new DNA and thereby extents from the 3′ end of 
the invading strand. The second DSB is captured to form a D-loop intermediate, which 
contains two crossed strands or Holliday junctions. The reaction is completed by gap-filling 
DNA synthesis and ligation. Finally Holliday junctions are resolved to give a crossover and 
non-crossover product (Weterings and Chen, 2008, Rass et al., 2010). 
1.7.2 Non homologous end joining (NHEJ) 
The core elements in mammalian classic NHEJ are the heterodimer Ku70/80, the catalytic 
subunit of DNA-dependent protein kinase (DNA-Pkcs), and the DNA Ligase IV – XRCC4 
complex. C-NHEJ is initiated by the binding of the Ku70/80 heterodimer to two broken ends 
of the DSB. The two Ku heterodimers are presumed to provide a scaffold for the members 
of C-NHEJ and thereby allowing the modification of both DNA ends in preparation for 
joining. The two Ku proteins in turn recruit DNA-PKcs, thus linking the two DNA ends and 
thereby forming the active DNA-PK complex. Active DNA-PK interacts with different 
nucleases and polymerases and starts DNA processing by phosphorylating several proteins 
including Ku and itself. In a final step, the DNA ligase IV/XRCC4 complex is recruited, further 
stabilising the broken DNA ends and finally mediating the rejoining of the modified break 
side.  
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1.8 Oxidative damage 
The large proportions of guanines in telomeres are considered to cause sensitivity to 
damage by oxidative stress.  Moreover, nucleobase damage due to oxidation has been 
shown to increase in the life a cell or an organism, causing high chances of senescence. 
Senescent cells are characterized by 30% more oxidized guanine in their DNA and presence 
of four times free 8-oxodG bases (8-oxo-deoxyguanosine) (Nasir et al., 2014). In addition, 
there is production of single-strand breaks by oxygen free radicals and ROS, especially 
hydroxyl radicals cause oxidative base changes. 
The causing features for oxidative stress may be many, starting with inheritance or genetic 
problems or environmental changes to pure stochastic happenings such as metabolic 
problems.  
The effects of Reactive Oxygen Species are counteracted by a variety of antioxidants, by 
both enzymatic and non-enzymatic mechanisms. Oxidative stress is considered to be the 
result of an imbalance of ROS and antioxidants where by the effects of ROS are more 
powerful than the compensatory ability of antioxidants. In the case of mitochondrial-
derived ROS, superoxide is the first radical produced (Loft and Polsen, 1996). Because the 
main site of superoxide production is the inner mitochondrial membrane, the mitochondrial 
DNA (mtDNA) has been thought to be a major target for ROS damage. Hydrogen peroxide is 
another mitochondrially derived ROS which arises from superoxide detoxification by 
manganese superoxide dismutase (MnSOD) (Loft and Polsen, 1996). Although H202 lacks 
free electrons, its role in ROS-mediated damage is extremely important.  H2O2 is used as a 
substrate in many biochemical and abnormal chemical pathways. Because of its small size 
and relatively high reactivity, compared to the rest of the ROS, H2O2 is able to diffuse fast 
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cross several cells and cause toxic effects far from the site of its production (Ames, 1989) 
Mitochondria do not contain catalase, hence their only defence against toxic properties of 
H2O2 is glutathione peroxidise (GSPx) which requires reduced glutathione (GSH) as a 
cofactor and which acts H2O2 converting it to water hence detoxifying ROS. The in the 
presence of reduced transition metals, H2O2 can produce the  reactive hydroxyl ions which 
may cause  extensive damage to DNA, proteins, and lipids  as argued by Loft et al., (1992). 
1.8.1 Reactive oxygen species ROS ‘Mitochondria’ 
In Mitochondria there are numerous oxidative pathways. Mitochondria are crowded with 
various redox carriers that can potentially liberate electrons to oxygen and change it into 
superoxide anion which is a Reactive oxygen species (ROS). Mitochondria are unique 
organelles, as they are the main site of oxygen metabolism and most of the oxygen 
produced in the cell is used by Mitochondria. Release of free electrons due to partial use of 
oxygen will result in the formation of free radicals. Mitochondria continuously metabolize 
oxygen leading to production of reactive oxygen species (ROS) as a by product (Ames, 1989). 
Mitochondria have their own their own ROS scavenging mechanisms required for cell 
survival. It has been shown, however, that mitochondria produce ROS faster than their 
scavenging capacity. By products of incomplete oxygen metabolism are superoxide ions, 
hydrogen peroxide, and hydroxyl radical. These reactions usually occur at specific sites of 
the electron transport chain (ETC), in the inner mitochondrial membrane (Chandel et al., 
1998).  ETC complexes I (NADH dehydrogenase) and III (ubisemiquinone) produce most of 
the superoxide which is then acted upon by the mitochondrial enzyme manganese 
superoxide dismutase (MnSOD) to produce H2O2 (Chandel et al. 1998). Other important 
free radical includes nitric oxide (NO) and peroxynitrite (ONOO−). Nitric oxide has also been 
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involved in ROS mediated damage (Turrens, 2003). It may be involved in inflammatory, 
eurodegenerative, and cardiovascular pathological processes. Nitric Oxide (NO) can regulate 
aerobic respiration by reversible inhibition of cytochrome c oxidase. NO short half-life and 
the ability to diffuse any cell that produces excess NO may inhibit its own respiration and 
respiration of surrounding cells, which may lead to the cytotoxic effects of NO. Peroxynitrite 
is a highly damaging agent with many targets and harmful cellular effects. ONOO− changes 
proteins by nitrating tyrosine residues, forming dityrosine, and oxidizing tryptophan and 
cysteine. Main mitochondrial targets of peroxynitrite are complexes I, II, IV and V, aconitase, 
creatine kinase, superoxide dismutase. Recent findings have shown that mitochondria has 
its own nitric oxide synthase and can release endogenous NO and ONOO− (Chandel et al., 
1998; Turren, 2003). 
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1.9 G-quadruplex formation 
G-quadruplexes are secondary structures which are formed in guanine-rich DNA sequences. 
Two or more guanine tetrads in DNA can stack upon each other forming a four-stranded 
structure known as G-quadruplexes (Blackburn, 1991). Sequences that exhibit G-quadruplex 
formation motifs are extensively found in eukaryotic genomes. However there is no 
evidence to support the occurrence of such motifs in prokaryotes. Telomeres can form G-
quadruplex structure with its guanine-rich sequences (Blackburn, 1994). Similarly 
immunoglobulin switch regions, promoter regions of c-myc and other oncogenes, 
retinoblastoma susceptibility gene are also known to possess elements responsible for the 
formation of G-quadruplex structures (Sen and Gilbert, 1990; Simonsson et al., 2002).  
1.9.1 Structure of G-quadruplex 
G-quadruplex consists of two parallel strands and have four thymine loops which lie 
diagonally at the top and bottom of the G-quadruplex structure. Guanine bases are held in 
G-quadruplex by hydrogen bonds. The guanine glycosidic angles show alternating pattern 
along the strands of G-quadruplex. In the two ends of the G-quadruplex structure, one 
guanine base is tilted more compared to the others to increase the stack with the thymine 
loop. The four grooves have water bridges which link to phosphate groups with amino group 
of guanine to increase its strength and stability (Haider et al., 2003; Han and Hurley, 2000) 
(Figure 8).    
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Figure 8: (A) G-quadruplex structure (Leonetti et al., 2004) 
1.9.2 G4 ligands  
A group of small ligands show ability to stabilize G-quadruplex structure. These ligands all 
contain pronounced planar aromatic electron deficient chromophores. Example of these 
ligands include: di-substituted aminoalkylamido acridine, pentacyclic acridine (RHPS4) 
(Figure 9), potassium ions, small molecules and proteins besides others.  RAPI is a protein 
produced by Saccharomyces cerevisiae which is known to bind to G-quadruplex while Gq1 is 
an artificially derived protein which as acts as a G-quadruplex ligand. Many of the features 
of both ligand-bound quadruplex and native quadruplex structure are shared, but the ligand 
will induce some conformation changes in quadruplex structure (Haider et al., 2003).  
 
                                                        
Figure 9: RHPS4 structure (G4 ligand) (Leonetti et al., 2004). 
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1.10 Telomeres and Fragile sites 
1.10.1 Fragile sites 
Fragile sites are heritable chromosome loci that have high frequency of gaps, constrictions 
or breaks when chromosomes are exposed to partial DNA replication inhibition (Sfeir et al., 
1999). They are found in areas of chromatin which fail to compact in mitosis. They can 
either be common or rare based on their frequency in the population. They are divided 
further depending on the basis of their specific induction chemistry into various groups. 
Example of fragile sites inducers include: Andaphidicolin,  bromodeoxyuridine and  5-
azacytidine(Sutherland et al, 1998).  Most of the known inducers of fragility share in 
common their capability to slow down DNA replication notably in the fragile sites. 
1.10.2 Telomeres considered as fragile site  
Expression of fragile sites shows a genetic instability at specific sites on the chromosomes 
and may lead to chromosome breakage and unwanted recombination events. The telomere 
repeat sequence present in eukaryotic cells  also found in non-telomeric sites called 
intrachromosomal telomeric sequences (ITSs)(Coquelle et al., 1997) which are said to be 
remnants of ancestral chromosome arrangements (Finato et al., 2000). Of late it has been 
argued that telomeres are similar to fragile sites, and shelterin, specifically TRF1, is essential 
for preventing telomere breakage that is associated with replication fork stalling at 
telomeres. Since fragile sites are susceptible to breakage, it is expected that on oncogenic 
signaling telomeres are potential sites of which trigger genome instability. Oncogenic 
signaling telomeres have been shown to be involved in the in vivo occurrence of 
duplications or other chromosomal changes related to human congenital diseases (Coquelle 
et al., 1997). Hence there is evidence that these loci are concerned in the in vivo 
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chromosomal rearrangements observed in tumour cells. Fragile sites have been shown to 
colocalize with breakpoints leading to deletions and translocations in various tumours. 
Understanding fragile sites is thus vital for the management of a series of human diseases 
(Ruiz-Herrera et al., 2004).  
1.10.3 Replication fork stalling 
Maintaining replication fork integrity is important to conserve genomic stability and avoid 
serious genetic diseases. DNA damage and distorted nucleotide or proteins indicate 
replication challenges. Various cellular responses have emerged to make sure that there is 
successful DNA replication despite various obstacles. Comprehending such responses is vital 
to prevent genetic diseases notably cancer (Mirkin and Mirkin, 2007).  Re-priming is a 
mechanism which makes it possible for DNA replication to resume past a fork-stalling lesion. 
This explains why gaps are formed during DNA replication on injured DNA. The break left 
behind a re-primed fork must be stabilized to keep off replication fall down.  In bacterial 
cells, replication forks often come across damaged DNA template and this inactivates the 
DNA replication process. Replication forks are occasionally inactivated under growth 
conditions. The replication forks initiating at the bacterial origin, oriC, encounter damage 
under normal growth conditions along the way and which inactivate the replication forks 
which prompts for re-priming (Torres at al.,2004). 
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1.11 Telomere Length Analysis 
 1.11.1 Terminal Restriction fragment (TRF) analysis 
TRF method used to determine telomere length utilizes Southern blotting technique to 
analyse terminal restriction fragments (TRF) obtained following the digestion of genomic 
DNA with restriction enzymes such as; HinfI and RsaI. The resulting TRFs usually contain 
DNA with telomeric (TTAGGG) repeats and other degenerate DNA repeats (Dunburn et al., 
2000). After digestion, the DNA fragments are separated by gel electrophoresis and then 
subjected to southern blotting. TRFs are visualized directly or indirectly by hybridization 
with labelled oligonucleotides corresponding to the TTAGGG repeat sequence. Size 
distribution of the TRFs is then compared to a standard DNA strand of known length 
(Dunburn et al., 2000).  
TRF analysis has been viewed as fast, reliable and broadly applicable to different type of 
tissues (Kitts, 2001). Despite its advantages, TRF method has disadvantages; it requires large 
numbers of cells, which is difficult to achieve within senescent cells. As TRF is a hybridisation 
based technique, very short telomere will produce lower hybridisation signal that might be 
undetectable.  
1.11.2 Quantitative fluorescence in situ hybridization (Q-FISH) 
Fluorescence In Situ Hybridization is a method involving microscopy observation of specific 
hybridized DNA. FISH is based on the hybridization of labeled nucleic acid probes to 
metaphase chromosome preparation which can be detected via fluorescence microscopy. 
Besides, the FISH procedure can be done in a short period of time which allows rapid in situ 
analysis (Amann and Fuchs, 2008; Justé et al., 2008). Peptide Nucleic Acid (PNA) (CCCTAA) 
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probes is frequently used in Quantitative FISH for individual telomeres which are highly 
specific to complementary sequences chromosomes.    
Q-FISH technique quantifies the telomere length and telomere lengths are measured as 
Telomere Fluorescent Units (TFU). TFU is measured and translated to value number by (TFL-
TELO) computer program software. However, the translation of TFU accurately into 
telomere length is difficult. Moreover, as TRF is a hybridisation based technique, very short 
telomere might be undetectable. Q-FISH requires metaphase chromosomes which is a 
problematic in senescent cells. However, Q-FISH has been highly successfully used in many 
different research fields. 
1.11.3 Flow FISH 
It is another method for determining the lengths of telomeres. Flow FISH is adapted from Q-
FISH which uses interphase telomere FISH with flow cytometry and its procedure as 
following; cell separation, denaturation, hybridization to probe, washing and flow cytometry 
analysis. Telomere lengths are measured and assessed by the multicolor produced by flow 
FISH. Flow FISH is able to detect telomere length in cycling and non-cycling cell of 
metaphase. Moreover, flow FISH is used to measure telomere length as prognostic tool for 
hematopoietic stems cells diseases. However, it is required high level of florescence to 
analyse and detect telomere length which is difficult to achieve in senescent cells (Lansdorp, 
1996).  
1.11.4. Quantitative PCR  
Quantitative PCR (qPCR) involves primers labeled with a fluorescent dye and a quencher, 
designed such in a way that reduce the formation of dimers. One of the most common 
techniques for measuring telomere length by means of qPCR is Cawthon’s method 
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(Telomere/Single Copy Gene ratio also known as T/S method) (Cawthon, 2002). This method 
measures the how the ratio of the TTAGGG telomere repeat copy number to single-gene 
copy number varies between the sample tested and a control sample. Cawthon method 
relies on the evaluation of the kinetics of the amplification of a telomere fragment and a 
single-copy gene fragment so as to come up with a telomere/single-copy gene ratio. Sample 
tested is then compared to the standard control sample whose length is known. The 
number of telomere repeats in the sample tested is calculated using the level of dilution of 
the control DNA that would make the number of cycles of PCR required to produce a given 
amount of telomere PCR product from the sample tested comparable to the number of 
cycles needed to come up with the same amount of telomere product from the control 
sample. Other variations of the qPCR method for measuring telomere length use internal 
oligomer standards with known number of telomere repeats sequences to avoid relative 
quantification by comparison with a control of known length (Cawthon et al., 2003). Q-PCR 
is often used for measurement of telomere length since it demands relatively small amounts 
of DNA. Moreover, Q-PCR is rapid and high-throughput. However, since PCR is sensitive 
technique, the qPCR method for measurement of telomere length has a danger of 
contamination among samples and this may produce biased results. In addition, due to the 
nature of PCR, shorter telomeres are preferentially amplified whereas larger fragments may 
not be amplified to the point of visualized. Furthermore, the exact shorter telomere length 
may be hard to estimate as this method provides no information on telomere length 
distribution.  
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1.11.5 Single Telomere Length Analysis (STELA)  
STELA was invented and developed to overcome the limitations of other telomere 
determination techniques. High quality resolution, the accuracy and sensitivity of analysis 
telomere length and the applicability to numerous cell and different type of tissue samples; 
those are STELA technique advantages. 
STELA is a long-range single-molecule PCR technique that determines the length of the 
telomeric repeats from specific chromosome ends (Baird, 2005). STELA utilises a linker 
‘Telorette’ that contains TTAGGG sequences followed by 20 nucleotides of non-
complimentary tail that ligates to the 5’end of the C-rich telomeric strand. Teltail primer is 
the second requirement, which is annealed to the 20 nucleotides of non-complimentary tail 
of telorette. A third requirement is chromosome specific upstream primer, is located in the 
subtelomeric region. By all three requirements, STELA PCR can be performed across the 
double-straded telomere repeat region (Figure10).  
In each STELA PCR reaction, DNA is diluted to 4-10 amplifiable molecules to detect single 
telomere length accurately.  PCR products are resolved by agarose gel electrophoresis and 
detected by southern hybridisation with a telomere repeat probe.  
The end of chromosome XpYp was the first telomere analysed by STELA. STELA has since 
been further developed and designed to be able to analyse other chromosomes ends such 
as; 2p, 9p, 11q, 12q, 16q, 17p and 18q (Britt-compton et al., 2006). STELA has facilitated and 
demonstrated detailed of telomere loss through the process of the end replication problem. 
Furthermore, by its sensitivity and ability to detect extremely short telomere, STELA has 
defined a new mean senescent telomere length of 1Kb, when telomere has eroded and 
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become dysfunctional, whereas 4 Kb was the previous telomere length threshold described 
by TRF method (Baird et al., 2003).  
In STELA, primers have been designed to extensive sequence polymorphisms in telomere 
adjacent of the chromosomes, which makes STELA limited to that primers sequence 
designed. Technique demands high quality DNA sample, is unlikely to be applicable to 
egraded or fixed samples (Baird, 2005).  
 
 
Figure 10: STELA method. Telorette ligates to the 5’end of the C-rich telomeric strand, then 
teltail anneales to the 20 nucleotides of non-complimentary tail of telorette. Together 
telorette, teltail with telomere specific primers designed within subtelomeric sequence are 
making telomere amplification. (Baird et al., 2003)   
1.12 This work 
Short dysfunctional telomeres are capable of fusion to other chromosome ends; this can 
lead to genomic instability that may drive tumour progression. As a consequence of end-
replication losses, telomeres undergo gradual erosion with ongoing cell division. However 
this erosion is superimposed by large-scale telomeric deletion events. These deletions were 
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not consistent with end replication losses, but instead must arise via as yet unknown 
additional mutational mechanisms. These events have been detected in normal human cells 
and tissues (Figure 11).  
Our hypothesis that oxidative damage, replication fork stalling and G-quadruplex structures 
at telomeric DNA could act as mutational mechanisms that may participate in the induction 
of large scale telomeric deletion and dysfunction.  
The triplet guanines within telomeric repeats (TTAGGG) make telomeres more susceptible 
to oxidative damage and oxidative guanine damage may be induced preferentially in 
telomeres (Rhee et al., 2011); thus oxidative stress is one hypothesised mutational 
mechanism that may result in deletion. 
Moreover, telomeres have been described as fragile sites, which may arise due to the 
inability of DNA polymerases to replicate telomere repeat sequences resulting in replication 
fork stalling. Consequently polymerase dissociation from DNA and the cessation of 
replication, may result in telomeres that are not fully replicated and may cause telomeric 
deletion.        
Furthermore, telomeric strands tend to form G-quadruplex structures, these structures are 
difficult to resolve. Replication fork stalling and resolution as a double-stranded DNA breaks 
may result in telomeric mutation.  
In this study will investigate these putative mutational mechanisms that may underlie 
telomeric deletion, using STELA technique, due to its ability to detect the extremely short 
telomeres of the length at which both senescence can be triggered and telomere fusion can 
occur.  
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Figure 11: STELA reveals gradual telomere erosion with on-going cell division, superimposed 
by stochastic deletion events (arrowed) (taken from Baird et al Nat Genet. 2003) 
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Chapter 2 
Materials and Methods 
2.1 Chemicals and Reagents   
Chemicals and reagents used in the experiments were obtained from: Fisher Scientific, 
Thermo Scientific, Bio-Rad, Abcam, Sigma-Aldrich, Roche, Amersham Biosciences/GE 
healthcare, Invitrogen, Applied Biosystems, and New England Biolabs. Table 2.1 showed 
drugs used during study. 
Drug Formula  Molecular Weight  Product No. 
Hydrogen Peroxides  H₂O₂ 34.01g/mol 216763Sigma-Aldrich 
Aphidicolin (APH) C₂ₒH₃₄O₄ 338.48g/mol A0781 Sigma-Aldrich 
Hydroxyurea (HU) CH₄N₂O₂ 76.05g/mol H8627 Sigma-Aldrich 
RHPS4 CH₃OSO₃ 458.48g/mol Sigma-Aldrich 
Table2.1: Drugs used during study     
2.2 Plastic Labware 
Plastic and glassware were obtained from Becton Dickson labware, Gilson, thermo Electron 
Corporation and Eppendorf. 
2.3 Equipment 
Specialised equipment was from Bio-Rad, MJ research, MSE, Limited, Hybaid, Bioquell Ltd, 
DJB Labcare Ltd/Heraeus, Labcold, Patterson scientific, GRANT instruments Ltd, Thermo 
electron corporation, Amersham Biosciences, IBS integrated biosciences, Molecular 
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dynamics, Qiagen and scientific laboratory supplies Ltd. Microscopes were supplied by 
Olympus UK Ltd.       
2.4 Oligonucleotides 
Primers were designed based on human DNA sequences obtained from H. Reithman at 
Wistar institute and the national centre for Biotechnology information (NCBI). They were 
synthesised by MWG-Biotech AG (Ebersberg, Germany). Table 2.2 showed all primers were 
used in this project. 
1- STELA Primers 
Telorette2  5′-TGCTCCGTGCATCTGGCATCTAACCCT-3′ 
Teltail 5′-TGCTCCGTGCATCTGGCATC-3′ 
XpYpE2 5′-TTGTCTCAGGGTCCTAGTG-3′ (406 bp) 
17pseqrev1 5′-GAATCCACGGATTGCTTTGTGTAC-3′ (311bp) 
2- Fusion Assay Primers  
XpYpM 5′-ACCAGGTTTTCCAGTGTGTT-3′ 
17p6 5′-GGCTGAACTATAGCCTCTGC-3′ 
21q1 5′-CTTGGTGTCGAGAGAGGTAG-3′ 
3- Fusion Reamplification Primers 
17p7 5′-CCTGGCATGGTATTGACATG-3′ 
21qseq1 5′-TGGTCTTATACACTGTGTTC-3′ 
XpYpO 5′-CCTGTAACGCTGTTAGGTAC-3′ 
Table 2.2: Oligonucleotide sequences used during study.  
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2.5 Cell Culture  
2.5.1 Cells  
IMR90, MRC5 and Seckel cells human diploid fibroblasts were obtained from Coriell Cell 
Repository (Institute for Medical Research, Camden, New Jersey, USA). U138 cells and HeLa 
cells were obtained from Prof. Paul Smith (school of Medicine, Cardiff University). Ntera 
cells were obtained from Prof. Peter Andrews (Department of Biomedical Science, The 
University of Sheffield). For further details see table 2.3.   
Name / ID IMR90 MRC5 SCK U138 Hela Ntera 
Description   Seckel 
Syndrome 
(ATR-) 
glioblastoma Cervix 
carcinoma 
embryonal 
carcinoma of the 
testis 
Cell Type fibroblast fibroblast fibroblast glioblastoma epithelial epithelial 
Tissue Type Lung Lung Skin brain cervix Testis (lung 
metastasis) 
Species Homo  
sapiens 
Homo  
sapiens 
Homo  
sapiens 
Homo  
sapiens 
Homo 
 sapiens 
Homo  
sapiens 
Age 16 weeks 14 weeks 6 years 47 years 31 years 22years 
Sex female male male male female male 
Race Caucasian Caucasian Indian Caucasian Black Caucasian 
 Table 2.3 Cell lines used in this study 
2.5.2 Medium 
IMR90, MRC5, U138 and Seckel (SCK) cells were cultured in Eagle’s minimum essential 
medium (EMEM, Invitrogen) supplemented with Earle’s salts containing Sodium Bicarbonate 
(7.5% solution, Gibco), 2x nonessential amino acids (Sigma), 10% (v/v) fetal calf serum 
(Autogenbioclear), 25mM HEPES Buffer, 1x10⁵ U/l penicillin, 100 mg/l streptomycin and 2 
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mM L-Glutamine (all Sigma). In SCK cells, 1X vitamins were added to medium. Hela cells 
were cultured in Dulbecco’s Modified Eagle’s Medium DMEM (Invitrogen) with 1x10⁵ U/l 
penicillin, 100 mg/l streptomycin and 2 mM L-Glutamine (all Sigma) and 10% (v/v) fetal calf 
serum (Autogenbioclear). Ntera cells were cultured in Dulbecco’s Modified Eagle’s Medium 
DMEM (Gibco) containing 4.5 g/L glucose with 10% Foetal Bovine Serum (FBS), 2mM L-
Glutamine and Pen/Strep (1x 105 U/l penicillin, 100 mg/l streptomycin). Cells were 
incubated in 5% Co₂ at 37 °C and medium was changed every 2-3 days and cells were 
passaged when ~80% confluence was reached.  
2.5.3 Seeding and Passage  
Medium were removed from flask and cells were washed once with fresh trypsin (0.05% 
trypsin and 0.2% EDTA (Gibco)) to remove all remaining serum. An appropriate volume of 
pre-warmed trypsin was added to the flask and cells were incubated at 37 °C for 5 minutes 
or until the cells were detached. Fresh medium was added to stop trypsiniation and cells 
suspension was transferred into a 15ml falcon tube. For re-plating sufficient numbers of 
cells and fresh medium were added to a new flask or well. Cells were passed at different 
densities adjusting according to the shape and type of cells and size of the dish or flask were 
used. 
2.5.4 Counting Cells and Population Doublings Calculations 
To monitor population doublings (PDs) of the cells, cells were counted at every passage with 
haemocytometer (Improved Neubauer, Hawksley). Total cell number was calculated as 
follow: number of counted cells × 10⁴ × volume of cell suspension (in mL)  
Population doublings (PDs) then could be calculated as follow;  
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PD = [Log (total cell number) - log (seeded cell number)]/Log2 
2.5.5 Cell Freezing  
Cells were frequently frozen to enable the cells to re-grown and works as a back-up for 
further experiments or in case of infection or contamination of the original cell culture. For 
freezing; cells were centrifuged and re-suspended in 0.5ml of medium and equal amount of 
freezing mixture (1:4 dimethyl- sulphoxide (DMSO, Sigma); foetal calf serum). The 
suspension then transferred to freezing ampoule and stored at (-80 °C) for short term 
storage or in liquid nitrogen (-196 °C) for long term storage, in a freezing box containing 
isopropanol. This method facilitates gradual freezing and reduces the ice damage of the cells 
by preventing ice crystal formation in the cells.   
2.5.6 Cell Thawing  
Ampoules of cell suspensions was removed from the -80°C freezer or from liquid nitrogen 
and thawed quickly in water bath (Grant) at 37°C to prevent ice crystal formation. Thawed 
cell suspension was transferred to 15ml falcon tube and 9ml of fresh medium was added 
drop wise to avoid the damage through osmotic shock. The falcon tube of the cell 
suspension was centrifuged at 1000 rpm for 5 minutes and supernatant was removed and 
an appropriate volume of fresh medium was added for re-plating. 
2.5.7 Senescence Assay  
Senescent cells were measured by using Senescence Detection Kit (Abcam). Cells were 
cultured overnight in a 12- well plate then, medium was removed and the cells were washed 
once with 1xPBS. Culture was fixed with fixative solution for 15 minutes at room 
temperature. Fixative solution was removed and culture washed twice with 1xPBS. Cells 
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were stained overnight at 37°C with staining solution mix (staining solution, staining 
supplement and X-gal in dimethyl-sulphoxide DMSO (1mg/ml)). Percentage of senescent 
cells was calculated by counting number of blue staining cells in a total cell number of 500.  
Percentage of senescent cells (%) = (number of stained cells / total number of cells) x 100. 
2.5.8 Cell Cycle Analysis Using Propidium Iodide (PI) 
Harvested cells were washed twice in (PBS + 0.1% BSA) buffer and 1x10⁶cell/ml was re-
suspended in buffer. 1ml of 70% cold ethanol was added as drop wise while vortexing to 
avoid cell loss or clumping. Cells were fixed for at least one hour at -20°C or several days 
prior to PI staining. Fixed cells were washed in PBS and then centrifuged at 12000 rpm for 5 
minutes. 0.5ml of PI staining solution (50µg/ml PI in PBS) and 50µl of RNase A were added 
to cell pellet and were mixed well and incubated for one hour at 4°C. Then the sample was 
analysed by flow cytometry (BD Bioscience accuri c6 flow cytometer) and cells in the 
different phases of cell cycle was determined by flow cytometry.      
2.5.9 Apoptosis Analysis  
Annexin V Staining kit from (eBioscience) was used. 10X binding buffer was diluted to 1X 
using distilled water. Cells were washed once in PBS, then once in 1x binding buffer. Cells 
were resuspended in 1x binding buffer at 1-5x10⁶/ml. 5µl of fluorochrome-conjugated 
Annexin V was added to 100µl of cell suspension and then were incubated at room 
temperature for 10-15 minutes. Suspension were washed in 1x binding buffer and 
resuspended in 200µl of 1x binding buffer and then 5µl of Propidium Iodide (PI) staining 
solution was added to suspension. Suspension were incubated at 4°C for 2 hours and then  
apoptotic cells fractions were analysed and determined by flow cytometry.     
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2.5.10 Metaphase Spread Analysis 
Cultured cells were incubated one hour to two hours in regular medium with 0.1µg/ml 
demecolcin (colcemid solution from Sigma-Aldrich). Cells were checked under microscope 
rounded and refractile cells with blebby membrane were seen as effects of colcemid. Cells 
were harvested and trypsinised and collected in conical tube and centrifuged at 1000 rpm 
for 5 minutes. Supernatant was removed following centrifugation, pellet was resuspended 
in 5ml of (0.075M KCl pre-warmed to 37°C), and incubated for 10-30 minutes at 37°C, in this 
step cells were swollen. Suspension was centrifuged at 1000 rpm for 5 minutes. Supernatant 
was removed following centrifugation, pellet was resuspended again in small volume of KCl. 
1ml of fixative solution (3:1 methanol and glacial acetic acid) was added as drop wise, 
suspension was kept overnight at 4°C. Slides (Fisher Scientific) were prepared and placed in 
cold water. The hot block was set to 70°C and wet paper towels were placed on top of the 
block. Resuspended cells were dropped using (Pasteur pipette) from a couple of inches on 
each end of wet slides. Fresh fixative solution was dropped across the slides, all cytoplasmic 
membrane washed off and nuclei stayed. Slides were checked under light microscope for 
spreading efficiency. Slides were dried overnight in a fume hood, fixed in methanol for 10 
minutes and air dried. Then the slides were immersed for 45 minutes in Giemsa stain 
(Giemsa stain solution from (Sigma-Aldrich) were diluted 1:20 with distilled water), and 
were rinsed with distilled water. Slides were checked under microscope (100X 
magnification) in (Medical Genetics Department, Cardiff University). Breaks and gaps in 
chromosomes were visualised under microscope and counted in 50 metaphases.    
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2.6 Single Telomere Length Analysis (STELA)  
2.6.1 Preparation Cells for DNA Extraction 
Cells were alternatively either frozen or sampled for single telomere length analysis (STELA). 
Cells were centrifuged at 1000 rpm for 5 minutes at room temperature, then supernatant 
was removed and cell pellet was washed twice with PBS to remove any trypsin and culture 
medium and centrifuged again at the same conditions. After centrifugation supernatant was 
removed and cell pellet was stored at -20 °C for up to 12 months. 
2.6.2 DNA Extraction 
2.6.2.1 Maxwell 
DNA was extracted from cell pellets by using the Maxwell 16 LEV Blood DNA Kit (Promega) 
along with the Maxwell 16 machine. Cells were lysed by 300µl of lysis buffer and 30µl of 
proteinase K at 56°C for at least one hour. After a quick centrifugation cell lysates were 
loaded into the cartridges and placed into the Maxwell 16 machine. The research mode with 
LEV hardware was adjusted to extract the DNA from cell lysates. DNA was eluted with 
elution buffer into 50µl.    
2.6.2.2 DNA Extraction Using QIAamp DNA Micro Kit 
For cell samples which contained less then 1x 10⁵ cells, genomic DNA was extracted using 
QIAamp DNA Micro Kit. The kit enables the purification of genomic DNA from small samples 
sizes by binding the DNA to a silica-based membrane. DNA was extracted from the cell 
pellets by adding 100μl of the provided ATL buffer (tissue lysis buffer) and 10μl of the 
provided Proteinase K solution. After adding 100μl of the provided AL buffer (containing 
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guanidinium chloride to denature proteins), the samples were pulse-vortexed for 15s. The 
lysis of the samples was carried out at 45°C for 10 min. After a quick spin to remove all 
condensation from the tube lid, 50μl 100% ethanol was added to the sample. Afterward the 
sample was pulse-vortexed for 15s and incubated at RT for 3 min. The entire lysate was 
transferred to the QIAamp MinElute Column. The samples were centrifuged for 1 min at 
6000x g in a Heraeus centrifuge to bind the DNA to the silica-based membrane. Residual 
contaminations were removed by washing twice with the provided buffers AW1 (containing 
guanidinium chloride to denature proteins) and AW2 (70% ethanol to remove salt). The DNA 
was eluted from the column with 30μl 10mM Tris-HCl pH 8.0. 
2.6.3 DNA Quantification 
DNA concentration was quantified in triplicate using Hoechst 33258 fluorometry (Bio Rad) 
as described previously (Baird et al., 2003), NanoDrop-100 system (Thermo Scientific) 
supplied by (Central Biotechnology Service (CBS) Cardiff University) or by performing a pilot 
STELA to determine band number, after which relatives DNA quantities to add to reactions 
were then calculated.  
2.6.4 STELA PCR 
To enable the accurate detection of telomere length within STELA, the DNA was diluted to 
10ng/µl in 10mM Tris-HCL PH 8, leaving typically 4-10 amplifiable molecules per reaction. 
Firstly, 40µl of Tel2/DNA working dilution was prepared containing: (1µl of diluted DNA 
(10ng), 38µl of Tris-HCL (10mM, pH 8) (Sigma) and 1µl of telorette2 primer (10µM)). 
Typically 6 PCR reactions were carried out per sample in a volume of 10µl containing: Taq 
reaction buffer (Tris-HCl (75mM, PH8.8), (NH₄)₂SO₄ (20mM), 0.01% Tween-20) (Abgene), 
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MgCl₂ (2mM), dNTPs (1.2mM), telomere specific primer (0.5µM), teltail primer (0.5µM) and 
0.5U Taq (Abgene)/PWO (Roche) at ratio of 10:1. Finally, 1µl of telorette2-linked DNA 
(250pg) was added to each reaction and 10µl drop of mineral oil on top of the reaction was 
added as well to prevent evaporation through the program cycles. All PCR reaction steps 
were prepared on ice. The reactions were then cycled in a Bio-Rad DNA Engine Tetrad 
Thermal Cycler using following program: denaturation at 94°C for (20 second), annealing at 
59°C for (17peseqrev1 primer) or at 65°C for (XpYpE2 primer) for (30 second) and elongation 
at 68°C for (8 minutes)X 22 cycles.       
2.6.5 Fusion PCR 
DNA was diluted to 50ng/µl in Tris-HCL (10mM, pH 8). 18 PCR reactions were carried out per 
sample in a volume of 10µl containing: 50ng DNA, Taq reaction buffer (Tris-HCl (75mM, 
PH8.8), (NH₄)₂SO₄ (20mM), 0.01% Tween-20) (Abgene), MgCl₂ (2mM), dNTPs (1.2mM), 
telomere adjacent primers (17p6, XpYpM, & 21q1) (0.5µM), teltail primer (0.5µM) and 0.5U 
Taq (Abgene)/PWO (Roche) at ratio of 10:1. 10µl drop of mineral oil was added on top of 
the reaction. All PCR reaction steps were prepared on ice. The reactions were then cycled in 
a Bio-Rad DNA Engine Tetrad Thermal Cycler using following program: denaturation at 94°C 
for (20 second), annealing at 59°C for (30 second) and elongation at 68°C for (8 minutes) X 
25 cycles.         
2.6.6 Gel Electrophoresis for STELA and Fusion PCR Products 
Amplified DNA fragments generated by STELA or fusion PCR were resolved by submarine gel 
electrophoresis using 0.5% Tris-acetate-EDTA agarose gel containing 0.1% ethidium 
bromide. 2µl of a Ficol based gel loading dye (5% bromophenol blue, 5% xylene and 15% 
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ficol) were added to PCR reactions, then 5µl of STELA PCR reactions were loaded and run 
onto 40 cm long gel at 120V for overnight or at least for 16 hours under circulating cooling 
system at 4°C. 0.5µl of 1Kb DNA ladder and 0.5µl of 2.5Kb DNA ladder (Stratagene) were run 
(to track the molecular weight of PCR products). Fusion products were loaded and run a 
third to half the length of the 40cm gel at 50V for 16hours.          
2.6.7 Southern Blot 
DNA ladder bands were stained by ethidium bromide and were visualised under UV 
transilluminator and gels were cut to the ladder size. Gels were washed twice for 6 minutes 
with depurination (0.25M HCl), gels were rinsed in ddH₂O, and then DNA fragments for 
STELA or for fusion were denaturated in 1.5M NaCl, 0.5M NaOH for 15 minutes. DNA 
fragments then were transferred to a positively charged membrane (Hybond XL 
(Amersham)) by alkaline southern blotting for 4-6 hours; denaturation buffer was used as 
transfer buffer. Membrane was washed with H₂O and left to dry at room temperature.  
2.6.8 Southern Hybridisation Probes for STELA and Fusion Assay 
The hybridisation probe for STELA and fusion was labelled by using rediprime random 
hexamer labelling beads (Ready-To-Go DNA, GE Healthcare). 1µl of 25ng of probe template 
in 44µl of TE buffer (10mM Tric-Hcl and 1mM EDTA) was denatured at 96°C for 5 minutes 
and then chilled on ice for 5 minutes. Denatured DNA was added to ready-made labelling 
mix containing random hexanucleotides, the klenow fragment of DNA polymerase, NTPs 
and [α-ᶟᶟP]dCTP. The reaction mix was incubated at 37°C for 15 minutes at water bath, 
resulted in DNA synthesis and incorporation of ᶟᶟP radioactive label. To detect molecular 
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weight markers on the blots, 1µl of [α-ᶟᶟP] labelled 1Kb and 2.5Kb DNA markers was added 
to the reaction mix of telomere specific probe.  
2.6.9 Hybridisation 
After 4-6 hours of Southern blotting, the apparatus was dismantled and the membrane was 
rotated at 60°C in a hybridisation oven with 15 ml of church buffer (0.5M sodium phosphate 
buffer [1M disodium hydrogen phosphate and 1M sodium dihydrogen phosphate], 1mM 
EDTA, 1% BSA and 7% SDS, (pH 7.2)) for 15 minutes. The labelled telomere specific probe 
was denatured again at 96°C for 5 minutes and then 25µl of probe was added to 
hybridisation bottle. Hybridisation was carried out overnight at 60°C in a hybridisation oven.   
2.6.10 Hybridisation Washes 
After the hybridisation process, the hybridised membrane was washed several times with 
0.1X sodium chloride sodium citrate (SSC)/ 0.1% sodium dodecyl sulphate (SDS) at 60°C in 
hybridisation oven for 1-2 hours, to remove all non-specific bound hybridisation probe. 
Washed membrane was dried for 30 minutes in the oven.   
2.6.11 Visualisation of Radiolabelled DNA Fragments 
Dried membrane was placed in a cassette with a phosphoimager screen (Amersham) for 24 
hours. Phosphoimager screen was scanned by using Typhoon 9419 biomolecular imager (GE 
healthcare). Prior to re-hybridisation with a second probe, STELA and fusion blots were 
stripped with boiling 0.1% SDS for at least 6 hours.   
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2.7 Protein  
2.7.1 Protein Extraction (Cell Lysis) 
Protein was extracted from cells seeded in 100mm dish which containing 70-80% of 
confluence. Cells were washed twice with 5ml of ice cold sterile PBS, to remove any culture 
medium. Cells were scraped and transferred from the dish into 15ml falcon tube with 2ml of 
ice cold sterile STE buffer (10mM Tris-Hcl, 150mM NaCl and 1mM EDTA (pH8.0)). Cell 
suspension was centrifuged at 1000rpm, 4°C for 5 minutes. Supernatant was removed 
carefully. Cells were lysed by 30µl of ice-cooled lysis buffer (1ml of cell lysis buffer (150mM 
NaCl, 50mM Tris, 5mM EDTA and 1% NP40 (pH8.0)), 30µl of (phenylmethylsulfonyl fluoride 
(PMSF)), 10µl of phosphatase inhibitor and 10µl of protease inhibitor), tubes were kept on 
ice for 5 minutes. Samples were centrifuged at 1000rpm, -5°C for 30 minutes. Tubes were 
gently removed from the centrifuge and placed on ice, the supernatant was aspirated and 
placed in a fresh tube and kept on ice, and the pellet was discarded. Protein was stored at -
80 °C. 
2.7.2 Protein Quantification 
Bradford method, was used to determine protein concentration, it depends on quantitating 
the binding of a dye coomassie blue to unknown protein (samples) and comparing this 
binding to different amounts of a standard protein (BSA). Coomassie Plus Protein Assay 
Reagent (Pierce No 23236) kit was used in the experiment. Samples were prepared and 
diluted in H₂O (1/10). Standards were also prepared from BSA and lysis buffer as in (table 
2.4) in triplicate, ranging from 0, 100, 200, 300 and 400µg/ml, allowing for comparing.   
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BSA Lysis Buffer Concentration 
0µl 150µl 0µg/ml 
7.5µl 142.5µl 100µg/ml 
15µl 135µl 200µg/ml 
22.5µl 127.5µl 300µg/ml 
30µl 120µl 400µg/ml 
Table 2.4 Standard concentrations that used in the experiment.      
From each standard or sample, 40µl was taken into semi-micro cuvettes and 1ml of the 
coomassie blue reagent was added. Standards and samples were mixed well and were read 
on spectrophotometer at 595 nm. Standards were carried out in triplicate, and samples in 
duplicate. Protein concentrations were calculated using excel software.       
2.7.3 Prepare Samples 
3X loading buffer and lysis buffer were added to samples. 3X loading buffer was prepared 
from (0.5M Tris 300µl, Glycerol 300µl, 10% SDS 300µl and 1% bromophenol blue 60µl) and 
fresh 5µl of 2-mercaptoethanol blue was added to 160µl of 3X loading buffer mixture. Then, 
mixtures were incubated for 5 minutes in hot block 100 °C before loading.   
2.7.4 Running Gel 
10% Gel precast gel from (BioRad) with 15 wells and loading capacity 15µl and the system 
Mini-protean II Electrophoresis from (BioRad) was used. 250mM of running buffer was 
prepared (15g of Tris base, 94g of Glycine, 5g of SDS and 1 litter H₂O) pH 8, buffer was kept 
at 4°C. 15µl of mixtures (samples, 3X loading buffer and lysis buffer) were loaded into 
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precast gel. 5µl of molecular weight marker (rainbow marker from Amersham) and 10µl of 
loading buffer was run along with the samples. Gel was run at 100-200V for one hour.  
2.7.5 Prepare Membrane  
Millipore Immobolin-P (IPVH30470), PVDF transfer membrane (BioRad), was used. 
Membrane was immersed for 3 seconds in methanol, and then washed for 2 minutes in 
H₂O. Membrane was kept in transfer buffer (4.6g of Tris base, 21.6g of Glycine, 300ml of 
methanol and 1.5 litters H₂O, pH 8). Clamp, pads (x2) and 3MM paper (x4) were kept soaked 
in transfer buffer as well.  
2.7.6 Transfer Proteins from Gel to Membrane (Western Blot) 
Mini Trans-blot Electrophoresis Transfer Cell, the same tank that was used for 
electrophoresis was used for transfer as well. Gel was removed from plates, and one corner 
was nicked to help orientation. Gel was placed in transfer buffer. The immunoblot sandwich 
was assembled as (1- white face of clamp, 2- pad, 3- 2X 3MM papers, 4- membrane, 5- gel, 
6- pad, 7- 2X 3MM papers any bubbles were rolled out and 8- black face of clamp). The 
immunoblot sandwich was clamped together and placed in holder black face was next to 
black side of holder and white face next to red side of holder. Transfer buffer was poured 
and stir bar/flea was placed at bottom and ice block was placed as well in holder. Holder 
was placed on stirrer and transferred at 20-30V over night.  
2.7.7 Membrane Blocking and Antibody Incubation 
Membrane was washed with Tris Buffer Saline (TBS) for 5 minutes at room temperature. 
One litter x10 TBS was prepared as (24.2g Tris base, 80g NaCl and pH was adjusted to 7.6 
with HCl and was stored at 4°C. x1 of TBS was used. Membrane was incubated for one hour 
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with blocking buffer at room temperature. Blocking buffer was prepared previously as (1X 
TBS, 0.1% Tween-20 with 5% nonfat dry milk). Following blocking, membrane was washed 
three times for 5 minutes with washing buffer (1X TBS 0.1% Tween-20). Then, membrane 
was incubated with diluted primary antibody from (Cell Signaling) over night at 4°C, table 
2.5 showed antibodies and dilutions used. Primary antibodies were diluted in primary 
antibody dilution buffer (1x TBS, 0.1% Tween-20 with 5% BSA). Then, membrane was 
washed three times for 5 minutes with washing buffer. Membrane was incubated with 
diluted HRP-conjugated secondary antibodies (anti-rabbit or anti-mouse depending on type 
of primary antibody used) (Cell Signaling) for one hour at room temperature. Secondary 
antibodies were diluted (1:2000) in (1x TBS, 0.1% Tween-20 with 5% BSA). Then, membrane 
was washed three times for 5 minutes with washing buffer. 
Antibodies used  Molecular weight  Isotype  Dilution  Product No. 
Phospho-Chk1 (Ser345) 56 KDa Rabbit 1:500 2348 
Phospho-Chk2 (Thr68) 62 KDa Rabbit 1:500 2661 
Phospho-p53 (Ser15) 53 KDa Mouse 1:1000 9286 
Table 2.5: Antibodies used during study.   
2.7.8 Protein Detection  
Membrane was incubated with developing solution from (Amersham) for 5 minutes, and 
then excess solution was removed from membrane. Membrane was wrapped in plastic and 
exposed to x-ray film (Amersham) for 1 minute to 5 minutes, then membrane was removed 
to develop.            
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2.8 Statistical Analysis 
Scanned STELA blots were analysed using Molecular Dynamics ImageQuant 5.0 (GE). The 
calculation of the molecular weight of the DNA fragments was carried out by using Phoretix 
1Dsoftware (Nonlinear Dynamics). Telomere length measurements were exported to 
Microsoft Excel where the distance between telomere adjacent primer and telomere repeat 
array was subtracted and giving an accurate telomere length measurement. All mean 
values, standard derivations (SD), standard errors (SE) and median values were calculated 
with Microsoft Excel and GraphPad Prism. All presented diagrams were generated in 
Microsoft Excel, Power Point and GraphPad Prism. 
2.8.1 T-test 
The t-test was calculated in GraphPad Prism using unpaired t-test. The calculated p-value is 
the probability of the null hypothesis being true. At a p-value below 0.05 the null hypothesis 
was rejected. 
2.8.2 Repeat Measure ANOVA 
A repeat measure ANOVA (analysis of variance) was used to determine if there was a 
significant difference between one sample subjected to three or more different 
concentrations. No difference between the different concentrations was stated as the null 
hypothesis. The repeat measure ANOVA was calculated in GraphPAD Prism. At a p-value 
below 0.05 the null hypothesis was rejected.  
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Chapter 3 
Oxidative Stress and Telomere Erosion 
3.1 Summary  
Telomeres are nucleoprotein structures that contain non-coding (TTAGGG) tandem repeats 
and associated telomere binding proteins at the end of chromosomes. As a consequence of 
end-replication losses, telomeres undergo gradual erosion with ongoing cell division. It is 
hypothesised that in addition to the end-replication problem, mutational mechanisms may 
contribute to telomere erosion by generating large-scale telomeric deletion events. As short 
dysfunctional telomeres are capable of fusion to other chromosome ends, large-scale 
telomeric deletions can lead to genomic instability which in turn may drive tumour 
progression. The aim of this chapter is to observe if oxidative stress contributes to telomere 
erosion and large-scale telomeric deletion. 
 By undertaking a comprehensive analysis of telomere dynamics following the induction of 
oxidative stress, the data presented here showed that oxidative damage does not appear to 
affect the rate of telomere erosion or the frequency of large-scale telomeric deletions. 
Instead prolonged exposure to oxidative stress results in the preferential loss of sub-
populations of cells exhibiting short telomeres from the culture. We conclude that loss of 
these cells from the culture may be due to a preferential sensitivity to damage that may be 
related to these cells being closer to their replicative limit.  These data are more consistent 
with the view that premature senescence does not arise as a consequence of accelerated 
telomere erosion, but instead more likely results from stochastic DNA damage across the 
rest of the genome. 
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3.2 Introduction    
3.2.1 Telomere-Dependent Replicative Senescence 
The ends of eukaryotic chromosomes are capped by telomeric sequences that are lost as a 
result of the end replication problem with each cell division in telomerase negative cells 
(Henderson et al., 1996). Cell division and telomeric erosion occur until critically short un-
capped telomeres predominate resulting in the triggering of a DNA damage response 
(Fagagna et al., 2003). This response includes the ATM/p53 and the Rb/p16 pathways that 
serve as the signals of the DNA damage response and lead to a permanent cell-cycle arrest 
(Fagagna et al., 2003). The termination of cell growth, commonly referred to as Replicative 
Senescence and the repression of the proliferation promoting genes are also involved 
(Hayflick, 1965). Replicative cellular senescence is a non-dividing but biologically active 
state, that represents a limit to the number of times cells can divide referred to as the 
Hayflick limit (Hayflick, 1965; Allsopp et al., 1995). Replicative senescence can provide a 
tumour suppressive mechanism, preventing end-to-end fusions and chromosomal 
abnormalities (Campisi, 2005; Krtolica et al., 2001). Replicative senescence resulting from 
the end-replication problem can be circumvented in telomerase negative cells by forced 
expression of the catalytic subunit of telomerase (Bodnar et al., 1998). However, telomerase 
expression alone cannot completely prevent the occurrence of senescent cells resulting 
from other senescence triggers (Campisi and d'Adda di Fagagna, 2007).  
3.2.2 Telomere-Independent Cellular Senescence 
 Cellular senescence is not just caused by telomere erosion alone. In some cases, cell stress 
has been associated with triggering of early replicative senescence (Dumont et al., 2000; 
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Serrano et al., 1997). For example, in vitro stresses of tissue culture conditions including 
hyperoxia, the distributions of cells in a culture, cell-to-cell contact and the medium to cell 
ratios call all considerably restrict a cellsreplicative lifespan (Sherr and DePinho, 2000). A 
number of cell types have been observed to undergo senescence in telomere independent 
manner, for example, the telomerase positive Human fetalventricular cardiomyocytes (HFC) 
(Ball and Levine, 2005) and Syrian hamster embryonic cells (Carman et al., 1998). Moreover, 
oxidative stress, oncogene over-expression and DNA damaging agents can also induce early 
replicative senescence (Dumont et al., 2000; Serrano et al., 1997). Oxidative stress can be 
induced by H₂O₂ treatment. H₂O₂ is considered as a reactive oxygen species and can react 
with intracellular iron to produce the hydroxyl radicals (Liu et al., 2002). Hydroxyl radicals 
are highly reactive species that can lead to DNA attack, breaking single strands and 
subsequently causing a premature senescence (Dumont et al., 2000). Cellular senescence 
can also be induced by the over-expression of active oncogenes within normal cells, for 
example the expression of mutant RAS oncogene leads to a senescence response (Serrano 
et al., 1997). Furthermore, human cells have been observed to undergo cellular senescence 
as a result of the build-up of DNA damage (Di Leonardo et al., 1994). Telomere independent 
senescence has probably evolved as a tumour suppressor mechanism, preventing on-going 
cell division of damaged cells.  
3.2.3 Telomere Deletion Events 
Single Telomere Length Analysis (STELA) is a single molecule approach to determine 
telomere length distributions at specific chromosome ends (Baird et al., 2003). Through this 
technique, it has been observed that telomere erosion with ongoing cell division results in a 
decrease in the mean and an increase in the variance of the telomere length distribution 
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that is entirely consistent with gradual telomere erosion arising as a consequence of the 
end-replication problem (Baird et al., 2003). However, this was superimposed by the 
occurrence of stochastic deletion events resulting in extremely short telomeres (Baird et al., 
2003). These have been observed in both telomerase positive and negative cells (Baird et 
al., 2003; Britt-compton et al., 2006).  These events result in dysfunctional telomeres that 
are capable of fusion, even in normal cells in which the mean telomere lengths are 
consistent with long-stable telomeres (Capper et al 2007; Letsolo et al. 2009).  Such events 
have the potential to trigger genomic instability which may lead to tumourgenesis or aging 
phenotypes. A telomere deletion phenomenon, telomere rapid deletion (TRD), was first 
described in yeast (Li and Lustig, 1996) and was considered to arise from an intra-telomeric 
recombination event. TRD as described in yeast results in the deletion of artificially 
lengthened telomeres resetting them to the length of the genome average (Li and Lustig, 
1996). In contrast Human (hTRD) events result in the deletion of telomeres from genome 
average to a critically short length (< 1kb). Thus the mutational mechanisms underlying TRD 
in yeast may be distinct from those observed in human (hTRD). The mechanisms generating 
hTRD events are unclear. Possible mechanisms for TRD include oxidative stress (Von Zglinicki 
et al., 1995) replication fork stalling (Crabbe et al., 2004) unequal sister chromatid exchange 
(Bailey et al, 2004) and intra-allelic mechanisms that may include replication slippage (Baird 
et al., 1995). Other mechanisms for TRD include the fragility of telomere repeat region and 
stability of G-quadruplex structures in the telomeres may also be involved in generating 
hTRD, both of which are investigated in chapters 4 and 5.  
In human cells TRD events do not increase with on-going cell division implying that they may 
either be repaired back to mean telomere length, or that the cells may have exited the cell-
cycle or that fusion event may occur rendering the molecules undetectable with STELA 
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(Baird et al., 2003). hTRD events at the XpYp telomere were estimated to occur at a rate of 
3%. Assuming that hTRD events occurs at the same frequency at the other telomeres, hTRD 
may represent a significant contributor to genome-wide telomere losses which have the 
potential to result in genome instability (Baird et al., 2003; Britt-compton et al., 2006).  
3.2.4 Oxidative Stress and Telomere Structure 
The canonical telomere repeat sequence contains a triple guanine sequence that has been 
shown to be sensitive to damage by oxidative stress. Oxidised guanine increases in 
senescent cells that are characterised by an increase of up to four times in free 8-oxodG 
bases (8-oxo-deoxyguanosine) (Nasir et al., 2014). 8-oxodG bases can be very mutagenic if 
unrepaired, 8-oxoG base pairs with adenine resulting in a GC to AT transversion just after 
two replication cycles. These mutations can lower the affinity of the telomere binding 
proteins and result in telomere uncapping and increased rate of recombination (Boiteux and 
Radicella, 1999).      
3.2.5 Reactive Oxygen Species (ROS) 
The effects of Reactive Oxygen Species can be counteracted by a number of antioxidants 
through both enzymatic and non-enzymatic mechanisms. Oxidative stress is related to the 
imbalance of ROS and antioxidants whereby the effects of ROS can overwhelm the 
compensatory ability of antioxidants. In the case of mitochondrial-derived ROS, a 
superoxide is the first radical produced (Loft and Polsen, 1996). Based on the fact that the 
main site of superoxide production is in the inner mitochondrial membrane, the 
mitochondrial DNA (mtDNA) has been regarded as the major target for ROS damage. 
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 Reactive oxygen species such as superoxide radical anion, hydrogen peroxide, hydroxyl 
radical, peroxynitrite, hypochlorous acid can all be formed within cells.  Transfer of electrons 
to oxygen from mitochondrial Electron Transport Chains leads to the formation of 
superoxide ions (Liu et al., 2002). Reaction of superoxide radicals with MnSOD produces 
hydrogen peroxide. Within cells, several oxidases also produce hydrogen peroxide. Catalase 
and glutathione peroxidase react with hydrogen peroxide and change it to water. At times 
reaction of hydrogen peroxide with superoxide radical can form more superoxide radicals.  
In the presence of heavy metals and UV, lysis of hydrogen peroxide can react with the heavy 
metals leading to formation of hydroxyl radicals. Hydroxyl radicals are highly reactive and 
can disturb the integrity of DNA (Liu et al., 2002). Formation of nitric oxide is catalysed by 
nitric oxide synthase may produce highly reactive peroxynitrite radical when reacted with 
superoxide ions. In addition, peroxynitrite radical is able to form various reactive oxygen 
species. For instance, the conjugate acid of the peroxynitrite, i.e. ONOOH may dissociate 
and form reactive free radicals like NO2 and OH (Chandel et al., 1998). 
Telomeres are considered to be extremely sensitive to oxidative damage and this may be 
due to the sensitivity of the GGG repeat regions to ROS and the reduced capacity for DNA 
repair within telomeres. The high rate of telomere erosion that has been reported in cell 
cultures subjected to high oxygen tensions has been reported to occur as a consequence of 
the apparent low antioxidant capacity of the cell strains. This is considered to result in an 
accumulation of single stranded breaks and elevated rates of telomere shortening (Von 
Zglinicki, 1995).  
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3.2.6 Oxidative Stress and Cell Culture   
The proliferative capacity of human fibroblasts in culture is modulated by oxygen 
concentrations and seeding densities (Balin et al., 1984). It has been shown that lowering 
oxygen concentrations from 20% to around 5% and/or adding antioxidants to growth media 
can facilitate an increase in replicative lifespan of the cell cultures from human colorectal 
mucosa, amniotic fluid and primary melanoma cells (Pritchett et al., 1985; Brackertz et al., 
1983). Several studies have been demonstrated that IMR90 fibroblasts can enter premature 
senescence early in their replicative lifespan following the treatment with hydrogen 
peroxide (H₂O₂) (Chen et al., 2004). Premature senescence induced due to the effect of 
oxidative stress. Reactive oxygen species (ROS) are the source of oxidative stress which 
constitutes the majority of DNA damage in human cells. Oxidative stress induces DNA 
damage response via p53, p21 and p16 activation and result in cell cycle arrest (Chen et al., 
2004; Itahana et al., 2001). 
A link between oxidative damage and telomere biology has been observed. This observation 
has been emerged from the growth fibroblast cells such as WI38 cells in 20% and 40% 
oxygen. WI38 in 40% oxygen underwent premature senescence but this was associated with 
an increased rate of telomere erosion compared to cells cultured at the 20% oxygen. This 
leads to the hypothesis that the oxidative stress and oxygen tension in the culture was the 
primary driver of telomere erosion in WI38 cells (Von Zglinicki, 2002). In contrast to WI38 
strains, BJ and MRC5 fibroblast strains showed no observable difference in cell proliferation 
and telomere shortening at varying oxygen tension. Thus it was concluded that different cell 
strains react differently to varying oxygen tensions and that such differences may be due to 
differing antioxidant capacities (Lorenz, 2001; Britt-Compton, 2009). Further observations 
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using G6PD deficient primary foreskin fibroblasts HFF1 and HFF3 showed that these cells 
prematurely senesce after H₂O₂ treatment without significant telomere loss (Cheng et al., 
2004). Therefore the role that oxidative stress plays in driving telomere erosion is 
controversial. 
3.2.7 Analysis of Stochastic Deletion Events 
STELA is a single telomere length analysis technology that determines the distributions of 
telomere lengths at a specific chromosome ends (Baird, 2005). The technique is considered 
as a sensitive method that can detect telomere lengths up to 28 kb and can also detect 
telomeres which are have almost completely lost their telomeric sequences, thus revealing 
full spectrum of telomere length at specific chromosome ends. Critical short telomeres that 
have potential to trigger replicative senescence or initiate chromosome instability now are 
detectable with the technique. The technique was first developed for the analysis of the 
dynamics at XpYp telomere (Baird, 2003) and has since been extended for 2p, 9p, 11q, 12q, 
16q, 17p and 18q chromosomes end (Britt-Compton et al., 2006) and also C. elegans 
(Cheung et al., 2004).  
Analysis of clonal populations of human cells with STELA shows that with on-going cell 
division a decrease in the mean and an increase in variance of the telomere length 
distributions. These dynamics were consistent with the predicted losses as a consequence of 
the end replication problem, with a requirement to invoke addition mutational process such 
that those that occur as a consequence of oxidative damage. However superimposed on the 
gradual telomere erosion, were large-scale telomere deletion events resulting in truncated 
telomeres (Baird, 2003). These stochastic deletion events are not predicted as a 
consequence of end-replication losses, instead it is likely that they arise as a consequence of 
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some additional mutational process. One example of which may be telomere specific 
oxidative damage. 
3.3 This Work 
In this chapter, I have examined whether oxidative stress has the potential to drive 
stochastic telomeredeletion events and therefore resulting in extremely short telomeres 
which are detecteable with STELA. In order to do so, I analysed the effect of different 
concentrations of hydrogen peroxide (H₂O₂) on cell growth and on telomere dynamics in 
IMR90 and U138 cancer cells. IMR90 cells were previously described to be subjected to 
higher rates of telomere erosion compared to other fibroblasts. To investigate whether this 
is due to oxidative stress, cells were cultured in different concentrations of H₂O₂ in a parallel 
with cells cultured in normal conditions. DNA samples were taken at various points during 
proliferation of the cultures (recover period), enabling detailed analysis of telomere 
dynamics using STELA.  
3.4 Results 
3.4.1 Effects of Oxidative Stress on Culture Growth  
In order to monitor the influence of oxidative stress on fibroblast cultures, human diploid 
fibroblast IMR90, derived from human foetal lung, were cultured at PD 28 in 6 well plates 
(35-mm dish) and treated with different concentrations of hydrogen peroxide H₂O₂ (25µM, 
50µM, 150µM & 300µM) for two hours. Afterwards the cells were allowed to recover for 
seven days before the next treatment. Three serial treatments were undertaken. Before 
each treatment cells were collected for DNA extraction, after 7 days, 14 days and 21 days of 
recovery, allowing detailed analysis of telomere dynamics. Figure 3.1 illustrate the 
experimental plan. 
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Figure 3.1: The experimental plan. IMR90 fibroblast treated with different concentrations of H₂O₂ 
for two hours, then the cells were allowed to recover seven days before the next treatment. For 
each of the three different treatments cells were collected for STELA analysis. 
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The cells were passaged serially after treatments and the average of population doublings 
(PDs) was calculated and plotted as a function of time (Figures 3.2, 3.3 and 3.4)  
The data showed that the replicative capacity of IMR90 fibroblasts in standard culture 
conditions was PD 48.72. Whereas, treated IMR90 cells exhibited a truncated replicative 
lifespan compared to normal control fibroblasts (~ 40.5 PD’s were achieved for cells treated 
with 25µM & 50µM H₂O₂) and (~39.5 PD’s for those treated with 150µM & 300µM) at the 
third treatments. Thus normal control of IMR90 fibroblasts grew on average 8 additional 
PDs compared to those treated with (H₂O₂) for first, second and third treatments (p<0.0001; 
ANOVA), the H₂O₂ treated cells became senescent and stopped growing in cultures earlier 
than the control. 
The overall growth rates were determined to be on average of ~ 0.256 PD/day for the 
normal control and ~ 0.163 PD/day for (300µM H₂O₂ third treatments). It was obvious that 
with cells approaching the end of their replicative lifespan, the growth rates slowed at both 
normal and recovered cultures. This data is in line with previous observations, as fibroblast 
cell cultures reach their replicative capacity, the growth rate slows with an increasing 
proportion of cells senescent and fewer cells capable of cell division.   
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Figure 3.2: PDs of IMR90 Clone 4 (First Treatment H₂O₂) 
   
   
First Treatment Growth Rate PD/day Total PD’s 
Control 0.256 PD/day 48.72 
25µM (H₂O₂) 0.221 PD/day 42.60 
50µM (H₂O₂) 0.216 PD/day 42.20 
150µM (H₂O₂) 0.211 PD/day 41.80 
 300µM (H₂O₂) 0.196 PD/day 40.99 
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Figure 3.2: Growth curves of IMR90 clone 4 (First Treatment). 
IMR90 control (untreated) (Black Line) was compared to treated 
(Red Line) with different concentrations of H₂O₂ (25µM, 50µM, 
150µM & 300µM) for 2hours. Plotting growth curves as function 
of population doublings (PD) verus time in days. Treated cells 
were senesced and stopped growing earlier than control.     
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Figure 3.3: PDs of IMR90 Clone 4 (Second Treatment H₂O₂) 
  
 
Second Treatment Growth Rate PD/day Total PD’s 
Control 0.256 PD/day 48.72 
25µM (H₂O₂)  0.207 PD/day 42.00 
50µM (H₂O₂) 0.192 PD/day 41.50 
150µM (H₂O₂)  0.189 PD/day 40.30 
 300µM (H₂O₂)  0.181 PD/day 40.00 
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Figure 3.3: Growth curves of IMR90 clone 4 (Second 
Treatment).  IMR90 control (untreated) (Black Line) was 
compared to treated (Red Line) with different concentrations of 
H₂O₂ (25µM, 50µM, 150µM & 300µM) for 2hours. Plotting 
growth curves as function of population doublings (PD) verus 
time in days. Treated cells were senesced and stopped growing 
earlier than control.     
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Figure 3.4: PDs of IMR90 Clone 4 (Third Treatment H₂O₂) 
 
 
 
Third Treatment Growth Rate PD/day Total PD’s 
Control 0.256 PD/day 48.72 
25µM (H₂O₂)  0.188 PD/day 40.80 
50µM (H₂O₂) 0.184 PD/day 40.50 
150µM (H₂O₂)  0.167 PD/day 39.70 
 300µM (H₂O₂)  0.163 PD/day 39.30 
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Figure 3.4: Growth curves of IMR90 clone 4 (Third 
Treatment). IMR90 control (untreated) (Black Line) was 
compared to treated (Red Line) with different 
concentrations of H₂O₂ (25µM, 50µM, 150µM & 
300µM) for 2hours. Plotting growth curves as function 
of population doublings (PD) verus time in days. Treated 
cells were senesced and stopped growing earlier than 
control.  
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Another set of experiments was carried out using a higher concentration of H₂O₂ and lower 
duration of exposure. IMR90 fibroblasts were cultured at PD28 in 6 well plates and were 
treated with different H₂O₂ concentrations (1.15mM, 2.25mM and 4.5mM) for 10 minutes. 
U138 cancer cells (mutant p53) were cultured and treated as well with 4.5mM H₂O₂ for 10 
minutes. After treatment cells were counted and half were collected for DNA extraction and 
the remaining half were reseeded in normal media allowing the cells to recover, cells were 
collected for DNA extraction after 7 days, 14 days, 21 days and 27 days of recovery.  
The cells were passaged serially after treatments and the average of population doublings 
(PDs) was calculated and plotted as a function of time (Figure 3.5). 
The overall growth rates during experiment were determined to be 0.177 PD/day in IMR90 
treated with 4.5mM and 0.203 PD/day in the control. The growth rates of U138 cancer cells 
were slightly higher than IMR90 fibroblasts. U138 treated with 4.5mM was 0.305 PD/day 
and 0.321 PD/day for the control of U138. 
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Figure 3.5: PDs of IMR90 and U138 (Treatment 4.5mM H₂O₂) 
 
Treatment Growth Rate PD/day 
Control IMR90 0.203 PD/day 
1.15mM (H₂O₂)  0.200 PD/day 
2.25mM (H₂O₂) 0.193 PD/day 
4.5mM (H₂O₂)  0.177 PD/day 
 Control U138   0.321 PD/day 
4.5mM (H₂O₂) 0.305 PD/day 
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Figure 3.5: Growth curves of IMR90 fibroblasts and U138 
cancer cells. Control (untreated) cells (Black Line) was 
compared to treated cells (Red Line) with different 
concentrations of H₂O₂ (1.15mM, 2.25mM & 4.5mM) IMR90 
for 10 minutes. U138 cancer cells were treated with 4.5mM 
H₂O₂ concentration only for 10 minutes. Plotting growth curves 
as function of population doublings (PD) verus time in days.  
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3.4.2 Effect of Oxidative Damage on Cell Cycle Progression 
In order to examine the effects of oxidative damage on the cell cycle progression, cell 
cultures were collected and fixed on the seventh days of the cell’s recovery and then the cell 
cycle progression was investigated after the first, second and third treatment (Figure 3.6)   
In the control IMR90 fibroblasts, which were cultured without H2o2, the cell cycle preceded 
without interruptions in G1, S and G2 phases. These checkpoints monitor of the movement 
through cell cycle and they generate pause in cell cycle progression when damage occurs. If 
the cells treated with H₂O₂ suffer damage, they may arrest temporarily in G1, S or G2 phase 
depending on the point in the cell cycle in which the damage occurred.  
Treatment with hydrogen peroxide resulted in a reduction in the number of cells in G2/M 
phase, as shown in (Figure 3.6), where only 8% of treated IMR90 with 300μM H₂O₂ (third 
treatments) in G2/M phase compared to IMR90 untreated cells were 24% in G2/M phase. 
Moreover, the oxidative stress that was induced by the exposure to hydrogen peroxide 
diminished the DNA synthesis in treated cells compared to the control cells. Only 1% of the 
IMR90 cells treated with 150µM H₂O₂ (second treatment) were in S phase compared to ~4% 
of control cells.  
In contrast, the percentage of control cells in G0/G1 phase were about 70%, whereas 
around 83% of IMR90 fibroblasts treated with 300μM H₂O₂ (first treatment) were in G0/G1. 
This percentage increased even further after the third treatment where 90% of treated cells 
arrested in G0/G1.  
This data is in line with previous studies (Chen et al., 1998; Chen et al., 2000) which showed 
that H₂O₂ induced senescence in human fibroblasts results in a permanent cell cycle arrest 
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in G1 phase. Other studies have demonstrated that the arrest in G1 phase is related to 
protection of the cell against oxidative damage and apoptosis (Barzilai and Yamamoto, 
2004). 
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Figure 3.6: Cell cycle of IMR90 Clone 4 (H₂O₂) 
 
   
Figure 3.6: Cell cycles of IMR90 cells clone 4. Showed percentage 
of cells accumulated at G0/G1, S and G2/M phases. G0/G1, S and 
G2/M fraction was calculated by flow cytometry. IMR90 
(control) was compared to treated with different concentrations of 
H₂O₂ (25µM, 50µM, 150µM & 300µM) for 2hours. Cell cycle 
progression was investigated on the day seven of the treated cell’s 
recovery. (A) First, (B) Second and (C) Third Treatments). Oxidative 
stress induced by the exposure to H₂O₂ make a reduction in the 
number of cells in the synthesis phase, G2/M phase & more cells 
were accumulated and arrested in G0/G1 phase. Error bars 
represent standard error (SE).  
 
 
 
A 
 
B 
 
C 
 
 84 
 
In order to examine the effect of fragile site induction on cell cycle checkpoints, MRC5, SCK 
and U138 cells were cultured with APH (1µM) and HU (1mM) and incubated for 24 hours in 
100mm dishes. Controls and treated cells were collected from culture and fixed in 70% 
ethanol then were stained with Propidium Iodide (PI) and the G1, S and G2/M fraction was 
determined by flow cytometry.  
 
3.4.3 Oxidative Damage Induce Cellular Senescence 
 3.4.3.a Cellular Morphology 
Morphological changes were investigated in treated cells and were compared to 
morphological changes in control cells under the microscope (X20). Treated cells lost their 
original morphology as shown in (figure 3.7), became larger than their untreated control 
with a much larger flattened cytoplasm and bigger nuclei. These features are typical of the 
morphological characteristics of senescent cells (Toussaint et al., 2000; Chainiaux et al., 
2002).  
 3.4.3.b Senescence Associated Beta Galactosidase Activity (SAβ-gal)  
In order to examine the impact of H₂O₂ treatment on the cellular senescence, the activation 
of senescence-associated β-galactosidase enzyme was investigated on control and treated 
IMR90 cells using the Senescence Detection Kit (‘ab65351 Abcam’). SAβ-gal activity was 
determined by counting positive stained cells under microscope (X20). The proportions of 
positive cells were given as percentages of the total counted cells.  
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It was observed that the activation of senescence-associated β-galactosidase enzyme 
(cellular senescence marker) in treated cells increased with higher H₂O₂ concentrations. This 
can be clearly seen from the result of the SAβ-gal assay (Figure 3.8.a). The average of 
senescent untreated cells at 34.5 PDs was 40% of the total counted cells whereas the 
average of senescent 25µMH2O2 treated cells was 58% after the third time of treatment 
and the cells were at (~32.4 PDs). This average activity increased with higher concentrations 
of H2O2 reaching 92% for those cells treated with 300µM at PD32.  
IMR90 fibroblasts at 28 PDs which were treated with 4.5mM H₂O₂ for 10 minutes showed an 
average of 47% of senescent cells (Figure 3.8.b).   
These data strongly indicate that H₂O₂ treatment successfully induced cellular senescence in 
IMR90 fibroblasts. In contrast cell cultures derived from p53 deficient (U138 tumour cells) 
showed no induction of senescence markers despite exposure high concentration of (H₂O₂) 
(Figure 3.7.b).  
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Figure 3.7: Cellular Senescence of IMR90 (H₂O₂) 
 Control IMR90 IMR90 (25µM H₂O₂) IMR90 (50µM H₂O₂) IMR90 (150µM H₂O₂) IMR90 (300µM H₂O₂) 
 
(A) Cellular 
morphology 
 
 
 
 
 
 
 
 
 
 
 
(B) SAβ-gal 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: A Cellular Morphology. Morphological changes were monitored in treated cells and were compared regularly to the morphological changes in 
control cells. Treated cells displayed features similar to those observed in senescent cells; became larger, they had a flattened cytoplasm and bigger nuclei. 
B Senescence-associated-beta-galactosidase (SAβ-gal) activity is detectable at pH6 and produces a blue colour in positive senescent cells; as shown the 
number of blue positive cells increased with higher H₂O₂ concentrations.  
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Figure 3.8: Senescence-Associated β- galactosidase Activity (H₂O₂) 
   
Figure 3.8.a: Senescence-Associated β-galactosidase Activity of IMR90 cells. Shows percentages of positive cells for SAβ-gal assay. SAβ-gal activity was 
determined by counting positive stained cells under microscope (X20). The proportions of positive cells were given as percentages of the total counted cells. 
cells treated with different concentrations of H₂O₂ (25µM,50µM, 150µM & 300µM) for 2 hours first, second and third treatment respectively. Error bars 
represent standard error (SE).        (SIGNIFICANT) (p<0.0001, ANOVA) 
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Figure 3.8.b: Senescence-Associated β-galactosidase 
Activity of IMR90 fibroblasts and U138 cancer cells. 
Shows percentages of positive cells for SAβ-gal assay; 
IMR90 treated with different concentrations of H₂O₂ 
(1.15mM, 2.25mM & 4.5mM) for 10 minutes     (NOT 
SIGNIFICANT; ANOVA). U138 cancer cells treated with 
4.5mM H₂O₂ for 10 minutes. Error bars represent 
standard error (SE). 
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3.4.4 Analysis of Telomere Dynamics 
 In order to examine if oxidative damage induced by exposure to H₂O₂ result in large-scale 
changes to telomere length, the XpYp telomere length distributions of IMR90 and U138 
treated with hydrogen peroxide were investigated using single telomere length analysis 
(STELA) (Baird et al., 2003). In line with previous studies in the group (Baird et al., 2003), the 
XpYp telomere was analysed because it is considered to be representative for average 
chromosomal telomere length and average telomere erosion rates resulting from the end-
replication problem. Multiple cell samples were taken during the course of the experiment. 
STELA was used to track the telomere dynamics and detect any stochastic shorter telomeres 
with ongoing cell division. STELA for the experiment are shown in figures (3.9, 3.10, 3.11 and 
3.12).  
It has been previously defined that stochastically shorter telomeres as those which deviate 
significantly from the normal distribution of expected telomere length. However we have 
observed that both control and treated IMR90 fibroblasts clone 4 displayed bimodal 
distributions at the XpYp telomere. The bimodal distributions made it more difficult to 
determine these deleted telomeres and thus for the purposes of this study short deleted 
telomeres were defined as those that were shorter than 2kb. 
In treated IMR90 fibroblasts, an apparent change in the bimodal distributions could be 
observed after approximately 14 days of recovery periods after three treatments. The lower 
modal distribution disappeared which was consistent across all four different treatments. 
For example the loss of the lower distribution was clearly seen and was statistically 
significant in IMR90 fibroblasts treated with 50µM H₂O₂ after the 21 days recovery period 
following the third treatment (p < 0.0001; Figures 3.10 and 3.13).  
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By looking at Figure 3.14 the proportion of short telomere that were  calculated below 2kb 
showed that IMR90 after the second treatment had a higher short telomeres frequency 
compared to those after the third treatment indicating that thus cells with short telomeres 
had disappeared after three treatments. Interestingly, IMR90 fibroblasts treated with 50µM 
had the highest frequency of short telomeres. This means that IMR90 treated with 50µM 
H₂O₂ after 21 days recovery in culture from the third treatments drastically lost their lower 
model distribution.     
In IMR90 fibroblasts treated with higher concentration (1.15mM, 2.25mM & 4.5mM) of 
H₂O₂ and lower duration (10 minutes), cells remained in culture up to 27 days after 
treatment, the mean telomere length declined in both control and treated IMR90 over time. 
IMR90 treated with 2.25mM displayed a higher short telomere frequency (~4.14%) 
compared to the control (2.25%) and the cells treated with 1.15mM (2.19%) and 4.5mM 
(1.69%) (Figures 3.15 and 3.16).      
Cultures derived from p53 deficient (U138 tumour cells) showed no significant differences in 
mean telomere length between treated and untreated U138 tumour cells. Both treated and 
untreated cultures slightly reduced in mean telomere length as a result of the end 
replication problem (Figure 3.17 and 3.18). Short telomere frequency was higher in control 
cultures.  
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Figure 3.9: STELA of Treated IMR90 Clone 4 at XpYp Telomere (25µM H₂O₂) for (First, Second &Third treatments) 
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1
st
 Treat 7 Days 14 Days 21 Days 2
nd
Treat 7 Days 14 Days 21 Days 3
rd
 Treat 7 Days 14 Days 21 Days 
PD 29.88 31.43 33 PD 31.4 32.66 34.22 PD 32.63 33.95 35.26 
Mean 6.50 8.04 5.13 Mean 7.706 6.376 6.523 Mean 7.05 6.76 6.82 
SD 3.85 3.56 2.98 SD 3.49 3.26 3.52 SD 3.66 3.37 2.89 
 
A 
B C Figure 3.9: STELA gels of XpYp telomere in 
the IMR90 clone 4 treated with 25µM 
H₂O₂ for 2 hours and the tables of 
descriptive data for telomeres. The gels 
illustrate the telomere length distributions 
while the tables give the mean, standard 
deviations (SD) and population doublings 
(PD), (PD) was calculated after cells 
harvested.  (A) IMR90 fibroblasts were 
treated with 25µM H₂O₂ for 2 hours once, 
then cells were refreshed with normal 
media and recovered for 7 days, 14 days, 
21 days, cells were collected for DNA 
extraction subsequently. (B) IMR90 
fibroblasts were treated with 25µM H₂O₂ 
for 2 hours twice. (C) IMR90 fibroblasts 
were treated with 25µM H₂O₂ for 2 hours 
three times. Dot Plot made in (Prism) 
represent dot plots (Telomere length 
distributions) from the gels, were 
quantified using Phortetix software, then 
they were compared (Days of recovery) 
and p value was calculated using t-test in 
Prism (P value in Red is Significant) (in 
Black is NS).    
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Figure 3.10: STELA of Treated IMR90 Clone 4 at XpYp Telomere (50µM H₂O₂) for (First, Second &Third treatments)  
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C A B 
Figure 3.10: STELA gels of XpYp telomere in 
the IMR90 clone 4 treated with 50µM H₂O₂ 
for 2 hours and the tables of descriptive 
data for telomeres. The gels illustrate the 
telomere length distributions while the 
tables give the mean, standard deviations 
(SD) and population doublings (PD), (PD) 
was calculated after cells harvested.  (A) 
IMR90 fibroblasts were treated with 50µM 
H₂O₂ for 2 hours once, then cells were 
refreshed with normal media and recovered 
for 7 days, 14 days, 21 days, cells were 
collected for DNA extraction subsequently. 
(B) IMR90 fibroblasts were treated with 
50µM H₂O₂ for 2 hours twice. (C) IMR90 
fibroblasts were treated with 50µM H₂O₂ for 
2 hours three times. Dot Plot made in 
(Prism) represent dot plots (Telomere 
length distributions) from the gels, were 
quantified using Phortetix software, then 
they were compared (Days of recovery) and 
p value was calculated using t-test in Prism 
(P value in Red is Significant) (in Black is NS).    
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Figure 3.11: STELA of Treated IMR90 Clone 4 at XpYp Telomere (150µM H₂O₂) for (First, Second &Third treatments) 
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C 
B A Figure 3.11: STELA gels of XpYp telomere in 
the IMR90 clone 4 treated with 150µM 
H₂O₂ for 2 hours and the tables of 
descriptive data for telomeres. The gels 
illustrate the telomere length distributions 
while the tables give the mean, standard 
deviations (SD) and population doublings 
(PD), (PD) was calculated after cells 
harvested.  (A) IMR90 fibroblasts were 
treated with 150µM H₂O₂ for 2 hours once, 
then cells were refreshed with normal 
media and recovered for 7 days, 14 days, 21 
days, cells were collected for DNA 
extraction subsequently. (B) IMR90 
fibroblasts were treated with 150µM H₂O₂ 
for 2 hours twice. (C) IMR90 fibroblasts 
were treated with 150µM H₂O₂ for 2 hours 
three times. Dot Plot made in (Prism) 
represent dot plots (Telomere length 
distributions) from the gels, were quantified 
using Phortetix software, then they were 
compared (Days of recovery) and p value 
was calculated using t-test in Prism (P value 
in Red is Significant) (in Black is NS).    
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Figure 3.12: STELA of Treated IMR90 Clone 4 at XpYp Telomere (300µM H₂O₂) for (First, Second &Third treatments)      
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Figure 3.12: STELA gels of XpYp telomere 
in the IMR90 clone 4 treated with 
300µM H₂O₂ for 2 hours and the tables 
of descriptive data for telomeres. The 
gels illustrate the telomere length 
distributions while the tables give the 
mean, standard deviations (SD) and 
population doublings (PD), (PD) was 
calculated after cells harvested.  (A) 
IMR90 fibroblasts were treated with 
300µM H₂O₂ for 2 hours once, then cells 
were refreshed with normal media and 
recovered for 7 days, 14 days, 21 days, 
cells were collected for DNA extraction 
subsequently. (B) IMR90 fibroblasts were 
treated with 300µM H₂O₂ for 2 hours 
twice. (C) IMR90 fibroblasts were treated 
with 300µM H₂O₂ for 2 hours three times 
Dot Plot made in (Prism) represent dot 
plots (Telomere length distributions) from 
the gels, were quantified using Phortetix 
software, then they were compared (Days 
of recovery) and p value was calculated 
using t-test in Prism (P value in Red is 
Significant) (in Black is NS).    
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Figure 3.13: Comparison of Mean Telomere Length between Control and Treated IMR90 
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Figure 3.13: Comparison between mean 
XpYp telomere length distributions in IMR90 
control and treated (25µM, 50µM, 150µM & 
300µM H₂O₂) for (A) first treatment; after 7 
days recovery, 14 days recovery and 21 days 
recovery). (B) Second treatments; after 7 
days recovery, 14 days recovery and 21 days 
recovery. (C) Third treatments; after 7 days 
recovery, 14 days recovery and 21 days 
recovery.. Differences in mean telomere 
length between control and treated cells 
were measured by t-test.  IMR90 treated 
with 50µM H₂O₂ had a significantly shorter 
mean telomere length compared to the 
control in the second time treatments (21 
days recovery). The same cells when treated 
for the third time (50µM H₂O₂ third 
treatments) (21 days recovery) they had 
significantly longer mean telomere length. 
Dot Plot made in (Prism) represent dot plots 
(Telomere length distributions) from the gels, 
were quantified using Phortetix software, 
then they were compared (control and 
treated samples) and p value was calculated 
using t-test in Prism (P value in Red is 
Significant) (in Black is NS).    
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Figure 3.14: The proportion of Short Telomere frequency (IMR90, H2O2) 
  
Figure 3.14: The proportion of short telomere frequency was calculated under 2kb. IMR90 
fibroblasts displayed a high proportion of short telomeres after 21 days recovery of H₂O₂ 
treatment in second treatment (A) more than those in the third treatments (B). The cells 
with short telomeres disappeared after third treatments.    (Significant) p value was 
calculated using (ANOVA). Error bars represent standard error (SE). 
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Figure 3.15: STELA of IMR90 Clone 4 at XpYp Telomere (Control, 1.15mM, 2.25mM & 4.5mM H₂O₂) 
  
Control PD Mean SD 1.15mM PD Mean SD 2.25mM PD Mean SD 4.5mM PD Mean SD 
Time 0 28 8.407 3.76             
AT 28 7.97 3.58 AT 28 6.36 3.52 AT 28 7.76 3.28 AT 28 7.66 3.36 
7Days  29.42 7.10 3.80 7Days  29.4 7.45 3.93 7Days  29.35 7.78 3.27 7Days  29.23 6.54 3.47 
14Days  30.84 6.40 3.75 14Days  30.8 6.10 3.59 14Days  30.7 5.84 3.62 14Days  30.47 6.84 3.92 
21 Days 32.26 5.95 3.79 21 Days 32.2 5.42 3.53 21 Days 32.05 6.14 4.10 21 Days 31.71 5.39 3.60 
27 Days 33.48 5.52 3.54 27 Days 33.4 5.77 3.49 27 Days 33.21 5.66 3.19 27 Days 32.77 5.48 3.32 
 
Figure 3.15: STELA gels of XpYp telomere in the IMR90 clone 4 treated with H₂O₂ for 10 minutes and the tables of descriptive data for telomeres. The gels 
illustrate the telomere length distributions while the tables give the mean, standard deviations (SD) and population doublings (PD), (PD) was calculated 
after cells harvested.  (A) Control IMR90 fibroblasts. (B) IMR90 fibroblasts were treated with 1.15mM H₂O₂ for 10 minutes, then cells were washed with PBS 
and trypsinised and spilt into half, half were collected for DNA extraction after treatment directly and the remaining half were reseeded in normal media 
and recovered for 7 days, 14 days, 21 days and 27 days, cells were collected for DNA extraction subsequently. (C) IMR90 fibroblasts were treated with 
2.25mM H₂O₂. (D) IMR90 fibroblasts were treated with 4.5mM H₂O₂.      
A C B D 
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Figure 3.16: IMR90 Clone 4 at XpYp Telomere Length Distributions (Control, 1.15mM, 2.25mM & 4.5mM H₂O₂) 
 
IMR90,H2O2
Co
nt
ro
l
1.1
5m
M
2.2
5m
M
4.5
m
M
0
5
10
15
20
25
P= 0.008
(After Treatment)
Te
lo
m
er
e 
le
ng
th
 (k
b)
    
IMR90,H2O2
Co
nt
ro
l
1.
15
m
M
2.
25
m
M
4.
5m
M
0
5
10
15
20
25
(7 Days Recovery)
T
el
o
m
er
e 
le
n
g
th
 (
kb
)
        
IMR90,H2O2
Co
nt
ro
l
1.
15
m
M
2.
25
m
M
4.
5m
M
0
5
10
15
20
25
(14 Days Recovery)
Te
lo
m
er
e 
le
ng
th
 (
kb
)
 
IMR90,H2O2
Co
nt
ro
l
1.
15
m
M
2.
25
m
M
4.
5m
M
0
5
10
15
20
25
(21 Days Recovery)
Te
lo
m
er
e 
le
ng
th
 (
kb
)
         
IMR90,H2O2
Co
nt
ro
l
1.
15
m
M
2.
25
m
M
4.
5m
M
0
5
10
15
20
25
(27 Days Recovery)
Te
lo
m
er
e 
le
ng
th
 (
kb
)
    
 Figure 3.16: Dot Plot made in (Prism) represent dot plots (Telomere length distributions) from the gels, were quantified using Phortetix software. Any 
significant differences in mean telomere length between control and treated cells as measured by t-test were highlighted. Bar chart showed 
the proportion of short telomere frequency, calculated below 1kb, IMR90 treated with 2.25mM had high short telomere frequency compared 
to the control and the cells treated with 1.15mM and 4.5mM. Error bars represent standard error (SE).    
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Figure 3.17: STELA of U138 at XpYp Telomere Control and treated with 
(4.5mM H₂O₂) 
         
Figure 3.17: STELA gels of XpYp telomere in U138 treated with H₂O₂ for 10 minutes. The 
gels illustrate the telomere length distributions, (mean, and standard deviations (SD) 
displayed under the gels. Control U138 cells gel on the RIGHT and U138 treated with 4.5mM 
H₂O₂ gel on the LEFT. Cells were recovered for 7 days, 14 days, 21 days and 27 days, cells 
were collected for DNA extraction subsequently.  
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Figure 3.18: Telomere length distributions of U138 at XpYp Telomere (comparison between control and treated) 
(4.5mM H₂O₂) 
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Figure 3.18:  A- Telomere length 
distributions were quantified using 
Phoretix software, comparison 
between mean telomere length of 
control and treated cells revealed no 
significant differences as measured 
by t-test. 
B- Bar chart showed the proportion 
of short telomere frequency after 27 
days recovery, it was calculated 
below 1kb. Control cells had higher 
short telomere frequency than 
treated cells. Error bars represent 
standard error (SE).    
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3.5 Discussion 
3.5.1 Culture Growth 
In the study presented here, IMR90 foetal lung fibroblasts treated with various 
concentrations of H₂O₂ displayed a truncated replicative lifespan (~39-42 PDs) compared to 
the cells grown in normal conditions (~48.72 PDs). Moreover, it was obvious that with cells 
reaching the end of their replicative lifespan, the growth rates slowed at both normal and 
recovered cultures. This data is in line with previous observations, as fibroblast cell cultures 
reach their end of their replicative capacity, the growth rate slows with an increasing 
proportion of cells senescening and fewer cells capable of cell division.   
In IMR90 fibroblasts treated with 4.5mM H2O2 the growth rate was determined to be 0.177 
PD/day and 0.203 PD/day were in the control. U138 cancer cells were higher in their growth 
rate compared to IMR90 fibroblasts. U138 treated with 4.5mM was 0.305 PD/day and 0.321 
PD/day for control. 
Such observations illustrate that levels of oxidative stress influences the replicative life span 
of primary human cell culture. IMR90 cells appears to be sensitive to oxidative stress, as 
previously observed, many studies have shown that IMR90 cells in conditions of low 
oxidative stress, their replicative lifespan is significantly increased (Packer and Fuehr 1977; 
Chen et al., 1995; Saito et al., 1995). It was also observed that when the media was 
supplemented with free radical scavengers, IMR90 cells significantly extended their 
replicative capacity (Britt-Compton et al., 2006).  
Our data, together with previous studies using IMR90 (Chen et al., 1995; Saito et al., 1995; 
Forsyth et al., 2003), indicate that these cells may be less able to adapt to conditions of 
 101 
 
oxidative stress which is obvious from their limited replicative capacity in culture. A study 
suggested that the reason behind the attenuation of replicative lifespan of IMR90 cultures 
in conditions of high oxidative stress is that the telomeres structure of IMR90 cells are more 
sensitive to oxidative damage. This damage accelerates telomere erosion which in turn 
reduces the replicative capacity (Von Zglinicki, 2002). A Previous study from our laboratory 
showed that the ectopic expression of telomerase in IMR90 cells results in IMR90 
immortalised in conditions of lower levels of oxidative stress, but not in conditions of high 
oxidative stress (Britt-Compton, 2009). Thus it was concluded that telomerase is incapable 
of counteracting telomeric specific damage resulting from oxidative stress. In contrast to 
IMR90 cells, MRC5 fibroblasts have previously been shown to be immortalised with 
telomerase in high oxidative stress (20% oxygen) (McSharry et al., 2001). Different cell 
strains react differently to varying oxygen tensions and that such differences may be due to 
differing antioxidant capacities (Lorenz, 2001; Britt-Compton, 2009). 
3.5.2 Cell Cycle Progression under Oxidative Stress 
Previous studies have observed that hyperoxia initiates growth arrest. Dependenting upon 
the cell type, cell cycle arrest may occur in G1, S or G2 phase of the cell cycle. Furthermore 
the arrest may be transient,permanent or can even lead to apoptosis or necrosis (Boonstra 
and Andries Post, 2004). These checkpoint responses allow damaged cells to either repair 
the damage, enter a permanently growth-arrested state (G0) or if the damage is too 
severe,cells can undergo apoptosis. Thus depending on the level of oxidative stress, cells 
display a broad spectrum of responses. 
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 The usage of Hydrogen peroxide in the concentration of 300μM on Fibroblast cells has 
shown that cells were not been able to adapt to the oxidative stress and therefore entered a 
permanently growth-arrested state (Barzilai and Yamamoto, 2004).  
It has been observed that severe DNA damage inhibits the activity of CDK-cyclin complexes. 
(Barzilai and Yamamoto, 2004). These complexes are responsible for the cellular progression 
through the cell cycle. Their inhibition will result in cells arresting at G1 phase. The Inhibition 
of CDK-cyclin is modulated by p53, which in turn activates protein p21. p21 will bind to CDK-
cyclin complex in the cells and prevents the phosphorylation of the proteins and thus 
inhibits the kinase activityof the complex. The cells will not be able to progress in the cell 
cycle and result in cells arrested at G1 (Barzilai and Yamamoto, 2004).       
Around 24% of untreated IMR90 cells were in G2/M phase. This percentage was drastically 
decreased in treated cells with 300μM H₂O₂ (third treatment) where only 8% of treated cells 
were in G2/M phase. Moreover, Hydrogen peroxide treatment results in a reduction of cells 
in synthesis phase (S phase) as well. IMR90 firborblasts which were treated with 150μM 
H₂O₂ (second treatment) displayed around 1% of cells in S phase. 
In contrast, in this study we have shown that oxidative stress induced by H2O2 results in the 
increased frequency of cells arresting in G0/G1 phase. 
These findings suggest that the cells had been injured severely by hydrogen peroxide and 
they were not been able to re-enter the cell cycle again. Furthermore, the data obtained 
from SAβ-gal assay support this observation, where a high percentage of IMR90 cells were 
senescent and positive for SAβ-gal (senescence marker) after the exposure to H₂O₂. 
Furthermore population doublings (PDs) and growth rate were decreased after treatment 
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with hydrogen peroxide. These data indicate that oxidative damage induced by exposure to 
H₂O₂ result in a premature senescence while the percentages of senescent cells produced 
vary dependent upon the H₂O₂ concentrations.           
3.5.3 Telomere Dynamics 
Telomere deletion events have been observed in primary culture fibroblasts (Baird et al., 
2003), these represent a significant mutational mechanism creating dysfunctional telomere 
that are capable of fusion (Capper et al., 2007). The objective of this study was to determine 
if oxidative stress plays a role in generating telomere deletion events.  
In order to examine this hypothesis, the XpYp telomere length distributions of IMR90 and 
U138 cancer cells treated with hydrogen peroxide were investigated using STELA (Baird et 
al., 2003). In line with previous studies in the group (Baird et al., 2003), the XpYp telomere 
were analysed as the average telomere length and the average telomere erosion rates 
resulting from the end-replication problem is similar at most chromosome ends. Multiple 
samples were taken during the proliferative lifespan of the cultures and subjected to STELA. 
STELA was used to track the telomere dynamics and detect any stochastic shorter telomeres 
with ongoing cell division.  
IMR90 control and treated cells displayed bimodal distributions at XpYp telomere. However 
bimodal distributions make it difficult to determine these deleted telomeres. Bimodal 
distributions or extensive telomere length variation could arise from inter-allelic differences, 
which are set in zygote and resulting of contribution of maternal and paternal telomere 
alleles, or they may be due to the presence of sub populations of cells with shorter 
telomeres that may have a shorter replicative capacity.  
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Allelic variation has been previously described. Previous studies have shown that MRC5 
fibroblasts display bimodal distributions at XpYp. These distributions were a consequence of 
allelic variation as determined using allele-specific amplification (allele-specific STELA) (Baird 
et al., 2003).  In contrast IMR90 fibroblasts were characterised having a uni-modal allelic 
distribution at XpYp. A smaller subset of these telomeres was not consistent with allelic 
variation instead represented a sub-population of cells with shorter telomeres. 
The IMR90 cultures used in this study also displayed bimodal distributions at XpYp. 
Reproducible changes in these distributions were observed after approximately 14 days of 
recovery periods specifically after the third treatments; i.e. the cells with shorter telomeres 
disappeared from the culture. This was clearly seen and statistically significant in IMR90 
treated with 50µM H₂O₂ after 21 days of recover periods after the third treatment.  
Our data showed that IMR90 in the third treatment had a lower frequency of short 
telomeres compared to those after the second treatment. These short telomeres had 
probably disappeared as those cells reach the end of their replicative capacity.  
In IMR90 fibroblasts, treated with higher concentration of H₂O₂ and a shorter duration, the 
mean telomere length declined in both control and treated cells over time. IMR90 treated 
with 2.25mM had higher short telomere frequency.  
U138 tumour cells showed no significant differences in mean telomere length between 
treated and untreated cells. Both control and treated cultures decreased in mean telomere 
length.   
Taken together these data suggest that the cells had been damaged by exposure to 
hydrogen peroxide and they were prematurely senescent. From data obtained from cell 
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cycle analysis showed that higher numbers of treated cells accumulated at G1. The SAβ-gal 
assay showed high percentage of treated cells was senescent. Furthermore population 
doublings (PDs) and growth rate of the cells were decreased in treated cells. 
In this data we made the key observation that the telomere length in IMR90 cells was longer 
after the third treatment of H₂O₂ compared to the untreated cells and the lower modal 
distributions had disappeared. This could be explained by different scenarios (Figure 3.19). 
Firstly, that oxidative stress preferentially damages short telomeres and therefore they had 
disappeared. As described previously, telomeres are considered to be sensitive to oxidative 
damage. This might be due to the sensitivity of the GGG repeat regions to ROS and in turn 
might induce premature senescence in effected cell. However it difficult to conceptualise 
how, given the apparent sensitivity to the oxidative stress, short telomeres would be 
preferentially subjected to the oxidative damage compared to longer telomeres that 
represent a larger target for damage. A second and potentially more plausible scenario 
could be that the cells with short telomeres are closer to the point of replicative senescence 
and are more sensitive to exposure to hydrogen peroxide and thus undergo premature 
senescence or apoptosis, such that they are no longer detectable in the culture.  
Moreover, our data showed that exposure IMR90 fibroblasts to hydrogen peroxide 
treatments did not produce an increase in the proportions of short deleted telomeres and 
telomeric deletion events were not detectable under different levels of oxidative stress. The 
role of p53 has been also investigated. p53 were knockdown in IMR90 cells and hydrogen 
peroxide treatment was carried out; telomere deletion events were undetectable at 17p 
telomere (data not shown). Furthermore, U138 tumour cells (p53 deficient) showed no 
significant differences in telomere deletion events were not seen in treated cells as well.  
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The original hypothesis that oxidative stress might work as a mutational mechanism and 
result in telomeric deletion events has not been substantiated with the data presented 
here. However it remains formally possible that telomeric deletion events may still occur 
but that they render the telomere undetectable with STELA.  
Together these data are consistent with the previous observations that IMR90 cells had 
longer telomere length at higher oxidative stress (20% oxygen) than at 3% oxygen (Britt-
Compton et al., 2006). Thus it was concluded that senescence of IMR90 at high level of 
oxidative stress is telomere-independent manner and telomere dependent in case of low 
level of oxidative stress (Britt-Compton et al., 2006). Other study by Chen et al. (2001) used 
H₂O₂ and induced premature senescence in IMR90 cells and no telomere erosion was 
detectable. 
 Our present data, and data from others may be important because others have argued that 
oxidative stress drives the majority of telomere erosion (Von Zglinicki 2002). Our data are 
not consistent with this view and indeed others have concluded that premature senescence 
does not arise as a consequence of accelerated telomere erosion, but instead more likely 
results from stochastic DNA damage across the rest of the genome (Dumont et al., 2001; de 
Magalhaes et al., 2002).    
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Figure 3.19: illustrate scenarios that might explain losing of lower modal distributions in 
IMR90 fibroblast after the exposure to oxidative stress.  
3.6 Conclusion 
The data generated in this study indicates that the original hypothesis that oxidative stress 
might work as a mutational mechanism and result in telomeric deletion events was not 
valid. Instead these data are more consistent with the view that premature senescence does 
not arise as a consequence of accelerated telomere erosion, but instead more likely results 
from stochastic DNA damage across the rest of the genome. 
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Chapter 4 
Telomere Fragile Site 
 
4.1 Summary 
Telomeres can resemble fragile sites and can pose a challenge to the replication fork 
machinery. Moreover, replication fork stalling is a characteristic of fragile site that may be 
resolved as single or double-stranded breaks within telomeres, potentially resulting in 
telomeric-deletion events. The aim of this work was to investigate if the induction of 
telomere fragility has the potential to drive stochastic telomeric deletion events.  
In order to test this hypothesis, chromosome fragility was induced in cultured MRC5 
fibroblasts, Seckel cell fibroblasts (SCK) and U138 cancer cells using the DNA replication 
inhibitors Aphidicolin (APH) and Hydroxyurea (HU).  
The induction of chromosome fragility was monitored in metaphase chromosomes.  Cell-
cycle checkpoints, cell growth and the induction of senescence were also documented. 
Telomere dynamics and stochastic telomeric deletion events were investigated using STELA. 
The telomere dynamics in treated SCK fibroblasts were significantly different from those 
untreated SCK fibroblasts following treatments with APH, with an increase in stochastic 
telomeric deletion. Whilst in MRC5 fibroblasts, the induction of the telomere fragility 
impacted on the upper to lower allele ratio, with a loss of the longer telomere length 
distributions.  The induction of fragility in U138 cancer cells did not produce any significant 
differences in the mean telomere length or the frequency of telomeric deletion events. 
Taken together these data indicate that fragile site induction can modulate telomere 
dynamics.  Moreover MRC5 fibroblasts were more resistance to the induction of fragility 
than SCK fibroblasts where the fragility appeared to be enhanced by ATR deficiency.   
 109 
 
4.2 Introduction 
In order to minimise mutation, the process of DNA replication needs to be as accurate as 
possible, but it is clear that some regions of the human genome, such as Common Fragile 
Sites (CFSs), are difficult to replicate and this can lead to mutation (Toledo et al., 2000). 
Recently, the role of common fragile sites in the generation of chromosome instability has 
become clear, so that they are now implicated in chromosomal aberrations in tumour cells 
(Lukusa and Fryns, 2008). The fragility of CFSs appears to arise as a consequence of mitotic 
entry prior to the completion of the replication process. However, the mechanisms behind 
these aberrations and incomplete replication are still unclear (Tallec et al., 2014). 
Chromosomal fragile sites are defined as specific regions of the genome that are prone to 
gaps or breaks within metaphase chromosomes following the partial inhibition of DNA 
replication (Glover, 2006). Late replication is a characteristic of these sites and it was found 
that the mutational expansion of nucleotide repeats (CGG or AT) at these sites could form 
secondary structures that can lead to replication fork stalling (Figure 4.1) (Durkin and 
Glover, 2007). Stalled forks are the most common cause of breakage at these sites and are a 
source of chromosome rearrangements and instability, which is important for tumorigenesis 
(Tallec et al., 2014). 
4.2.1 Telomeres and Fragile Sites  
Recently, telomeres have been characterised as fragile sites. Telomeric sequences, which 
are composed of long arrays (2–10 kb) of TTAGGG repeats, present a challenge for DNA 
replication, leading to phenotype similar to those seen at common fragile sites (Sfeir et al., 
2009). Specific protein complex (shelterin) proteins protect telomeres from DNA damage 
response and preventing potential chromosomal fragility at these sites (de Lange, 2005). A 
study by Sfeir et al., 2009 demonstrated that DNA replication is compromised at telomere 
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repeats and telomeres resemble the common fragile sites. Moreover, they reported that the 
shelterin protein TRF1 is important to protect telomere from breakage associated with 
replication fork stalling at telomeric sequences. The deletion of TRF1 led to unprotected 
telomeres and increased number of fusions and activation of the ATR protein, which is 
responsible for stabilising stalled replication forks during replication and prevents 
chromosomal breaks at fragile sites (Verdun and Karlseder, 2006). ATR has been found to be 
abundant at mammalian telomeres during late replication (Verdun and Karlseder, 2006).  
 
   
Figure 4.1. Fragile site. (A) Fragile sites originate from unreplicated DNA, when replication 
fork stalled, RPA, single strand DNA binding protein, binds to unreplicated ssDNA and 
activates DNA damage response. ATR activates S-phase or G2/M checkpoints in order to 
repair these regions. However, sometimes these sites escape checkpoint and left unrepaired 
and displayed as breakage and gap on metaphase chromosomes (B). Redrawn from (Durkin 
and Glover, 2007).          
 
4.2.2 History of Fragile Site 
The identification of chromosomal fragile sites had a major impact on the understanding of 
the molecular basis of genetics disease, for example fragile X disorder and the other 
A B 
 111 
 
mutational expansions of nucleotide repeats (Durkin and Glover, 2007). Fragile sites have 
been also involved in activation of DNA damage response to stalled replication and in 
genome instability in tumour cells (Durkin and Glover, 2007). In 1970, the term of fragile site 
was first described, when breaks on the long arm of chromosome 16 were found to 
segregate in a large family (Magenis et al., 1970). Since that time, more fragile sites have 
been identified and observed to segregate in pedigrees, for example the fragile site at Xq28 
in families with X-linked mental retardation (Turner et al., 1978). Fragile sites are stable in 
cell culture, but under certain conditions they form breaks and gaps on metaphase spreads 
chromosomes (Sutherland, 1977). For example a rare autosomal fragile site, in Australian 
families, and the fragile X in males, were induced follow culturing of cells in media 
containing low folic acid (Sutherland, 1979). This study and others observations identified 
that folate stress can lead to fragile sites expression. This work led to the identification of 
the essential conditions to diagnose individuals with fragile X disorder utilising a cytogenetic 
assay and also facilitate to discover other fragile sites over the genome. Nowadays, more 
than hundred fragile sites have been reported and identified.  
Un-replicated single stranded DNA, arising from replication fork stalling after partial 
inhibition of DNA synthesis, is most likely it is related to the localised DNA sequence and 
replication dynamics (Zlotorynski et al., 2003). DNA repair of single-stranded regions in 
fragile sites require DNA-directed homologous repair. They are recognised and arrested by 
ATR protein (S phase and/or G2/M checkpoints), however some fragile sites in normal cells 
can escape the ATR checkpoints and displayed as breakages on metaphase chromosomes 
(Casper et al., 2002). Sister chromatid exchange can be found within fragile sites, moreover 
deletions and translocations also can be seen and they usually as a result of DNA double 
stranded beaks at damaged forks (Casper et al., 2002). These breaks are recognised by ATM 
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checkpoints. Previous research has proposed that alterations found in replication 
checkpoint in tumour cells will display a high number of chromosomal rearrangements at 
fragile sites (Tallec et al., 2014; Casper et al., 2002).  
4.2.3 Classification of Fragile Sites       
Fragile sites are divided into two main groups: rare or common on the basis of their 
frequency within the population.  
4.2.3.1 Rare Fragile Sites 
They are the sites which are seen in less than 5% of population and nucleotide repeat 
expansion is the main cause of the gaps and breakages at these regions (Kremer et al., 
1991). Rare fragile sites are subdivided depending on their particular induction chemistry 
into as folate sensitive or non-folate sensitive fragile sites. The folate sensitive group are 
characterised by the expansion of CGG repeats and they are the most common group of 
rare fragile site. On the other hand, non-folate sensitive rare fragile sites are less in their 
frequency and are associated with the expansion of AT minisatellite repeats. 
Bromodeoxyuridine (BrdU) or distamycin A usually induce non-folate sensitive rare fragile 
sites (Kremer et al., 1991; Sutherland et al., 1998). 
4.2.3.2 Common Fragile Site (CFSs)  
(CFSs) are classified as the largest group among fragile sites, and are seen in the whole 
population. Unlike rare fragile sites, CFSs are not associated with nucleotide repeats 
expansion, CFSs display normal chromosome structure (Durkin and Glover, 2007).       
4.2.4 Fragile Site Inducers 
Most of inducers of chromosomal fragility (Table 4.1) share in common their ability to 
partially inhibit of DNA synthesis, specifically at fragile site loci. 
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Fragile site inducer Number of loci Sequence 
aphidicolin 76 AT rich repeats 
Bromodeoxyuridine (BrdU)  9 AT rich repeats 
distamycin A 5 AT rich repeats 
5-azacytidine,  4  
Table 4.1 fragile site inducer. Modified from (Durkin and Glover, 2007). 
4.2.5. Maintenance of Fragile Site Stability 
Little was known about the mechanisms of fragile site stability until 2002, when a study was 
carried out by Casper and his colleagues, who were the first who report the crucial role of 
the Ataxia-Telengiectasia and Rad3 Related (ATR) checkpoint in the maintenance of fragile 
site stability (Casper et al., 2002). They found that cells with ATR deficiency have high 
number of breaks and gaps at fragile sites even without the addition of aphidicolin, 
hydrouxyurea or any other replication inhibitor agents (Casper et al., 2002). Moreover, they 
noticed that cultured cells with (ATR knockdown) in the presence of aphidicolin have 
increased fragile sites instability (Casper et al., 2002). These results are important, as they 
indicated that replication fork inhibition that can occur at fragile sites is common and that 
ATR activation in response to fork stalling at these sites delays cell division and allows for 
repair the damage. In the absence of ATR, fragile site expression is observed as deletions, 
translocation and/or other rearrangements in metaphase chromosomes (Casper et al., 
2002). 
They have subsequently found that Seckel cells which have a mutation in ATR show high 
frequencies of chromosome breakages at fragile sites (O’Driscoll et al., 2003; Casper et al., 
2004). They have reported that Seckel disorder is the first human genetic disease has high 
susceptibility to fragile site instability (Casper et al., 2004).  
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In contrast, ATM-deficient cells did not display fragile site breaks or any of chromosome 
rearrangements. This suggests that DNA double stranded breaks, the lesion to which ATM 
responds to, are not the initial cause of fragile sites expression (Durkin and Glover, 2007). 
However, ATM plays an important role in modulating downstream events at fragile sites 
mainly in the resolution of double stranded breaks that happen at these sites. These double 
stranded breaks arise at these sites via action of nucleases (Durkin and Glover, 2007). 
In 1996, ATR was identified and found in all eukaryotic cells (Keegan et al., 1996). It is an 
important and critical activator in signalling responses to DNA damage and replicative 
stress, that induces S-phase checkpoint and G2 checkpoints and block cell cycle progression 
into mitosis (Keegan et al., 1996). Subsequent studies have investigated and characterised 
other mechanisms could involved in fragile site stability; they have found that Chk1 and 
BRCA1 play a role in the maintenance of these sites (Arlt et al., 2002). BRCA1, like ATR 
activates, Chk1 which in turn regulates CDC2/cyclin complex and thus manages the G2 
checkpoint and progression into mitosis (Arlt et al., 2002). Durkin et al., 2006 reported the 
effect of depletion of Chk1 on fragile sites expression following APH treatment. 
4.2.6 Fragile Sites as Indicators of Stalled Replication in Cancer 
It has been found that the rate of the recombination is increased at fragile sites compared 
to other regions in the genome. In cancer, fragile sites are the hotspots for deletions, 
translocation and other chromosomes rearrangements (Yunis and Soreng, 1984; LeBeau and 
Rowley, 1984). It has been reported that high frequencies of fragile site instability is 
considered as indicator of replication fork stalling in tumour cells (Durkin and Glover, 2007). 
This is associated with deficiencies in ATR or related repair genes during tumorigenesis. 
Previous studies have found phosphorylated ATR, Chk1 and P53 in precancerous lesions 
from bladder, breast, colorectal and lung (Gorgoulis et al., 2005). These results 
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demonstrated that replication forks stalling in premalignant cells leads to ATR activation and 
deletions preferentially target fragile sites in cells that escape the DNA damage checkpoints 
(Durkin and Glover, 2007).    
4.2.7 Analysis of Stochastic Deletion Events 
Telomeres were not originally classified as fragile sites, perhaps due to their terminal 
position, at the end of chromosomes, rendering it difficult to detect these events (Sfeir et 
al., 2009). However it is now clear that telomeres do resemble fragile sites and pose a 
challenge to the replication fork machinery (Sfeir et al., 2009). Stalled replication forks 
within telomeres could be resolved as single-stranded DNA breaks that result in truncated 
telomeres. Therefore, the characteristic of telomere fragility could play a role and have the 
potential to drive stochastic telomeric deletion events, resulting in the extremely short 
telomeres. Sensitive techniques, such as STELA, are able to detect mutational events in 
telomeric DNA, the resulting critically short telomeres have the potential to trigger 
replicative senescence or initiate chromosome instability (Baird et al., 2003).  
4.3 This Work 
In this chapter, I have examined whether the induction of chromosome fragility at 
telomeres has the potential to drive stochastic telomeric deletion events, resulting in the 
extremely short telomeres that can be detected with STELA. In order to test this hypothesis, 
fragile sites were induced with using Aphidicolin (APH) and Hydroxyurea (HU) (DNA 
synthesis inhibitors). The effects of fragility on the cell growth and on telomere dynamics 
were examined in MRC5 fibroblasts, Seckel cell fibroblasts (SCK) and U138 cancer cells. Cells 
were cultured in different concentrations of APH and HU in a parallel with cells grown in 
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normal conditions. DNA samples were taken during proliferation of the cultures, enabling 
detailed analysis of telomere dynamics using STELA.  
4.4 Results 
4.4.1 Effects of Fragile Site Induction on Culture Growth  
In order to examine the effect of fragile site induction on cells in culture, MRC5 cultured at 
PD 34.86, Seckel cells (ATR deficient cells) at PD 26 and U138 cancer cells (mutated P53), 
cells were cultured in 6-well plates (35-mm dish) and treated with different concentrations 
of APH (0.3µM) & (1µM) and HU (1mM) & (5mM) for 24 hours. After treatment cells were 
counted and half were collected for DNA extraction and the remaining half were reseeded 
in normal media for recovery, cells were later collected for DNA extraction after 5days of 
recovery. STELA was carried out allowing detailed analysis of telomere dynamics.  
The cells were passaged serially after treatments and the average of population doublings 
(PDs) was calculated and plotted as a function of time (Figures 4.2 & 4.3).  
These data showed the growth rate which was determined to be on average of 0.35 PD/day 
for MRC5 fibroblasts (Figure 4.2) in standard culture conditions and this average declined in 
cells cultured with APH and HU. It was about 0.24PD/day for those treated with 0.3µM APH 
and 0.14PD/day for cells cultured with 5mM HU.     
Figure 4.3 showed the growth rate of Seckel cells (SCK) control and treated. The growth rate 
of normal control SCK cells was lower than the normal growth rate of MRC5 cells, it was 
about 0.24PD/day. SCK cells cultured with 1µM APH was 0.19PD/day and it was 0.16PD/day 
for those treated with 5mM HU. Thus in both SCK and MRC5 fibroblast cultures the 
treatment with APH or HU resulted in clear reduction in the rate of growth. 
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The overall growth rates of U138 cells control and treated were higher than MRC5 
fibroblasts and SCK cells. In contrast to the SCK and MRC5 cells there was no difference 
between control and recovered U138 cells. 
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Figure 4.2: PDs of MRC5 cells (APH & HU) 
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Control &Treatment Growth Rate PD/day Total PD’s  
Control 0.35 PD/day 42.00 
0.3µM APH 0.24PD/day 39.66 
1µM APH 0.21 PD/day 39.06 
1mM HU 0.15 PD/day 37.86 
5mM HU 0.14 PD/day 37.66 
Figure 4.2: Growth curves of 
MRC5 cells. MRC5 control 
(untreated) (Black Line) and 
(treated) with different 
concentrations of APH 
(0.3µM (Red Line) & 1µM 
(Green Line)) & HU (1mM 
(Gray Line) & 5mM (Blue 
Line)) for 24 hours.  Plotting 
growth curves as function of 
population doublings (PD) 
verus time in days.  
 
MRC5 (1µM APH) = 0.21 PD/day 
 
MRC5 (1mM HU) = 0.15 PD/day 
MRC5 (Control) = 0.35 PD/day MRC5 (0.3µM APH) = 0.24 PD/day 
 
MRC5 (5mM HU) = 0.14 PD/day 
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Figure 4.3: PDs of SCK cells (APH & HU) 
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Control & Treatment Growth Rate PD/day Total PD’s 
Control 0.24 PD/day 30.8 
0.3µM APH 0.23 PD/day 30.6 
1µM APH 0.19 PD/day 30 
1mM HU 0.20 PD/day 30.1 
5mM HU 0.16 PD/day 29.4 
Figure 4.3: Growth curves of 
SCK cells. SCK control 
(untreated) (Black Line) and 
(treated) with different 
concentrations of APH (0.3µM 
(Red Line) & 1µM (Green Line)) 
& HU (1mM (Gray Line) & 5mM 
(Blue Line)) for 24 hours.  
Plotting growth curves as 
function of population 
doublings (PD) verus time in 
days.  
 
SCK (1mM HU)= 0.20 PD/day SCK (1µM APH) = 0.19 PD/day 
Control = 0.24 PD/day SCK (0.3µM APH) = 0.23 PD/day 
SCK (5mM HU)= 0.16 PD/day 
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4.4.2 Effect of Fragility Induces on Cell Cycle Checkpoints  
In order to examine the effect of fragile site induction on cell cycle checkpoints, MRC5, SCK 
and U138 cells were cultured with APH (1µM) and HU (1mM) and incubated for 24 hours in 
100mm dishes. Controls and treated cells were collected from culture and fixed in 70% 
ethanol then were stained with Propidium Iodide (PI) and the G1, S and G2/M fraction was 
determined by flow cytometry.  
Treatment with APH and HU resulted in an increase in the number of cells in S-phase 
compared to controls in MRC5, SCK & U138 cells, as shown in (Figure 4.4). 10.4% and 9.1% 
of treated MRC5 cells with 1μM of APH and 1mM of HU respectively were in S-phase, 
compared to the control which were only 3.3% of cells were in S-phase (Figure 4.4.A).  
The fragility induced by the exposure to APH and HU, also increased the number of cells in 
S-phase in ATR deficient cells (SCK cells). 14.7% of treated SCK cells with 1μM of APH and 
15.8% of treated cells with 1mM of HU were in S phase, where the control was only 8.3% in 
DNA synthesis phase (Figure 4.4.B).  
U138 cancer cells also showed an increase in the number of treated cells in S phase (Figure 
4.4.C). 
These observations were consistent with the action of APH and HU that induce a partial 
inhibition of DNA synthesis; thus treated cells were accumulated in S phase compared to 
their controls in all the cultures tested MRC5, SCK and U138. 
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Figure 4.4: Cell cycle of MRC5, SCK & U138 cells (Treatments (APH & HU) 
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Figure 4.4: Cell cycle progression of (A) MRC5, (B) SCK (C) U138 cells & (D) plots from flow cytometry. Percentage of cells accumulated at G0/G1, S and G2/M 
phases and fraction was calculated by flow cytometry. Controls were compared to treated cells with 1µM of APH & 1mM of HU for 24 hours. Cell cycle progression 
was investigated after (24 hours) of treatments. Treated cells with (APH & HU) were accumulated more in S phase compared to controls, due to drug induction 
partial inhibition of DNA synthesis. Error bars represent standard error (SE).  
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4.4.3 Cellular Senescence 
Cellular Morphology 
In order to examine the impact of the induction of fragility on cellular senescence, 
morphological changes were monitored in cells (MRC5, SCK & U138 cells) treated with APH 
and HU and compared to their controls (Figures 4.5, 4.6 & 4.7). The cellular morphology of 
treated cells (MRC5 & SCK cells) changed as shown in figure (4.5.A &4.6.A). They became 
larger than their controls and had bigger flattened cytoplasm and larger nuclei, consistent 
with cells undergoing cellular senescence (Toussaint et al., 2000). In contrast, U138 treated 
cells did not display any changes in their morphology compared to their control neither with 
APH nor with HU (Figure 4.7).      
Senescence Associated Beta galactosidase Activity (SAβ-gal) 
A chemical assay based on production of blue stain at pH 6.0 was developed, results from 
accumulation of the endogenous lysososmal β-galactosidase. In senescent cells, hydrolase 
enzyme catalyses β-galactosidase into monosaccharides and precipitate blue dyed. 
Senescence-associated beta-galactosidase is the most common reliable biomarker assay 
used for senescent detection. (Toussaint et al., 2000; Chainiaux et al., 2002; Dimri et al., 
1995). 
Senescence-associated β-galactosidase assay was used to investigate cellular senescence 
induction in cells treated with APH and HU and compared with untreated controls. Positive 
senescent cells were determined by counting 500 cells and the proportions of positive cells 
were given as percentages of the total counted cells. 
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It was observed that treated cells (MRC5 and SCK cells) had higher percentages of activation 
of senescence-associated β-galactosidase enzyme compared to their controls: this can be 
clearly seen from the result in figures (4.5.B & 4.6.B). Moreover, controls and treated of SCK 
cells had higher percentage of positive senescent cells compared to MRC5 cells.  
The average of senescent cells in the 1µM APH treated SCK and MRC5 cells was 49% and 
36% respectively; this average increased and reaching 56% and 39% for those cells treated 
with 5mM of HU; whereas control SCK cells was 18% and 8% for MRC5 senescent of the 
total counted cells.  
In contrast to the SCK and MRC5 cells, senescence-associated β-galactosidase activity could 
not be detected in U138 cancer cells, irrespective of the treatments with HU or APH.  
Taken together these data strongly indicate that APH and HU treatments successfully 
induced cellular senescence in SCK and MRC5 cells. In contrast U138 cells showed no sign of 
cellular senescence induction with either APH or HU treatments. 
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Figure 4.5: Cellular Morphology & Senescence-Associated β- galactosidase Activity of MRC5 Cells (APH & HU) 
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Figure 4.5: Cellular Morphology and SAβ-gal assay of MRC5 Cells. (A) 
Morphological changes for MRC5 cells were monitored and treated cells with 
APH (0.3µM & 1µM) & HU (1mM & 5mM) were compared to the 
morphological changes in control cells after 24 hours of treatments. 
Senescence-associated-beta-galactosidase (SAβ-gal) activity is detectable at 
pH 6 and produces a blue colour in positive senescent cells; as shown in the 
bars chart (B) the quantification of positive cells for SAβ-gal assay was 
determined by counting positive stained cells under microscope (X20). The 
proportions of positive cells were given as percentages of the total counted 
cells. Error bars represent standard error (SE).         
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Figure 4.6: Cellular Morphology & Senescence-Associated β- galactosidase Activity of Seckel cells (SCK) (APH & HU) 
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Figure 4.7: Cellular Morphology & Senescence-Associated β- galactosidase Activity of U138 (APH & HU) 
 
Figure 4.7: Cellular Morphology and SAβ-gal assay of U138 Cells. Morphological changes for U138 cells were monitored and treated cells with 
APH (0.3µM & 1µM) and HU (1mM & 5mM) were compared to the morphological changes in control post-treatments (24 hours). Senescence-
associated-beta-galactosidase (SAβ-gal) activity was not detectable in these cells as shown in the images. 
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4.4.4 Metaphase Chromosomes Analysis (Breaks and gaps) 
In order to test the impact of inducing fragility on chromosomal breaks and gaps at fragile 
sites, MRC5, SCK and U138 cells were cultured with APH (0.3µM & 1µM) and HU (1mM & 
5mM) incubated for 24 hours in 100mm dishes. After treatment, demecolcin (colcemid) 
were added to controls and treated cells and incubated for one-two hours then cells were 
trypsinised and KCl was added for 10-30 minutes, cells were fixed in (fixative solution 3:1 
methanol and glacial acetic acid) and can be kept at 4°C. Slides were prepared, metaphase 
chromosomes were stained with Giemsa. Then, breaks and gaps were counted in 50 
metaphases and was given as proportions as shown in figure 4.8.    
We did not observe any chromosomal instability in untreated MRC5 cells.  However both 
the SCK and U138 untreated cells had chromosomal breaks and gaps in 9% and 32% of the 
cells respectively. U138 cancer cells having mutated p53 and SCK cells fibroblast cells with 
ATR deficient, for these mutations might be that the chromosomal instability displayed 
more common in these cells, since p53 and ATR are important proteins play a crucial role in 
modulating DNA damage response. 
Following aphidicolin and hydroxyurea treatments, the average total gaps and breaks was 
increased in MRC5, SCK and U138 cells, as compared with their controls (Figure 4.8). In 
MRC5 treated cells an increase in gaps and breaks was observed from 0% in untreated cells 
to 26% in MRC5 cells treated with (1µM APH) and 21% for those treated with (5mM HU). 
SCK and U138 cells were treated with 0.3µM APH had 32% & 42% of breaks respectively; 
this average rose to 39% & 47% with cells treated with HU (5mM). These data clearly 
demonstrate that treatment of MRC5, SCK and U138 cells with APH and HU induces 
chromosomal fragility. 
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Figure 4.8 Metaphase Chromosomes Analysis in MRC5, SCK & U138 cells treated with (APH) and (HU) 
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Figure 4.8: Metaphase chromosomes analysis in 
(A) MRC5, (B) SCK & (C) U138 cells. APH and HU 
induced breakages and gaps at fragile sites in 
treated cells. Cells were treated with (0.3µM & 
1µM) APH and (1mM & 5mM) HU for 24h, 50 
cells were analysed in each case. Error bars 
represent standard error (SE).  
(D) Representative images of Giemsa-trypsin 
banding of metaphase chromosomes, (arrows) 
showing chromosomes breaks  
A C B 
D 
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4.4.5 Proteins Checkpoint Activation Analysis (Western Blotting)  
In order to investigate the effect of fragile site induction on key proteins involved with cell 
cycle checkpoint control, MRC5, SCK and U138 cells were cultured untreated and treated 
with APH (0.3µM & 1µM) and HU (1mM & 5mM) in 100mm dishes for 24 hours. Treated and 
untreated cells were trypsinised and collected for protein extraction. Western blots were 
carried out and phosphorylation of P53, Chk1 and Chk2 was investigated in treated cells and 
compared to untreated. Phosphorylations were determined by probing with anti-phospho 
P53 Ser15, anti-phospho Chk1 Ser345 and anti-phospho Chk2 Thr68 antibodies (Figure 4.9).   
Both Chk1 and Chk2 were phosphorylated following exposure to the higher concentration of 
APH (1µM) and at both concentrations of HU (1mM and 5mM) in MRC5 and U138 cells 
(Figure 4.9).   
In SCK cells (ATR deficient cells), it was observed that Chk1 was not fully phosphorylated or 
activated; Chk1 is an important ATR substrate regulating cell cycle checkpoint arrest. In 
contrast, Chk2, which is regulated by ATM, was phosphorylated in these cells after 
treatment with HU in both concentrations were used (Figure 4.9).   
Following exposure to HU (1mM and 5mM), P53 was phosphorylated in MRC5 cells and SCK 
cells but was not activated after treatment with APH in both concentrations were used in 
MRC5 cells.  
These data are consistent with the observed induction of cellular senescence and reduction 
in growth rates as a consequence of DNA damage arising following the induction of fragile 
site in the APH an HU treated cells. 
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Figure 4.9: Activation of key proteins required for cell cycle checkpoint control in MRC5, SCK & U138 cells treated with 
(APH) and (HU) 
 (Western Blotting) 
 
 
Figure 4.9: Checkpoints Activation Analysis. Western blot of MRC5, SCK and U138 cells, phosphorylations were determined by probing with 
antiphospho P53 Ser15, antiphospho Chk1 Ser345 and antiphospho Chk2 Thr68 antibodies. Cells treated with APH (0.3µM & 1µM) and HU 
(1mM & 5mM) for 24 hours Western blot was carried out for untreated and treated cells allowing comparison. Equal loading was confirmed by 
probing with Actin specific antibody.  
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4.4.6 Analysis of Telomere Dynamics 
It was clear that the treatments of MRC5, SCK and U138 cells with either APH or HU was 
sufficient to induce chromosome fragility.  In order to examine if the fragility induced by 
exposure to APH and HU resulted in large-scale changes to telomere length, the XpYp 
telomere length distributions of untreated MRC5, SCK and U138 cells and those treated with 
APH and HU were determined using single telomere length analysis (STELA). The XpYp 
telomere was analysed because it is considered to be representative for average 
chromosomal telomere length and average telomere erosion rates resulting from the end-
replication problem (Baird and Farr, 2006; Baird et al., 2003; Britt-Compton et al., 2006). 
Following treatments and 5 days recovery cell samples were taken in parallel with untreated 
cells and subjected to STELA to track the telomere dynamics and to detect any stochastic 
telomeric deletion events with ongoing cell division. STELA southern blots for the 
experiment are shown in figures (4.10, 4.12 & 4.13). 
As expected MRC5 fibroblasts displayed a bi-modal distribution at the XpYp telomere 
(Figure 4.10), and it is consistent with previous studies that MRC5 containing two differently 
lengths alleles at XpYp telomere, these distributions are a consequence of allelic variation in 
telomere length.  
Whilst no significant differences were observed in the telomere length distributions of the 
MRC5 cells following treatment, the proportion of molecules detected the upper and lower 
alleles appeared to change (Figure 4.11). 
Fewer molecules were detected in the upper alleles compared to the lower alleles following 
treatment. This appeared to be enhanced following 5 days of recovery after treatment of 
the MRC5 cells with 1µM APH. These changes are illustrated in Figure 4.11 that shows the 
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proportions of the long alleles to short alleles. Directly after treatment the proportions were 
41.66% to 58.33%, following 5 days of recovery the average for long allele decreased to 
32.8% whereas short allele increased to become 67.17%.   
The SCK fibroblasts displayed a uni-modal distribution at the XpYp telomere and displayed a 
more homogenous distribution. By looking at (figure 4.12) an apparent change in the mean 
telomere length distributions was observed in SCK fibroblasts after APH treatments directly. 
The shorter molecules observed in the control SCK disappeared in the cells treated with APH 
in both concentrations 0.3µM and 1µM and this resulted in a statistically significant changed 
to the mean telomere lengths distributions (p value 0.0001 and 0.0191 respectively).     
U138 cancer cells displayed a slight difference in mean telomere length between treated 
either with APH or with HU and untreated U138 cells (Figure 4.13) however this was not 
statistically significant. 
 U138 cells short telomere frequency was determined to be 19.4% below 3kb in control 
cultures while it was higher in cultures recovered from 1µM of APH was about 22.66%, 
similar average showed after treatment of 5mM HU (Figure 4.13).     
Figure 4.14 showed the proportion of short telomeres which was determined and calculated 
below 1kb for the MRC5 cells and below 3kb for the SCK cells, this due to the differences in 
the modal distributions between these cells. In MRC5 cells treated with 1mM HU showed 
4% of short telomere frequency while cells treated with 1µM APH was 0%. Moreover, in SCK 
cells post treatment with 0.3µM APH showed 0 % of short telomere and in SCK cells treated 
with 5mM of HU, short telomere frequency was 6.8% only.  
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Figure 4.10: STELA of MRC5 XpYp Telomere (Untreated, After treatment & Recovered) (APH & HU)  
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 Rec     Untreated 0.3uM APH 1uM APH 1mM HU 5mM HU 
PD 36.6 36.06 35.91 35.61 35.56 
Mean 4.24 4.733 4.376 4.444 3.956 
SD 2.63 2.35 2.55 2.46 2.35 
SE 0.16 0.19 0.22 0.24 0.23 
AT Time zero Untreated 0.3uM APH 1uM APH 1mM HU 5mM HU 
PD 34.86 35.21 35.1 35.07 35.01 35 
Mean 4.160 4.32 4.236 4.472 4.231 4.036 
SD 2.24 2.50 2.34 2.23 2.25 2.10 
SE 0.18 0.19 0.24 0.23 0.26 0.27 
Figure 4.10: STELA gels of XpYp 
telomere in the MRC5 untreated and 
treated with APH (0.3µM & 1µM) and 
HU (1mM & 5mM) for 24 hours and the 
tables of descriptive data for telomeres. 
The gels illustrate the telomere length 
distributions while the tables give the 
mean, standard deviations (SD), standard 
error (SE) and population doublings (PD), 
(PD) was calculated after cells harvested. 
(A) 50% of MRC5 fibroblasts were 
collected for DNA extraction after 24h of 
treatments (APH & HU). (B) The 
remaining 50%of cells were refreshed 
with normal media and recovered for 5 
days. Dot Plot made in (Prism) represent 
dot plots (Telomere length distributions) 
from the gels, were quantified using 
Phortetix software, then they were 
compared (control and treated samples) 
and p value was calculated using t-test in 
Prism (P value in Red is Significant) (in 
Black is NS).    
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Figure 4.11: The proportion of long to short alleles of MRC5 XpYp telomere 
(Untreated, After treatment & Recovered) (APH & HU) 
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Figure 4.11: The proportion of long to short alleles of MRC5 XpYp telomere. MRC5 
fibroblasts had the highest proportion of short alleles in cultures treated with 1µM APH 
following 5 days recovery.   
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Figure 4.12: STELA of Seckel cells (SCK) XpYp Telomere (Untreated, After treatment & Recovered) (APH & HU)   
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 Rec     Untreated 0.3uM APH 1uM APH 1mM HU 5mM HU 
PD 27.2 27.15 26.95 27 26.8 
Mean 5.84 6.088 5.539 5.564 5.769 
SD 2.37 2.58 2.10 2.17 2.14 
SE 0.17 0.18 0.15 0.19 0.18 
AT Time zero Untreated 0.3uM APH 1uM APH 1mM HU 5mM HU 
PD 26 26.24 26.23 26.19 26.2 26.16 
Mean 5.815 5.43 6.370 6.036 5.825 5.744 
SD 1.90 1.39 1.33 1.77 1.65 1.74 
SE 0.18 0.16 0.15 0.19 0.21 0.23 
Figure 4.12: STELA gels of XpYp 
telomere in the SCK untreated and 
treated with APH (0.3µM & 1µM) and 
HU (1mM & 5mM) for 24 hours and the 
tables of descriptive data for 
telomeres. The gels illustrate the 
telomere length distributions while the 
tables give the mean, standard 
deviations (SD), standard error (SE) and 
population doublings (PD), (PD) was 
calculated after cells harvested. (A) 50% 
of SCK cells were collected for DNA 
extraction after 24h of treatments (APH 
& HU). (B) The remaining 50%of cells 
were refreshed with normal media and 
recovered for 5 days. Dot Plot made in 
(Prism) represent dot plots (Telomere 
length distributions) from the gels, were 
quantified using Phortetix software, 
then they were compared (control and 
treated samples) and p value was 
calculated using t-test in Prism (P value 
in Red is Significant) (in Black is NS).    
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Figure 4.13: STELA of U138 cells XpYp Telomere (Untreated, After treatment 
& Recovered) (APH & HU) 
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U138 Cells  
U138 Untreated  1uM APH 
AT 
1uM APH 
Rec 
5mM HU 
AT 
5mM HU 
Rec 
Mean 3.87 3.91 3.79 3.78 3.73 
SD 0.99 0.78 0.95 0.86 0.86 
SE 0.14 0.14 0.11 0.15 0.14 
Figure 4.13: STELA gels of XpYp 
telomere in the U138 untreated and 
treated with APH (1µM) and HU 
(5mM) for 24 hours and the tables of 
descriptive data for telomeres. The 
gels illustrate the telomere length 
distributions while the tables give the 
mean, standard deviations (SD) and 
standard error (SE). 50% of U138 cells 
were collected for DNA extraction after 
24h of treatments (APH & HU). The 
remaining 50%of cells were refreshed 
with normal media and recovered for 5 
days. Dot Plot made in (Prism) 
represent dot plots (Telomere length 
distributions) from the gels, were 
quantified using Phortetix software, 
then they were compared (control and 
treated samples) and p value was 
calculated using t-test in Prism (P value 
in Red is Significant) (in Black is NS).   
Bar charts showed the proportion of 
short telomere frequency of U138 cells 
were calculated below 3kb for cells 
untreated, after treatment and 5days 
recovery, there were no significant 
differences observed. Error bars 
represent standard error (SE).  
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Figure 4.14: The proportion of Short Telomere frequency (MRC5, SCK cells) 
(Untreated, AT & Recovered) (APH & HU) 
 
 
Figure 4.14: The proportion of short telomere frequency. The proportion of short telomere 
frequency of MRC5 cells (A) were calculated below 1kb and SCK cells (B) were calculated below 3kb 
for cells untreated and after treatment. SCK cells post treatment with 0.3µM APH showed 0 % of 
short telomere; this increased reaching 6.8% in cells treated with 5mM HU. In MRC5 cells treated 
with 1mM HU showed 4% of short telomere frequency while cells treated with 1µM APH was 0%. 
Error bars represent standard error (SE).  
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4.5 Discussion 
4.5.1 Culture Growth 
In the study presented here, chromosome fragility was successfully induced in MRC5, SCK 
and U138 cells following treatment with APH or HU.  These treatments slowed the growth 
rates of the treated cultures in MRC5 and SCK. Data also showed that the growth rate of 
normal control SCK cells was lower than the normal growth rate of MRC5 cells. The overall 
growth rates of U138 cells control and treated were higher than MRC5 and SCK fibroblasts 
cells. Moreover, there was no difference in its growth rate between control and recovered 
U138 cells. 
These data are consistent with previous observations that the growth rate slows with an 
increasing proportion of cells damaged or senescent and fewer cells capable of division.  
4.5.2 Checkpoint Activation, Cell Cycle Arresting and Chromosomal Instability 
ATR and ATM, directly regulate Chk1 and Chk2. Chk1 and Chk2 are structurally distinct, 
however they have overlapping functions. Chk1 is placed downstream of ATR and is 
phosphorylation and activated in response to replication fork stalling and regulates cell cycle 
checkpoints in S phase and G2 phase of the cell cycle (Durkin et al., 2006). Chk1 has been 
shown to stabilise replication during the DNA synthesis phase in DT40 B-lymphoma cells. 
Chk2 is downstream target of ATM, and activated by double strand breaks, although it was 
argued that it may also be activated independently of ATM in some circumstances (Durkin et 
al., 2006). It was reported that Chk1 and Chk2 are activated during S phase in response to 
high doses of APH, suggesting that Chk1, and Chk2, regulate common fragile site stability 
(Durkin et al., 2006).  
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The Ser345 site in Chk1 and Th68 site in Chk2 are known to be preferred domains for 
phosphorylations by ATR and ATM respectively, after DNA damage or replication forks 
stalled (Zhao and Piwnica, 2001; Bartek et al., 2001). There has been controversy concerning 
what Chk1 and/or Chk2 respond to, also whether these kinases activated in response to 
genotoxic stress. It has been reported that Chk1 is inducibly phosphorylated in response to 
single strand breaks while Chk2 respond to double stranded breaks (Zhao and Piwnica, 
2001; Casper et al., 2002). 
Our data showed that in the MRC5 fibroblasts, the effects of low dose of Aphdicolin (0.3µM) 
concentration was able to induce the fragile site breakages and SAβ-gal activity, but did not 
signal efficiently to activate and phosphorylate Chk1. In contrast, the higher dose (1µM) 
concentration of APH was sufficient to induce Chk1 phosphoralytion. This can illustrate that 
a higher concentration of APH leads to more widespread damage across the genome and 
they are more likely as single stranded breaks which in turn activate the Chk1 
phosphoralytion but not Chk2.  
Our data also showed that ATR deficiency in SCK fibroblasts interfere with the 
phosphorylation of Chk1 on its target domain Ser 345 either with APH or HU. 
Previous findings have showed that ATM does not play a role in phosphorylation following 
replication stalling (Durkin et al., 2006), however in contrast our data showed that Chk2 was 
fully activated and phosphorylated after treatments mainly in the cultures where HU were 
applied. HU in both concentrations (1mM and 5mM) were able to induce Chk2 
phospholylation successfully on Thr68 domain more than what we have seen in APH 
treatment, this suggest that the damages produced from HU are more likely as double 
stranded breaks.   
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The occurrence of breaks at fragile sites is enhanced when replication stress is combined 
with deficiency in the ATR mechanism. ATR respond to the replication stress and delays the 
cell cycle progression.  
Our data showed that MRC5, SCK and U138 cells had a significant increase (p value 0.005 
ANOVA) in fragile site expression following treatments. Moreover, untreated SCK fibroblasts 
and U138 cells displayed fragile sites expressions, this suggests the frequency of fragile site 
instability in cultures lacking ATR or P53 and demonstrates the important role for ATR and 
P53 in regulating fragile sites. Moreover, SCK cells displayed higher proportions of 
chromosomal breaks and gaps compared to MRC5 cells following exposure to APH and HU. 
This is due to ATR deficiency. ATR which plays an important role in response to replication 
stalling following APH and HU treatments, delays the cell cycle progression at the S phase or 
G2/M checkpoints, allowing for repair the damages and prevents improper progression into 
mitosis. In SCK fibroblasts where this important kinase is absent, improper progression into 
mitosis occurs and chromosomal instability is more common in these cells. While in MRC5 
fibroblasts, where the checkpoints proteins are proficient and the progression through cell 
cycle are monitored, the chromosomal instability were less frequent.   
4.5.3 Telomere Dynamics 
Different mutational mechanisms may contribute to telomere erosion and generate large-
scale telomeric deletions. The aim of this chapter was to observe if the induction of 
chromosome fragility could contribute to telomere erosion and large-scale telomeric 
deletion. In order to examine this hypothesis, the XpYp telomere length distributions of 
MRC5, SCK and U138 cells treated with APH and HU were investigated using STELA (Baird et 
al., 2003). In line with previous studies in the group (Baird et al., 2003), the XpYp telomere 
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was analysed because it is considered to be representative for average chromosomal 
telomere length and average telomere erosion rates resulting from the end-replication 
problem.  
SCK fibroblasts showed uni-modal distribution at the XpYp telomere and displayed a more 
homogenous distribution compared to MRC5 cells. In contrast, MRC5 fibroblasts displayed 
bi-modal distributions at the XpYp telomere, and it is consistent with previous studies that 
MRC5 containing two differently lengths alleles at XpYp telomere, arise from inter-allelic 
differences which are set in zygote and resulting of contribution of maternal and paternal 
telomere alleles (Baird et al., 2003). 
SCK cells showed significant differences in mean telomere length between treated with 
0.3µM, 1µM APH and untreated cells. Treated SCK fibroblasts with APH displayed higher 
mean telomere length (~ 6Kb) compared to control (~5Kb). This suggests that cells with 
shorter telomeres in treated SCK fibroblasts disappeared from the culture; this lost made 
the mean telomere length higher in these cells than their control statistically significant. This 
could be explained by that Aphidicolin preferentially damages the cells with shorter 
telomeres in cultures of Seckel fibroblasts and that cells in which this occurs subsequent 
disappear from the culture. As described previously; TTAGGG repeat of telomeres pose a 
challenge to replication process and they resemble the fragile sites characteristics (Sfeir et 
al., 2009) accordingly, telomeres considered being sensitive to replication inhibition and 
forks stalling that induced by exposure to APH. To sum up, the fragility of telomere repeats, 
and consequently exposure to APH, which is a replication inhibitor, and the SCK fibroblasts 
its self containing ATR deficiency, which is playing an important role in DNA damage 
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response, all these factors play as a synergetic effect and induce damages preferentially in 
these cells. 
In contrast, the mean of telomere length showed no significant differences between treated 
either with APH or with HU in both cells MRC5 and U138 cells. However, the proportion of 
molecules detected in the upper and lower alleles in the MRC5 following treatments 
appeared to change. More molecules were observed in the lower alleles compared to the 
upper alleles; this increasing were observed following 5 days of recovery and were mainly 
seen in the cells treated with 1µM of APH. This could be explained by that, MRC5 fibroblasts 
are more resistance to APH treatment compared to SCK fibroblasts. Unlike SCK fibroblasts, 
exposure to APH treatment in MRC5 did not induce a statistically significant change in the 
mean telomere length distribution.  However a change in the proportions of long to short 
alleles was induced. It is possible that the upper alleles in MRC5 may have been 
preferentially targeted by APH treatment and that replication fork stalled that induced by 
exposure to APH in these upper alleles were resolved as breaks resulting in a reduction in 
the length of these alleles. Moreover, our western blot data was consistent with this 
suggestion; as Chk1 was phosphorylated and activated following 1µM of APH treatment in 
MRC5 fibroblasts indicating that replication stress induced DNA-damage occurred.  
Furthermore, our data showed that exposure of U138 cancer cells to APH and HU 
treatments did not produce a detectible increase in the proportions of short deleted 
telomeres. This could be explained by the type of damage induced by exposure to APH or 
HU treatments in such type of aggressive cancer cells U138 are more likely to be in form of 
telomeres fusions, chromosomes translocations etc rather than deleted short telomere and 
these are un-detectable by STELA. This can be clearly seen in metaphase chromosomes 
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analysis, where the frequency of chromosomes breaks and gaps were highly induced 
following treatments.   Alternatively, the fast growing nature of the U138 cells may result 
the rapid loss or dilution of cells in which telomere-specific mutagenic events occurred thus 
rendering these events undetectable. 
4.6 Conclusion 
The data presented indicates that changes to telomere length distributions can be detected 
following the induction of fragile sites. The original hypothesis that the induction of 
chromosome fragility might result in telomeric deletion events was consistent with the data 
obtained from SCK fibroblasts where the fragility of telomeres was enhanced by ATR 
deficiency. Whereas, in MRC5 fibroblasts the induction of chromosome fragility impacted on 
its upper to lower alleles ratio, with a preferential loss of the longer telomere length 
distribution.   
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Chapter 5 
Examining the relationship between G-quadruplex stablisation and telomeric 
mutation 
5.1 Summary 
Superimposed on the end replication problem, mutational events have been observed in 
primary culture cells that create dysfunctional telomeres that are capable of fusion to other 
chromosome ends. This can lead to genomic instability that may drive tumour progression. 
The telomeric G–rich strand renders telomeres prone to form a unique secondary structure 
called G-quadruplex. The presence such structures at telomeric DNA and their potential 
resolution as double or single strand breaks could represent a mutational mechanism that 
may lead to the induction of telomeric dysfunction.  
The aim of this study was to determine if G-quadruplex structures, could contribute to 
telomere erosion and large-scale telomeric deletion. Moreover, the role of ATRX protein 
and its contributions in resolving G-quadruplex structures was also investigated. 
In order to test this hypothesis, G-quadruplex structures were stabilised using the G-
quadruplex ligand (RHPS4) in IMR90 fibroblasts, U138 cancer cells, Ntera cells (ATRX+) and 
(ATRX-) and Hela cells (ATRX+) and (ATRX-). The stabilisation of G-quadruplexes was 
monitored and the induction of cell-cycle checkpoints, senescence and a reduction in cell 
growth were observed. Telomere dynamics and stochastic telomeric deletion events were 
investigated using STELA. 
The data showed that an absence of ATRX sensitised cells to RHPS4, but that the 
stabilisation of G-quadruplexes did not significantly affect the telomere dynamics.     
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5.2 Introduction 
5.2.1 Formation of G-quadruplex  
The presence of G-rich single-stranded DNA oriented 5’ to 3’ toward the chromosome 
terminus makes telomeres prone to form secondary structures referred to as G-
quadruplexes (Tran et al., 2011). Telomeric sequences from different organisms have been 
shown to fold into several guanine-quadruplex structures by a single strand (intra-
molecular) or by two associated strands (bi-molecular) or (tetra-molecular) which form by 
four associated strands (Williamson et al., 1989). The stability of these structures was 
identified in the presence of several cations, mainly potassium and sodium (Sen and Gilbert, 
1990). In the single cellular eukaryotes Oxytricha and Tetrahymena telomeric repeats form 
G-quadruplex structure in sodium (Smith and Feigon, 1992; Wang and Patel, 1994), in 
human, the structure formed in sodium and in potassium cations and in Bombyx mori and 
Giardia formed in potassium (Phan et al., 2007; Amran et al., 2009; Hu et al., 2009). It has 
also been found that guanines that fold into G-quadruplex structures in the presence of 
potassium are more stable than in sodium (Tran et al., 2011).  
G-quadruplexes consist of hydrogen-bonded guanine tetrads (Hoogsteen hydrogen-bonding 
arrangement) these structures stack into various structures including a basket-like structure 
(Figure 5.1) identified in experiments using sodium chloride (Wang and Patel, 1993), whilst 
in potassium chloride solution experiments revealed two similar structures (hybrid 1 and 
hybrid 2) (Figure5.1) (Phan et al., 2007). The difference between these two structures is in 
their loop orientations. Propeller structures have been found in the solid-state experiments, 
and in the high concentrations of dehydrating solvents (Figure 5.1) (Parkinson et al., 2002).  
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Figure 5.1: Structures of G-guadruplexes. Basket, propeller, hybrid-1 and hybrid-2, are G-quadruplex 
structures. Purple spheres presented potassium ions, sodium ions are the (yellow spheres), anti G 
residues are shown in blue, and syn G residues are in magenta. Four guanines form G-quadruplexes, 
each guanine serves as both hydrogen bonding acceptor and donor and the stacking of guanine 
tetrads results in G-quadruplex DNA structures. Adapted from (Fleming and Burrows, 2013). 
 
5.2.2 Prevalence of G-quadruplexes in the Genome   
Although there is good evidence for G-quadruplex formation in vitro, demonstration of their 
occurrence in vivo has been difficult to establish. It has been suggested that the high 
thermodynamic stability of G-quadruplexes under near-physiological conditions means that 
these structures could occur in genomic DNA in vivo (Biffi et al., 2013).  Recent studies have 
provided evidence of G-quadruplexes in prokaryotic and eukaryotic genomes. The first 
indication that G-quadruplex formation occurred in vivo has been identified at telomeric 
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repeats of the macronucleus of stichotrichous ciliates using antibodies targeted to G-
quadruplex structures (Schaffitzel, 2001). It has been predicted that the human genome 
contains 376 000 of motifs that have the potential to from G-quadruplex structures (Lipps 
and Rhodes, 2009).  
The location of potential G-quadruplex structures is non-random, many studies revealed the 
prevalence of G-quadruplex in key regulatory regions of the human genome. They have 
been found frequently in the repetitive DNA regions such as telomeres (Lipps and Rhodes, 
2009). Similarly, immunoglobulin switch regions, promoter regions of eukaryotic genes and 
around 40% of human gene promoters are predicted to contain at least one G-quadruplex 
motifs including oncogenes and tumour suppressor genes (Biffi et al., 2013; Sen and Gilbert, 
1990; Simonsson et al., 2002).  
5.2.3 Impact of G-quadruplex Formation in the Genome  
Unresolved G-quadruplexes are considered to induce DNA damage responses, senescence 
and chromosomal end-to-end fusions. It has been found that G-quadruplex structures 
contribute to the inhibition of cellular proliferation following stabilisation with G-quadruplex 
ligands (Incles et al., 2004; Salvati et al., 2007). Recently, G-quadruplex structures have 
attracted attention due to their involvement in telomere-telomere interactions (Giraldo et 
al., 1994) and in the control of telomerase activity (Zahler et al., 1991). G-quadruplexes are 
also involved in maintaining chromosome stability and act as negative regulator of telomere 
elongation (Zahler et al., 1991). 
G-quadruplexs are potentially difficult to resolve structures and may lead to replication fork 
stalling (Leonetti et al., 2004). As described in chapter 4, telomeres resemble fragile sites 
and replication fork stalling is frequently occurs at these sites. The fragility of telomeres 
combined with G-quadruplex formation may make them susceptible to replication fork 
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stalling and resolution as a single or double-stranded DNA breaks, resulting in telomeric 
mutation and deletion events. 
5.2.4 G-quadruplex Ligands 
Telomerase is potential target for therapeutic intervention (Kelland, 2000), telomerase is 
up-regulated in approximately 80% of all cancer types (Gunaratnam et al., 2011). G-
quadruplex ligands are small molecules designed to fold DNA strand into G-quadruplex 
structure and prevent the interaction of telomerase with telomeres (De Cian et al., 2007). 
The original concept of targeting telomerase in cancer treatment was that telomeres would 
gradually erode until such time that they become critically short and inhibit cellular 
proliferation (Gowan et al., 2001).  
A large number of G-quadruplex- ligands have been reported and designed to stabilise G-
quadruplexes. In xenograft models anti-tumour activity has been identified with BRACO-
1922 (Burger et al., 2005). More examples of these ligands include: di-substituted 
aminoalkylamido acridine, pentacyclic acridine (RHPS4) (Figure 5.2); RAPI a protein 
produced by Saccharomyces cerevisiae which is known to bind to G-quadruplex and Gq1 an 
artificially derived protein which as acts as a G-quadruplex ligand (Haider et al., 2003).  
 
Figure 5.2: RHPS4 structure, adopted from (Leonetti et al., 2004). 
5.2.5 G-quadruplex Unwinding  
The replication of G-quadruplexes requires that they are resolved by the action of helicases, 
including the RecQ helicases, BLM and WRN (Fry and Loeb, 1999). RecQ helicase family plays 
 149 
 
essential role in genome stability particularly during DNA replication and in telomere 
metabolism, they contain domains that bind to G-quadruplexes suggesting that these 
helicases play a role in telomere and genome stability by resolving G-quadruplexes (Huber 
et al., 2006). Recent studies report that WRN and RTEL helicases also play a role in the 
regulation of telomeric D-loop structures (Barber et al., 2008).  
Mutations in BLM result in chromosomal instability, chromosomal fusions and cancer 
progression (German, 1993). Recent studies have shown that BLM co-localise with telomeric 
foci within an ALT cell line (Yankiwski et al., 2000). WRN localisation to the telomeres seems 
to be specifically during the S-phase of the replication cycle. By interacting with TRF2, 
WRN’s 3′-5′ exonuclease and weak 3′-5′ helicase activities become induced (Opresko et al., 
2002) and this may resolve telomeric D-loops. Thus, WRN is involved in normal telomere 
replication by resolving abnormal secondary telomeric structures during the progression of 
the replication fork. It has also been reported that RTEL helicase has a role as well in 
unwinding G-quadruplexes at telomeres (Uringa et al., 2011).   
Recently, it has been shown that ATRX binds to telomeric G-rich strand that form secondary 
structure G-quadruplex in vivo (Law et al., 2010) (Biffi et al., 2013). In addition, ATRX 
together with the histone chaperone DAXX, facilitate the deposition of the histone variant 
H3.3 into telomere chromatin (Wong et al., 2010). Interestingly, mutations in the 
ATRX/DAXX/H3.3 complex are found in cancers that display the ALT phenotype, these 
include pancreatic neuroendocrine tumours (Jiao et al., 2011), oligodendrogliomas and 
neuroblastomas (Molenaar et al., 2012). It has been suggested that ATRX is a tumour 
suppressor however; the actual mechanism of ATRX in ALT is still unclear (Clynes et al., 
2015).     
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5.3 This Work  
In this chapter, I have examined whether G-quadruplex stabilisation at telomeres has the 
potential to drive stochastic telomere deletion events. In order to test this hypothesis, G-
quadruplex formation was induced and stabilised with using the pentacyclic acridine 
(RHPS4) G-quadruplex stabilising ligand. The effect of G-quadruplex stabilisation on the 
cellular proliferation and on the telomere dynamics was examined in the cultured IMR90 
fibroblasts and U138 cancer cells. The effect of G-quadruplex formation was also examined 
in the context of ATRX knockdown in Ntera and Hela cells. Figure 5.3 illustrates the 
hypothesis, plan and the assays that have been used to test these hypotheses.      
IMR90 fibroblasts, U138 cancer cells, Ntera cells (ATRX+ and ATRX-) and Hela cells (ATRX+ 
and ATRX-), cells were cultured in 6 well plates (35-mm dish) in the presence of G-
quadruplex ligand (RHPS4). IMR90 and U138 cells were treated with different 
concentrations of RHPS4 (1µM, 2µM, 3µM & 4µM) for 24 hours and 4 days. Ntera cells 
(ATRX+ and ATRX-) were treated with a different range of RHPS4 concentrations. Ntera cells 
treated with 1µM of RHPS4 for 24 hours were chosen for DNA extractions and STELA. 5µM 
of RHPS4 for 24 hours treatment was chosen for Hela cells (ATRX+ and ATRX-). Cells were 
collected for DNA extraction, allowing detailed analysis of telomere dynamics with STELA.  
 
 
 151 
 
 
 
Figure 5.3 Illustrating the hypothesis, plan and the assays that have been used in this chapter.  
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5.4 Result  
5.4.1 Effects of G-quadruplex Stabilisation on Cell Proliferation  
In order to monitor the effects of G-quadruplex stabilisation on cellular proliferation of 
IMR90 fibroblasts and Ntera cells (ATRX+ and ATRX-) cells were seeded in 6 well plates (35-
mm dish).  24 hours after plating IMR90 cells, increasing concentrations of freshly dissolved 
RHPS4, ranging from 1µM to 4µM, were added to the culture medium and left for 4 days. 
Then, the drug was released and fresh medium was added and cells left for an additional 6 
days. Cell counts were determined daily, from day 1 to day 10 of culture and PD was 
calculated as shown in figure 5.4. 
The data showed that the growth rate of IMR90 fibroblasts in standard culture conditions 
was determined as 0.255 PD/day. Whereas, the RHPS4 treated IMR90 cells exhibited lower 
growth rate compared to normal control fibroblasts. The reduction in growth rate was 
inversely proportional to the concentration of RHPS4, with 0.112 PD/day achieved for cells 
treated with 4µM and 0.163 PD/day for those treated with 3µM (Figure 5.4).  
To examine the contribution of ATRX protein in resolving G-quadruplex structures, Ntera 
ATRX+ and Ntera ATRX- cells were exposed to 0.2µM, 1µM and 5µM of RHPS4 for 24 hours. 
Then, drug was released, fresh medium was added and cells left in culture. Following 24 
hours of exposure to 5µM RHPS4, ~95% of Ntera cells ATRX- had died, floated and detached 
from the plate. Whilst in 1µM of RHPS4, Ntera ATRX- cells lived longer, ~2 to 3 days after 
drug released. Furthermore, they lived in culture nearly 21 days following drug released of 
0.2µM RHPS4. In contrast Ntera ATRX+ cells were more resistant to RHPS4 and displayed 
cellular proliferation following drug released of different concentrations that have been 
used.   
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Ntera cells (ATRX+ and ATRX-) treated with 0.2µM of RHPS4 24 hours were passaged serially 
after treatment and the average of population doublings (PDs) was calculated and plotted in 
figure 5.5. 
The growth rate of Ntera ATRX+ was determined to be on average of 5.77 PD/day after 
treatment with 0.2µM of RHPS4. Interestingly, after day 5 of recovery, Ntera ATRX+ cells 
resumed their ability to proliferate. Whilst, Ntera cells (ATRX-) displayed lower growth rate 
(0.0132PD/day) compared to (ATRX+).  
These data indicate that the ATRX –ve cells exhibit a specific sensitivity to the G-quadruplex 
stabilising ligand RHPS4. 
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Figure 5.4: PDs of IMR90 cells (RHPS4) 
 
 
 
 
Figure 5.4: Growth curves of IMR90 cells. IMR90 cells were cultured at PD 30.3, control 
(untreated) (Black Line) and (treated) with different concentrations of RHPS4 (1µM (Red 
Line), 2µM (Green Line), 3µM (Gray Line) & 4µM (Blue Line)) for 4 days. Plotting growth 
curves as function of population doublings (PD) versus time in days.  
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Figure 5.5: PDs of Ntera cells Control (ATRX+) and Sh590 (ATRX-) (RHPS4)  
 
 
 
 
 
Figure 5.5: Growth curves of Ntera cells ATRX+ and ATRX-. Ntera control (ATRX+) (Black 
Line) and (ATRX-) (Red line) were Treated with RHPS4 (0.2µM) (24 hours). Ntera ATRX- cells 
lived up to ~21 days following drug released. Ntera ATRX+ was more resistant to RHPS4 than 
Ntera ATRX- cells.  
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5.4.2 Effects of G-quadruplex Stabilisation on Cell Cycle Progression 
In order to investigate the effects of G-quadruplex stabilisation on cell cycle progression and 
the role of ATRX protein in modulating this structure, cell cycle assay was carried out in 
Ntera cells (ATRX+) and was compared to Ntera cells (ATRX-). Cell cycle progression was 
investigated in Ntera cells (ATRX+) and (ATRX-) after 24 hours of 1µM RHPS4 treatment (AT) 
and after 24 hours of recovery (figure 5.6).  Cells were collected and fixed in cold 70% 
ethanol, washed with cold PBS and stained with Propidium Iodide (PI). The percentage of 
cells in the different phases of cell cycle was analysed by flow cytometry. 
As shown in figure 5.6, both Ntera (ATRX+) and (ATRX-) cells post one day treatment of 
RHPS4, showed an accumulation in G0/G1.  
Following drug release the cells were incubated for 24 hours with fresh medium and 
harvested (Day Recovery) and their cell cycle profile was analysed. These data showed that 
Ntera (ATRX+) had recovered and progressed through the cell cycle with higher numbers of 
cells at G2/M and S phases. On contrast, Ntera Sh590 (ATRX-) cells remained accumulated at 
G0/G1.  
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Figure 5.6: Cell cycle of Ntera cells Control (ATRX+) and Sh590 (ATRX-) (RHPS4) 
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Figure 5.6: Cell cycles of Ntera cells. (A) Ntera control cells were compared to Ntera Sh590 cells. Cells were treated with RHPS4 (1µM). Cell cycle 
progression was investigated after 24h of (1µM) treatment (AT) and 24h of recovery. As shown Ntera control (B) and Sh590 cells (C) after adding RHPS4 
(AT), cells were accumulated at G0/G1, after drug release (1 Day Recovery) Ntera control cells were progressed through the cell cycle and high numbers of 
cells were at S phases and G2/M, cells resume their ability of division whereas Ntera Sh590 cells were accumulated at G0/G1. Error bars represent standard 
error (SE). G0/G1, S and G2/M fraction was calculated by flow cytometry. 
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5.4.3 Cellular Morphology and Senescence Associated Beta galactosidase Activity (SAβ-
gal) 
In order to examine the impact of G-quadruplex formation on the cellular senescence, 
morphological changes were tracked in IMR90 fibroblasts, U138 cancer cells and Ntera 
(ATRX+) and Ntera (ATRX-) cells treated with RHPS4. Cells were compared to their controls 
under microscope (X20) and pictures were taken regularly (Figure 5.7).  
Treated IMR90 fibroblasts changed their morphology becoming larger with a flattened 
cytoplasm and had bigger nuclei compared to the untreated. These features are consistent 
with cells undergoing cellular senescence (Toussaint et al., 2000). Moreover, high number of 
floating cells, dead cells or affected cells were detached from dish, was observed in treated 
Ntera cells (ATRX+) and (ATRX-) and U138 cells compared to untreated. For those treated 
cells left in the dishes, stressed cells were observed following treatment directly (Figure 5.7).   
Senescence-associated β-galactosidase assay was used to investigate cellular senescence 
induction in IMR90 cells and U138 cancer cells. Senescent cells were determined by 
counting 500 cells and the proportions of positive cells were given as percentages of the 
total counted cells. It was observed that treated (IMR90) cells had higher percentages of 
activation of senescence-associated β-galactosidase enzyme compared to untreated. This 
can be clearly seen from the result in figure 5.8. In contrast U138 cells, as tumour cells and 
P53 deficient cells, no detectable senescence-associated β-galactosidase activity. 
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Figure 5.7: Cellular Morphology of IMR90, U138 & Ntera cells (ATRX+ and ATRX-) (RHPS4) 
 
Figure 5.7: Cellular Morphology of IMR90, U138 & Ntera (ATRX+ and ATRX-) Cells. IMR90 and U138 cells (A) were treated with 1µM 
of RHPS4 for 24h, morphological changes were monitored and treated cells were compared to the control. Ntera cells ATRX+ and 
ATRX- (B) were treated with 5µM of RHPS4 for 24h and were compared to untreated cells.  
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Figure 5.8: Senescence-Associated β- galactosidase Activity of IMR90 Cells 
(RHPS4) 
 
 
Figure 5.8: The quantification of senescence-associated β-gal-positive for IMR90 cells of 
total counted 500 cells. Percentage of senescent IMR90 cells treated with 1µM, 2µM, 3µM 
& 4µM of RHPS4 were compared to the percentage of senescent control cells. SAβ-gal assay 
was determined by counting positive stained cells under microscope (X20). The proportions of 
positive cells were given as percentages of the total counted cells. Error bars represent standard 
error (SE).         
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5.4.4 G-quadruplex Stabilisation and Cellular Apoptosis  
In order to test the impact of G-quadruplex stabilisation on the induction of cellular 
apoptosis, Ntera cells (ATRX+) and (ATRX-) were cultured in the presence of 5µM of RHPS4. 
Cellular apoptosis assays were carried out in cells (cells treated one hour then left one hour 
in fresh medium following drug released) and (cells treated six hours then left six hours in 
fresh medium) (Figure 5.9). Cultured cells were trypsinised, fixed and stained with 
Propidium Iodide (PI) and the apoptotic cells fractions were determined by flow cytometry. 
The number of apoptotic cells increased following exposure to RHPS4 in both Ntera cells 
(ATRX+) and (ATRX-). One hour post-treatment, the apoptotic cell fraction had slightly 
increased to 1.25% in the Ntera (ATRX+) compared to 1.20% apoptotic cells in untreated 
Ntera ATRX+. This percentage was higher in treated Ntera cells (ATRX-) at 6.25% and 
compared to the untreated cells 3.18%. The apoptotic cells increased dramatically following 
6 hours exposure to the drug with the apoptotic cell fraction of Ntera ATRX- cells was 37.5% 
whilst Ntera ATRX+ cells were 9.9%. 
These data further show that the absence of ATRX sensitises Ntera cells to treatment with 
RHPS4. 
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Figure 5.9: Apoptosis Assay of Ntera cells Control (ATRX+) and Sh590 (ATRX-) (RHPS4)  
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Figure 5.9: Apoptosis Assay of Ntera cells ATRX+ and ARX-. (A) 
Apoptosis assay was carried out in Ntera cells ATRX+ and ATRX- 
treated with 5µM RHPS4 for 1 hour and 6 hours. (B) Bar chart display 
percentage of apoptotic cells (Blue bar represent Ntera ATRX+) (Red 
bar represent Ntera ATRX-). The proportions of apoptotic cells were 
calculated by flow cytometry. Error bar represent SE.    
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5.4.5 Checkpoint Activation 
In order to investigate the effect of G-quadruplex stabilisation on key proteins involved with 
cell cycle checkpoint activation, Ntera cells (ATRX+) and (ATRX-) were treated with 1µM of 
RHPS4 24 hours, protein extracts were obtained for western blot analysis directly after 24 
hours of treatment and 24 hours following drug release. The treated Ntera cells (ATRX+) and 
(ATRX-) were compared to untreated as shown in figure 5.10. 
The phospholylation status of checkpoint proteins was determined using antiphospho Chk1 
Ser345, antiphospho Chk2 Thr68 and antiphospho P53 Ser15 antibodies.  
 The Western blot analysis showed that Chk1, Chk2 and P53 were phosphorylated following 
exposure to RHPS4 in the Ntera cells (ATRX+). These data indicate that DNA damage 
checkpoints proteins were activated following drug exposure.  
In contrast the Ntera cells (ATRX-), both Chk2 and P53 but not Chk1 were phosphorylated 
following of 24 hours of treatments. The phosphorylation of both Chk2 and P53 in Ntera 
ATRX- remained high even 24 hours following drug release.  
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Figure 5.10: DNA damage Checkpoint Activation in Ntera cells ATRX+ and 
ATRX- 
 
 
 
 Figure 5.10: DNA damage Checkpoint Activation in Ntera cells ATRX+ and ATRX-. Ntera 
cells treated with 1µM RHPS4 for 24h of treatment and one day of recovery. Equal loading 
was confirmed by probing with Actin specific antibody. 
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5.4.6 Analysis of Telomere Dynamics 
In order to examine if the stabilisation of G-quadruplexes in the G-rich telomeric strand 
results in large-scale changes to telomere length, the XpYp telomere length distributions of 
IMR90, U138 cells, Ntera cells ATRX+, Ntera ATRX- and Hela cells ATRX+ and ATRX- exposed 
to RHPS4 were investigated. The role of ATRX in overcoming the effect of such structure was 
also examined.  
Single telomere length analysis (STELA) was used to track the telomere dynamics with 
ongoing cell division and to detect the presence of short stochastically deleted telomeres 
(Baird et al., 2003). STELA for the experiment are shown in figures 5.11, 5.13, 5.15, 5.16 and 
5.19.  
We have observed that both control and treated IMR90 fibroblasts figures (5.11 and 5.12) 
displayed uni-modal distributions at the XpYp telomere.  
IMR90 fibroblasts showed no significant differences in mean telomere length between 
treated and untreated cells (figure 5.11). Moreover, the frequencies of short telomeres 
(below 5 Kb) (figure 5.12) following one day exposure to RHPS4 were lower at treated 
IMR90 fibroblasts than the control cells. IMR90 fibroblasts treated with 1µMof RHPS4 had 
9.67% of short telomere frequency, lower than 22.67% of control cells. On the other hand, 
post-four days treatment, treated cells had more frequencies of short telomere compared 
to the control. IMR90 fibroblasts treated with 4µMof RHPS4 had 22.22% of short telomere 
frequency, more than 19.35% of control cells. Moreover, IMR90 cells treated with 2µM of 
RHPS4 following one day exposure to drug had 12.90% of short telomere frequency while 
following 4 days of treatment the frequency increased to reach 19.44%.  
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Taken together these data indicate that that treatment of IMR90 cells with RHPS4 does not 
modulate telomere dynamics, either for overall mean telomere length or for the frequency 
of telomeric deletion events. 
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Figure 5.11: STELA of IMR90 XpYp Telomere (RHPS4)
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Figure 5.11: STELA gels of XpYp telomere in the IMR90 untreated and treated with RHPS4 (1µM), (2µM), 
(3µM) and (4µM) for 24 hours treatments (A) and 4 days treatments (B), the tables of descriptive data 
for telomeres. The gels illustrate the telomere length distributions while the tables give the mean, 
standard deviations (SD), standard error (SE).  Dot Plot made in (Prism) represent dot plots (Telomere 
length distributions) from the gels, were quantified using Phortetix software, then they were compared 
(control and treated samples) and p value was calculated using t-test in Prism (P value in Red is Significant) 
(in Black is NS).    
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Figure 5.12 Short telomere frequency of IMR90 XpYp (under 5kb) 
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Figure 5.12: Short XpYp telomere frequency in IMR90. Long telomeres (BLACK DOTS) compared to short telomeres (under 
5kb) (RED DOTS) for untreated and treated cells with RHPS4 (1µM), (2µM), (3µM) and (4µM) for 24 hours treatment (A) and 4 
days treatment (B). 
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U138 cancer cells displayed a significant difference (p value 0.036) in mean telomere length 
following 4 days of 2µM RHPS4 treatment compared to untreated U138 cells (Figure 5.13). 
The mean telomere length was longer at treated U138 cells. Furthermore, the frequencies 
of short telomeres (Figure 5.14) (below 2 Kb) following one day exposure to RHPS4 were 
higher in treated U138 than the control cells. U138 cancer cells treated with 1µM of RHPS4 
had 37.31% of short telomere frequency, more than 20.35% of control cells.  On the other 
hand, post-four days treatment, treated U138 cells with 2µM had lower frequency of short 
telomeres (8.19%) compared to the control (15.78%).  
As observed with IMR90, the subtle differences observed in the telomere length distribution 
in U138, are consistent with experimental variation. These data therefore indicate that 
RHPS4 treatment does not directly affect telomere length. 
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Figure 5.13: STELA of U138 XpYp Telomere (RHPS4) 
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Figure 5.13: STELA gels of XpYp telomere in the U138 untreated and treated with RHPS4 (1µM), (2µM), 
(3µM) and (4µM) for 24 hours treatments (A) and 4 days treatments (B), the tables of descriptive data 
for telomeres. The gels illustrate the telomere length distributions while the tables give the mean, 
standard deviations (SD), standard error (SE). Dot Plot made in (Prism) represent dot plots (Telomere 
length distributions) from the gels, were quantified using Phortetix software, then they were compared 
(control and treated samples) and p value was calculated using t-test in Prism (P value in Red is Significant) 
(in Black is NS).    
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Figure 5.14 Short telomere frequency of U138 XpYp (under 2kb) 
   
Figure 5.14: Short telomere frequency of U138 XpYp. Long telomere (BLACK DOTS) compared to short telomere (under 2kb) (RED DOTS) for 
untreated and treated cells with RHPS4 (1µM), (2µM), (3µM) and (4µM) for 24 hours treatments (A) and 4 days treatments (B). 
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Previously, in our lab, a study was carried out in order to assess the role of ATRX in 
modulating telomere dynamics. Ntera, MRC5 fibroblasts, Hela, MDA231, U138, U87, HT1080 
and caski cells, where knocked down for ATRX by Dr. Maira Tanikmanova. Cells (ATRX-) were 
cultured for ~ 52 PDs in a parallel with controls (ATRX+). The study showed that XpYp and 
17p STELA analysis revealed no significant difference in mean telomere length between 
ATRX+ve cells compared to ATRX-ve cells. Interestingly, following 2-3 PDs from ATRX 
Knockdown in Ntera cells, a significant difference in mean telomere length was observed 
between Ntera ATRX+ and Ntera ATRX- cells (Figure 5.15). However, this difference in mean 
telomere length disappeared following 5-10 PDs from ATRX knockdown. This is why Ntera 
cells were chosen for this study (combination of ATRX deficiency and G-quadruplex 
stabilisation).        
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Figure 5.15: STELA of Ntera Control (ATRX+) and Sh590 (ATRX-) XpYp &17p 
Telomere 
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Figure 5.15: STELA gels of XpYp (A) and 17p (B) telomeres in the Ntera ATRX+ and ATRX- and the 
tables of descriptive data for telomeres. The gels illustrate the telomere length distributions while 
the tables give the mean, standard deviations (SD), standard error (SE). Dot Plot made in (Prism) 
represent dot plots (Telomere length distributions) from the gels, were quantified using Phortetix 
software, then samples were compared and p value was calculated using t-test in Prism (P value in 
Red is Significant) (in Black is NS). STELA gels and experiment were done by Dr. Maira Tankimanova.   
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We examined the effects of a combination G-quadruplex stabilisation and ATRX deficiency 
on telomere dynamics. Ntera and Hela (ATRX+) and (ATRX-) cells were cultured in the 
presence of RHPS4 for 24 hours.    
No significant difference was observed in the mean telomere length in Ntera ATRX+ cells 
either following exposure to RHPS4 or after 5 days recovery (figure 5.16). Interestingly, the 
Ntera ATRX- cells displayed a significant difference in mean telomere length following 24 
hours exposure to 1µM of RHPS4 compared to untreated ATRX- cells (Figure 5.16). The 
mean telomere length was longer at treated Ntera ATRX- cells (2.32kb) compared to 
untreated cells (2.07kb) with p value = 0.006. However, this significant difference in mean 
telomere length disappeared after 5 days of recovery.  
The frequency of short telomeres (figure 5.17) (below 2 Kb) following 5 days of drug 
released in Ntera ATRX+ cells was higher in treated cells (38.68%) than the control cells 
(36.77%), although this difference did not reach the statistical significance (p value = 0.228). 
In the treated ATRX- cells, the short telomere frequency was lower than untreated post-
treatment and post 5 days of recovery and these differences were not significant as well, p 
value was 0.597 and 0.684 respectively. 
To examine if telomere dysfunction could be detected, telomere fusion assays were carried 
out in Ntera cells ATRX+ and ATRX-, no telomere fusion events could be detected (figure 
5.18) either in Ntera cells ATRX+ or ATRX- cells. 
Treated Hela cells did not display any change in telomere length compared to control either 
in ATRX+ or ATRX- cells (figure 5.19). Although, Hela cells were treated with higher 
concentration of RHPS4 (5µM) and Ntera cells treated with 1µM, Ntera ATRX- cells displayed 
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greater sensitivity to RHPS4 than Hela ATRX- cells. The frequency of short telomere 
significantly increased in Hela ATRX- following exposure to 5µM RHPS4 (figure 5.20) it was 
determined to be 20.66% compared to untreated Hela ATRX- (6.77%).  
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Figure 5.16: STELA of Ntera Control (ATRX+) and Sh590 (ATRX-) XpYp 
Telomere (RHPS4) 
 
  
 
Figure 5.16: STELA gels of XpYp telomere in the Ntera (ATRX+) (A) and (ATRX-) (B) untreated and treated 
with RHPS4 (1µM) for 24 hours and 5 days of drug released and the tables of descriptive data for telomeres. 
The gels illustrate the telomere length distributions while the tables give the mean, standard deviations (SD), 
standard error (SE). Dot Plot made in (Prism) represent dot plots (Telomere length distributions) from the gels, 
were quantified using Phortetix software, then they were compared (control and treated samples) and p value 
was calculated using t-test in Prism (P value in Red is Significant) (in Black is NS).    
 Ntera cells (control) (RHPS4 1M)
Treated (24h) & Recovered (5days)
Un
tre
at
ed
Tr
ea
te
d
Un
tre
at
ed
Re
co
ve
re
d
0
2
4
6
8 P value 0.447 P value 0.657
Te
lo
m
er
e 
le
ng
th
, k
b
 Ntera cells (Sh590) (RHPS4 1M)
Treated (24h) & Recovered (5days)
Un
tre
at
ed
Tr
ea
te
d
Un
tre
at
ed
Re
co
ve
re
d
0
2
4
6
8 P value 0.006 P value 0.286
Te
lo
m
er
e 
le
ng
th
, k
b
RHPS4 
Sh590 
Untreated AT  Unt Rec  
Mean 2.070 2.325 2.025 2.143 
SD 0.68 0.77 0.90 0.92 
SE 0.06 0.07 0.08 0.08 
RHPS4  
Cont. 
Untreated AT  Unt   Rec  
Mean 2.61 2.703 2.41 2.45 
SD 0.99 0.88 0.94 0.94 
SE 0.08 0.08 0.08 0.08 
A B 
 177 
 
 
Figure 5.17 Short telomere frequency of Ntera cells Control (ATRX+) and 
Sh590 (ATRX-) XpYp (under 2kb) 
  
 
Figure 5.17: Short telomere frequency of Ntera cells Control (ATRX+) and Sh590 (ATRX-) XpYp 
(under 2kb). Long telomere (BLACK DOTS) compared to short telomere (under 2kb) (RED DOTS) for 
untreated and treated cells with RHPS4 (1µM). A Ntera ATRX+ cells untreated, B Ntera ATRX+ cells 
treated with RHPS4, C Ntera ATRX- cells untreated and D Ntera ATRX- cells treated with RHPS4.   
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Figure 5.18: STELA of Ntera (Control (ATRX+) and Sh590 (ATRX-) XpYp Telomere (RHPS4) 
 
Figure 5.18 Fusion assays in Ntera cells Control (ATRX+) and Sh590 (ATRX-). HEK293 DNA that contains a high frequency of fusion events was 
used as positive control for the fusion assay. Molecular weight markers are identified on the left and right of the gels. Each reaction 
contains 50 ng of DNA and is detected by the xpyp specific probe. The fusion frequency was 0% after treatment (AT) and 24 hours of drug 
released for both ATRX+ and ATRX- cells. 
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Figure 5.19: STELA of Hela Control (ATRX+) and Sh590 (ATRX-) XpYp Telomere (RHPS4) 
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Figure 5.19: STELA gels of XpYp telomere in the Hela ATRX+ and ATRX- 
untreated and treated with RHPS4 (5µM) for 24 hours and the tables of 
descriptive data for telomeres. The gels illustrate the telomere length 
distributions while the tables give the mean, standard deviations (SD), 
standard error (SE). Dot Plot made in (Prism) represent dot plots 
(Telomere length distributions) from the gels, were quantified using 
Phortetix software, then they were compared (control and treated 
samples) and p value was calculated using t-test in Prism (P value in Red is 
Significant) (in Black is NS).    
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Figure 5.20 Short telomere frequency of Hela cells Control (ATRX+) and Sh590 
(ATRX-) XpYp (under 3kb) 
 
Figure 5.20: Short telomere frequency of Hela cells Control (ATRX+) (A) and Sh590 (ATRX-) 
(B) XpYp (under 3kb). Long telomere (BLACK DOTS) compared to short telomere (under 
3kb) (RED DOTS) for untreated and treated cells with RHPS4 (5µM). After treatment, the 
frequency of short telomeres of ATRX+ Hela cells was higher at untreated cells than treated 
cells. In the untreated ATRX- Hela cells, short telomere frequency was lower than treated.  
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5.5 Discussion 
Superimposed on the end replication problem, additional mutational mechanisms operate 
that create dysfunctional telomeres that are capable of fusion (Baird et al., 2003; Capper et 
al., 2007). The objective of this study was to determine if G-quadruplex structures, which 
can form in G-rich repeats sequences including those in the G-rich telomeric strand, could 
contribute to telomere erosion and large-scale telomeric deletion. Moreover, the role of 
ATRX protein and its contribution in overcoming the effects of such structure was also 
investigated.   
IMR90 fibroblasts, U138 cancer cells, Ntera cells (ATRX+) and (ATRX-) and Hela cells (ATRX+) 
and ATRX-) were cultured in the presence of G-quadruplex ligand (RHPS4) for 24 hours, then 
drug was released and fresh medium was added to cultured cells. In order to monitor any 
changes in cellular proliferation, DNA damage response, cell cycle arrest, cellular senescence 
and apoptosis, the untreated cells were compared to treated cells with different 
concentrations of RHPS4. 
5.5.1 Cellular Proliferation 
The data showed that the cellular proliferation of treated IMR90 fibroblasts decreased 
compared to the normal control and IMR90 fibroblasts displayed dose dependent sensitivity 
to RHPS4. This could be explained by the G-quadruplex ligand RHPS4 stabilising G-
quadruplex structures across the genome, inducing replication fork stalling and cellular 
proliferation inhibition (Rizzo et al., 2009).  
The Ntera ATRX- cells displayed a high sensitivity to G-quadruplex ligand RHPS4 and showed 
a dose dependent viability loss. ~ 95% of Ntera ATRX- cells died following one day of 5µM 
RHPS4 treatment. Ntera cells ATRX- were also treated with 1µM of RHPS4 for 24 hours and 
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they died off following 2 to 3 days of drug released.  Whereas, with 24 hours treatment of 
0.2µM of RHPS4, Ntera ATRX- cells, lived up to 21 days after drug released.  
This does dependency was consistent with recent work on brain tumor cells in vitro, where 
cells exposed to several doses of G-quadruplex ligand RHPS4 showed a dose-dependent 
inhibition of brain tumor growth (Lagah et al., 2014). They showed that several brain tumor 
cells exhibit dose-responsive to G-quadruplex ligand RHPS4.  
Our data also showed that in contrast to Ntera ATRX-, Ntera ATRX+ cells were more 
resistant to G-quadruplex ligand RHPS4 with variety of drug concentration (0.2µM, 1µM and 
5µM). They were able to resume their proliferation following drug released. This suggests 
that ATRX may help overcome the effect of G-quadruplex structures, enabling the cells to 
resume their proliferation and facilitate the replication fork progression. Indeed, it was 
recently shown that neuroprogenitor cells (ATRX-) display a high sensitivity to G-quadruplex 
ligand, they suggested that ATRX play a crucial role to overcome the effect of G-quadruplex 
structure (Watson et al., 2013). However it is unknown yet what part ATRX might play in 
this.  ATRX deficiency is linked to an increase replication fork stalling in different types of cell 
and this may arise from G-quadruplexe formation (Watson et al., 2013; Clynes et al., 2014; 
Leung et al., 2013).  ATRX deficiency together with G-quadruplex stabilising ligands such as 
RHPS4, enhance replication fork stalling which in turn induces replicative stress, DNA 
damage response and termination of cellular proliferation (Rizzo et al., 2009; Rodriguez et 
al., 2012). 
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5.5.2 Checkpoint Activation and Cell Cycle Arresting  
Cell cycle progression was investigated in Ntera cells (ATRX+) and was compared to Ntera 
cells (ATRX-). Both ATRX+ and ATRX- cells, after 24 hours of treatment (AT), were 
accumulated at G0/G1. This could be explain that RHPS4 induce and stabilise G-quadruplex 
formation and replication fork stalled in Ntera cells (ATRX+) and (ATRX-). When, drug was 
released and after 24 hours of recovery, Ntera (ATRX+) cells were able to replicate and 
progressed through the cell cycle and higher percentage of cells seen at S phase and G2/M. 
This suggests that cells were able to resolve the G-quadruplex structure and resume their 
ability of division. In contrast, Ntera (ATRX-) cells were accumulated at G0/G1. This suggests 
that cells had difficulty to resolve G-quadruplex and high percentage of cells were not being 
able to undergo the cellular division. This data support the role of ATRX in contribution of 
unwinding G-quadruplexes and facilitating replication fork progression (Clynes et al., 2015).     
Our data on cell cycle checkpoints proteins revealed that, Chk1, Chk2 and P53 were 
activated following exposure to RHPS4 (AT) in the Ntera cells (ATRX+). These 
phosphorylations decreased after 24 hours of drug released. This could explain that due to 
G-quadruplex stabilisation, replication forks stalled, the checkpoints proteins were activated 
following drug exposure. 
While in Ntera cells (ATRX-), Chk2 and P53 but not Chk1 were phosphorylated following of 
24 hours of treatment and the expression of the phsphorylations for both Chk2 and P53 in 
Ntera ATRX- cells were high even after 24 hours of drug released. This suggests that Ntera 
ATRX- cells experience replicative stress even after drug released and potentially a 
consequence of the cells being unable to resolve G-quadruplex structures. Our data from 
 184 
 
apoptosis assay support this suggestion, as treated Ntera ATRX- cells displayed higher 
frequency of apoptotic cells compared to Ntera cells (ATRX+).  
5.5.3 Telomere Dynamics  
Distinct differences in the responses of ATRX deficient Ntera cells compared to ATRX 
proficient cells was observed follow the exposure to RHPS4. We therefore examined these 
cells for differences in telomere dynamics using STELA. 
It is known that G-quadruplex structure inhibits the catalytic activity of telomerase, which in 
turn induce telomere shortening as a consequence (Zahler et al., 1991). In our experiments, 
data revealed that no telomere shortening was observed in exposed cells to RHPS4, indeed 
overall it appeared that treatment with RHPS4 did not have an obvious impact on telomere 
dynamics. The changes that were observed where quite subtle; telomere lengthening was 
observed in treated cells compared to controls. Such as in U138 cancer cells following 4 days 
exposure to 2µM of RHPS4, its mean telomere length in treated cells was significantly longer 
than untreated. Moreover, in Ntera ATRX- cells following one day exposure to 1µM of 
RHPS4, mean telomere length was longer as well in these cells compared to their controls.      
The following scenario could explain these observations: 
Previously, it was shown that ATRX binds to G-rich repeats, including the telomere G-rich 
strand (Law et al., 2010). It was suggested that ATRX plays a crucial role to overcome the 
effect of G-quadruplex structures and facilitate the replication of these structure (Watson et 
al., 2013). It was also revealed that ATRX interacts with MRN complex (MRE11-RAD50-
NBS1), which is facilitates chromosomal integrity, DNA replication, restart of stalled 
replication forks and DNA double strand break repair (Zhong et al., 2007). Indeed, ATRX 
deficiency has recently been related to a major of replicative stress responses (Wong et al., 
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2010; Watson et al., 2013; Clynes et al., 2014; Leung et al., 2013). Moreover, recent study 
suggests the role of ATRX in overcoming G-quadruplex structure, coming from interacting 
ATRX with DAXX and depositing histone H3.3 at telomeres, which is considered to enable 
DNA replication progression through G-quadruplex structures. Figure 5.21 showed the role 
of ATRX in modulating replication through G-quadruplex structure, model was reproduced 
from (Clynes et al., 2015).     
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Figure 5.21. Model for telomere length maintenance (ALT pathway) in ATRX proficient and 
ATRX deficient tumour cells. ATRX with DAXX deposits histone H3.3 at telomeres, facilitate 
DNA replication progression through G-quadruplexes. The presence of G-quadruplex 
structures in an ATRX deficient cells results in replication fork stalling, providing a substrate 
for MRN-dependent homologous recombination and maintenance of telomere length 
through ALT. ATRX additionally interacts with the MRN complex, facilitating its distribution 
away from PML bodies and telomeres, further limiting HR. Redrawn from (Clynes et al., 
2015). 
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The presence of G-quadruplex structures which induced by G-quadruplex ligand RHPS4 in 
Ntera ATRX- cells, result in high frequency of replication fork stalling, facilitating a substrate 
for MRN dependent homologous recombination (HR) and telomere length maintained 
through alternative lengthen telomere (ALT) (Clynes et al., 2015). It was reported that ATRX 
interacts with the MRN complex, to redistribute them away from sites of telomeric 
recombination and PML bodies, as a further limitation of HR (Clynes et al., 2015). 
 This scenario could explain why longer telomere was observed in Ntera ATRX- cells. When 
G-quadruplexes induced and ATRX suppressed, as tumour cells, they have to find a way to 
maintain their telomere length and proliferation active. Consequently, they might induce 
ALT to maintain their telomere length.  However ALT +ve cells display characteristic 
heterogeneous telomere length profiles, which were not apparent in the Ntera ATRX- cells.  
Thus either these cells were in the very early stages of the induction of the ALT phenotype 
or that a distinct elongation mechanism may be required. 
An alternative scenario, which could explain the results: 
Cells with short telomeres might display an increased sensitivity to the G-quadruplex ligand 
RHPS4. In this situation cells with short telomeres preferentially undergo apoptosis in 
response to the drug, which is consistent with the observed increase in apoptosis observed 
following drug exposure. This would result in a preferential loss of cells with short 
telomeres, a skewing of the telomere length distribution and an apparent increase in mean 
telomere length. This scenario is consistent with the observed telomere length distributions, 
where there a loss of the telomeres in lower length ranges, but this is not matched by an 
obvious increase in telomere length in upper length ranges; overall this results in a skewing 
of the telomere length distribution. 
 188 
 
5.6 Conclusions 
Overall the data presented in this chapter, show that the treatment of cells with G-
quadruplex stabilising ligands exerts a clear cellular phenotype, which is exacerbated in the 
absence of ATRX. However, the changes to telomere dynamics are subtle and it was 
apparent that the stabilisation of G-quadruplexes did not directly lead to the induction of 
stochastic telomeric deletion. 
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Chapter 6 
General Discussion and Future Investigations 
 
6.1 Previous Studies 
Superimposed on the end-replication problem, telomere deletion events have been 
detected both in the presence and in the absence of telomerase (Baird et al., 2003; Britt-
compton et al., 2006). This includes spermatogonial stem cells, where the majority of 
telomeres length are maintained at a mean 12kb in human population by telomerase 
activity, yet very short telomeres (~10 telomeric repeats) were observed (Baird et al., 2006). 
Moreover, telomere deletion events have been also detected in telomerase negative cells 
e.g. normal diploid fibroblasts with an intact DNA damage response, thus it was suggested 
that cells can endure at least one dysfunctional telomere without cell cycle arrest (Baird et 
al., 2003; Britt-compton et al., 2006).  
Previously, telomeres lacking a fluorescent signal from fluorescently labelled telomere-
repeat containing probes have been detected in normal human cells (Callen et al., 2002; 
Wang et al., 2004; Deng et al., 2007). The presence of telomeres lacking fluorescent signal 
were consistent with the telomeric deletion events detected using STELA (Baird, 2008).  
The data presented in this thesis examines the mutational mechanisms that underlying 
telomeric deletion events, using the STELA technique. STELA is the only method currently 
available to detect the extremely short telomeres of the length at which both senescence 
can be triggered and telomere fusion can occur.  
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6.2. Research Presented in This Thesis  
6.2.1 Oxidative Stress and Telomere Erosion  
Many studies have revealed that the replicative lifespan of IMR90 fibroblast is considerably 
increased in conditions that lower the levels of oxidative stress (Chen et al. 1995 and Saito 
et al. 1995). Our data are consistent with this view since we observed significant increased 
of replicative lifespan of IMR90 fibroblast when they grew in standard culture conditions. 
These data indicate that when cultured in low oxygen, IMR90 cells may display their 
maximal replicative capacity. These indications are consistent with the view that IMR90 
cells, as well as many different primary cells grown in standard conditions, are subjected to 
oxidative stress. The production of ROS, is limited by oxygen at normal levels within the cell, 
and will thus rise in high oxygen (Halliwell 2003). In IMR90 cells the levels of oxidative DNA 
damage, as determined by quantifying oxo8dG in DNA, are higher in senescent compared to 
young fibroblasts (Chen et al. 1995). This was attributed to decreasing mitochondrial 
efficiency resulting in an increase in superoxide and hydrogen peroxide production (Chen et 
al. 1995). A Previous study from our laboratory showed that the ectopic expression of 
telomerase in IMR90 cells results in IMR90 immortalised in conditions of lower levels of 
oxidative stress, but not in conditions of high oxidative stress (Britt-Compton, 2009). Thus it 
was concluded that telomerase is incapable of counteracting telomeric specific damage 
resulting from oxidative stress. In contrast to IMR90 cells, MRC5 fibroblasts have previously 
been shown to be immortalised with telomerase in high oxidative stress (20% oxygen) 
(McSharry et al., 2001). Different cell strains react differently to varying oxygen tensions and 
that such differences may be due to differing antioxidant capacities (Lorenz, 2001; Britt-
Compton, 2009). The role of telomere length in the induction of replicative senescence in 
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IMR90 has been examined previously and the the key observation made that the telomere 
length at senescence in IMR90 cells was longer in 20% oxygen compared to 3% oxygen, and 
that this difference was proportional to the difference in the lifespan (Britt-Compton, 2009).  
Our data, together with previously published observations (Britt-Compton, 2009; Chen et al. 
1995 and Saito et al. 1995), suggest that IMR90 fibroblast, are not capable of adapting to 
the high oxygen conditions that they encounter in standard culture, and thus may be 
subjected to high levels of oxidative stress. It is appears that the replicative capacity of 
different cells in culture is not always limited by telomere length, and in conditions where 
the levels of oxidative stress outweigh the antioxidant defences of the cells, senescence can 
be telomere independent. This conclusion may be important because others have argued 
that telomere repeat sequences are unusually sensitive to oxidative stress and that this may 
drive the majority of telomere erosion (von Zglinicki 2002). Thus in conditions of oxidative 
stress the onset of senescence occurs earlier and is telomere driven. Our data, and data 
from others also investigating stress-induced premature senescence (SIPS) in fibroblasts, 
suggest that this may not always be the case. Chen et al. (2001) induced a senescence-like 
arrest in 100% of IMR90 cells using H2O2 and observed no evidence of telomere erosion, 
either immediately or one week after treatment. These findings were also backed up similar 
observations using IMR90 cells expressing telomerase (Gorbunova et al. 2002). Another 
study showed that by using multiple discontinuous subcytotoxic tert-butylhydroperoxide (t-
BHP) or a single subcytotoxic H2O2 treatment in WI-38 fibroblasts, a significant increase in 
rates of telomeres erosion was detected (Dumont et al. 2001; de Magalhaes et al. 2002). 
However, this was accounted for by the cell division of a small proportion of cells that 
resumed proliferation following treatment and contributed disproportionally to the increase 
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in the PD of the culture as a whole. Thus it was concluded that SIPS does not arise as a 
consequence of accelerated telomere erosion, but more likely results from stochastic DNA 
damage in the rest of the genome (Dumont et al. 2001; de Magalhaes et al. 2002). 
Taken together these data indicate that the original hypothesis that oxidative stress might 
work as a mutational mechanism and result in telomeric deletion events may not be valid. 
Instead these data are more consistent with the view that premature senescence does not 
arise as a consequence of accelerated telomere erosion, but instead more likely results from 
stochastic DNA damage across the rest of the genome (Dumont et al., 2001; de Magalhaes 
et al., 2002). 
6.2.2 Telomere Fragile Site 
Our data showed that SCK fibroblasts display uni-modal distribution at the XpYp telomere 
and displayed a more homogenous distribution compared to MRC5 cells.  In contrast, MRC5 
fibroblasts displayed bi-modal distributions at the XpYp telomere, and it’s consistent with 
previous studies that MRC5 containing two differently lengths alleles at XpYp telomere, 
arise from inter-allelic differences which are set in zygote and resulting of contribution of 
maternal and paternal telomere alleles (Baird et al., 2003). 
Our data also showed that exposure of SCK fibroblasts to APH treatment resulted in 
significant differences in mean telomere length between cells treated with 0.3µM, 1µM APH 
and untreated cells. Treated SCK fibroblasts with APH displayed a longer mean telomere 
length compared to control. This suggests that cells with shorter telomeres in treated SCK 
fibroblasts disappeared from the culture; this loss made the mean telomere length higher in 
these cells than the controls. This might be explained by APH preferentially damaging the 
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cells with shorter telomeres in cultures of Seckel fibroblasts and that cells in which this 
occurs subsequently disappear from the culture. As described previously; telomeres repeats 
pose a challenge to replication process and they resemble the fragile sites characteristics 
(Sfeir et al., 2009) accordingly, telomeres considered being sensitive to replication inhibition 
and replication fork stalling that induced by exposure to APH.  
The potential fragility of telomere repeats following exposure to APH, which is a replication 
inhibitor, together with the fact that SCK fibroblasts are deficient for ATR, which plays an 
important role in the DNA damage response, is consistent with all these factors playing a 
synergetic effect and to induce damage preferentially in these cells. 
In contrast to SCK fibroblasts, the normal diploid fibroblast cell culture MRC5 did not show a 
statistically significant change in the mean telomere length distribution following treatment 
with APH. However subtle changes in the proportions of long to short alleles were observed. 
It is possible that the upper alleles in MRC5 may have been preferentially targeted by APH 
treatment and that replication fork stalling induced by exposure to APH in these upper 
alleles were resolved as breaks resulting in a reduction in the length of these alleles. Our 
western blot data was consistent with this suggestion; as Chk1 was phosphorylated and 
activated following 1µM of APH treatment in MRC5 fibroblasts indicating that replication 
stress induced DNA-damage occurred. Whereas, the effects of low dose of Aphdicolin 
(0.3µM) concentration was able only to induce the fragile site breakages and SAβ-gal 
activity, but did not signal efficiently to activate and phosphorylate Chk1. This can illustrate 
that a higher concentration of APH leads to more widespread damage across the genome 
and they are more likely as single stranded breaks which in turn activate the Chk1 
phosphoralytion but not Chk2.  
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Our data also showed that exposure of U138 cancer cells to APH and HU treatments did not 
produce detectible increases in the proportions of short deleted telomeres or changes in 
mean telomere lengths. This may arise a consequence of an intrinsic resistance to APH in 
these cells, or alternativily the fast growing nature of the U138 cells may result the rapid 
loss or dilution of cells in which telomere-specific mutagenic events occurred thus rendering 
these events undetectable. 
The original hypothesis that the induction of chromosome fragility might result in telomeric 
deletion events was consistent with the data obtained from SCK fibroblasts where the 
fragility of telomeres was enhanced by ATR deficiency. Whereas, in MRC5 fibroblasts the 
induction of chromosome fragility impacted on its upper to lower alleles ratio, with a 
preferential loss of the longer telomere length distribution.   
  6.2.3 G-quadruplex Structure at Telomere  
Our data revealed that no telomere shortening was observed in exposed cells to RHPS4, 
indeed overall it appeared that treatment with RHPS4 did not have an obvious impact on 
telomere dynamics. The changes that were observed where quite subtle; telomere 
lengthening was observed in treated cells compared to controls. Such as in U138 cancer 
cells following 4 days exposure to 2µM of RHPS4, where mean telomere length in treated 
cells was significantly longer than the untreated cells. Moreover, in Ntera ATRX- cells 
following one day exposure to 1µM of RHPS4, mean telomere length was longer as well in 
these cells compared to their controls. Possible scenarios that could explain these 
observations include: 
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The G-quadruplex structures induced by ligand RHPS4 in Ntera ATRX- cells, result in high 
frequency of replication fork stalling, facilitating a substrate for MRN dependent 
homologous recombination (HR) and telomere-length maintenance via the alternative 
lengthening of telomeres (ALT) mechanism (Clynes et al., 2015). It was reported that ATRX 
interacts with the MRN complex, to redistribute them away from sites of telomeric 
recombination and PML bodies, as a further limitation of HR (Clynes et al., 2015). In the 
absence of ATRX, ALT might be initiated, however ALT +ve cells display characteristic 
heterogeneous telomere length profiles, which were not apparent in the Ntera ATRX- cells.  
Thus either these cells were in the very early stages of the induction of the ALT phenotype 
or that a distinct elongation mechanism may be required. 
An alternative scenario which could explain these observations is that the cells with short 
telomeres, might display an increased sensitivity to the G-quadruplex ligand RHPS4. In this 
situation cells with short telomeres preferentially undergo apoptosis in response to the 
drug, which is consistent with the observed increase in apoptosis observed following drug 
exposure. This would result in a preferential loss of cells with short telomeres, a skewing of 
the telomere length distribution and an apparent increase in mean telomere length. This 
scenario is consistent with the observed telomere length distributions, where there a loss of 
the telomeres in lower length ranges, but this is not matched by an obvious increase in 
telomere length in upper length ranges; overall this results in a skewing of the telomere 
length distribution. 
Overall the data show that the treatment of cells with G-quadruplex stabilising ligands 
exerts a clear cellular phenotype, which is exacerbated in the absence of ATRX.  However, 
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the changes to telomere dynamics are subtle and it was apparent that the stabilisation of G-
quadruplexes did not directly lead to the induction of stochastic telomeric deletion. 
6.3 Future Investigations 
Extension of this work is required to clarify the observations made in this thesis and more 
studies are possible to illustrate other mechanisms that may play a role in generating 
telomere deletion events.  
Strategies could be employed to examine the genetic requirements for the induction of 
telomeric deletion.  For example, altering the expression of some factors that are 
responsible for the formation and resolution of secondary structures including G-
quadruplexes, T-loops, D-loops and holliday junctions may provide some sight into such 
mechanisms. For example using RNAi to decrease the expression of proteins involved in 
recombination, such as loss of RAD52 in yeast which resulted in an increase of telomere 
deletion (Polotnianka et al., 1998).  
Furthermore Ku protein in yeast is thought to regulate the capping of the telomere thus 
decreasing telomere deletion events. Down regulating its expression may also alter the 
generation of telomere deletion in human cells (Bulchoc et al., 2001). RNAi could be used as 
well to reduce the expression of the MRN complex components (MRE11, RAD50,NBS1). This 
complex is thought to modulate the formation of the secondary structure at telomeres (Zhu 
et al., 2000), and may relate to the MRX complex in yeast that is postulated to mediate 
telomere deletions (Bulcholc et al., 2001).      
The use of other cells such as WI38 and induce oxidative stress by using hydrogen peroxides 
in cultures, along with STELA would provide additional evidence of the role of oxidative 
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stress in generating telomere deletion events. Using antioxidants on the IMR90 cultured in 
high oxidative stress e.g. 300µM of H₂O₂ along with STELA would also provide further 
evidence that oxidative damage does indeed regulate the entry of IMR90 cells into 
senescence and it would clarify the role of oxidative stress with regard to replicative 
senescence. 
BLM, WRN, RTEL helicases are known to be required for complete telomere replication, by 
resolving replication fork stalling within telomeric DNA and facilitating replication fork 
progression (Crabbe et al., 2004; Opresko et al., 2002). It was shown that the reduction in 
BLM helicase markedly increases damage in the telomeres (Rizzo et al., 2009). It would be 
also a great of interest to decrease the expression of BLM, WRN or RTEL by using RNAi in 
treated cells with RHPS4, Aphidicolin or with Hydroxyurea (drugs induce replication fork 
stalling), along with STELA may provide evidence that might be consistent with replication 
fork stalling at telomeres contributing to telomere deletion.  
G-quadruplex secondary structures probably form during DNA synthesis, where the duplex 
strands become separated during DNA replication and single-stranded DNA may fold into G-
quadruplex structures (Sarkies et al., 2010). It would be of great interest to follow the G-
quadruplex formation during cell-cycle progression by using flow cytometry and 
synchronising cell populations and treating the cells with the RHPS4 ligand at specific stages 
of the cell-cycle, including S-G2 phase and G0-G1 phase. This would facilitate the 
comparison of telomere lengths following treatment in each phase of cell cycle. It may also 
be informative to synchronise the cell populations at S-G2 phase and applying DNA 
replication inhibitor e.g. (Aphidicolin) to facilitate more cells to fragility induction and use 
STELA to provide a clear evidence of the role of replication inhibition at telomeres and 
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resolving replication fork stalling as single or double stranded telomeric DNA in generating 
telomere deletion events. 
It was shown that the deficiency of ATR, ChK2 or p21 inhibits cell death, and it was 
suggested that ATR/ChK2/p21 all play important roles during RHPS4-induced telomere 
damage (Rizzo et al., 2009). It would be interesting to use RNAi to decrease the expression 
of these proteins ATR/ChK2/p21 and treat with the G-quadruplex stabilising ligand and use 
STELA to observe if such secondary structures may induce telomeric deletion events.     
It was shown that the difference in RHPS4 sensitivity between PFSK-1/ DAOY embryonal 
cells and C6/GB-1 glioma cells is due to competitive binding of RHPS4 and POT1 to the 3’ 
overhang (Lagah et al., 2014). The less sensitive of C6 and GB-1 cells exhibit higher levels of 
POT-1 protein at telomeres and it was suggested that potent DNA damage response at 
telomeres upon RHPS4 exposure is antagonized by overexpression of POT1 or TRF2 (Lagah 
et al., 2014). Therefore, would be a great interest to see if using RNAi to decrease POT1 or 
TRF2 expression and facilitating binding site of RHPS4 into telomere would display telomere 
deletion events that could be detected using STELA.    
 
6.4 Conclusion 
Taken together, the data presented in this thesis are not consistent with a role for oxidative 
stress, or the formation of G-quadruplex structures, in generating large-scale telomeric 
deletion; however telomeric mutational events may occur following the induction of 
chromosome fragile sites, specifically in the context of an ATR deficiency. Extension of this 
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work and more studies are required to illustrate other mechanisms that may play a role in 
generating telomere deletion events.  
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